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Abstract: 
Two smooth muscle (SM) myosin heavy chain isoforms, generated by alternative 
mRNA splicing, differ by the presence (SM-B) or absence (SM-A) of a 7 amino acid 
insert in the motor domain. The rate of actin filament propulsion (vrnax) of SM-B, as 
measured in the in vitro motility assay, is 2-fold greater than that of SM-A. 1 investigated 
the expression and function of these isoforms in healthy SM and in asthma. 
First,1 determined the sequence of the SM-B isoform in human SM and 
quantified its expression at the mRNA and protein levels in several human organs. The 
SM-B isoform was mostly expressed in rapidly contracting phasic SM. 1 then purified 
myosin from multiple rat organs and found a rank correlation between SM-B content and 
V rnax• 
1 then quantified the expression of SM-B and several other contractile protein 
genes in endobronchial biopsies from normal and asthmatic subjects. SM-B, myosin light 
chain kinase (MLCK), which is responsible for myosin activation, and transgelin, a 
ubiquitously expressed actin binding protein but whose function is unknown, were 
overexpressed in the asthmatic biopsies. The increased SM-B expression and myosin 
activation, due to the increased MLCK expression, both contribute to the increased rate 
of shortening of the asthmatic airway SM. In addition, 1 showed that beyond its 
enzymatic effects, MLCK mechanically enhances v rnax• The binding of SM22 to actin, 
however, did not alter V rnax• 
Finally,1 addressed the mechanisms behind the unique capacity of SM to 
maintain force at low energy cost, namely the latch-state. This property is mostly 
observed in SM-A containing, tonic muscle. Using a laser trap, 1 measured the binding 
force ofunphosphorylated (non-active) SM-A and SM-B myosin isoforms and found that 
they can both attach to actin and maintain force. 1 also measured V rnax at different MgADP 
concentrations and found that SM-A has a greater affinity for MgADP. Because MgADP 
must be released before myosin can detach from actin, the se results suggest that the SM-
A isoform remains attached longer to actin, allowing it to get into the latch-state. These 
findings explain the greater propensity of tonic muscle to get into the latch-state. 
VII 
Résumé: 
La chaîne lourde de myosine du muscle lisse existe sous deux isoformes qui sont 
générés par épissage alternatif de l'ARNm, et qui sont seulement différents par la 
présence (SM-B), ou l'absence (SM-A) de 7 acides aminés dans la région de la tête de la 
molécule. SM-B peut propulser des filaments d'actine (vmax) dans un essai de motilité in 
vitro deux fois plus vite que SM-A. J'ai donc étudié l'expression et la fonction de ces 
isoformes dans les tissues de muscle lisses sains et dans l'asthme. 
J'ai tout d'abord identifié la séquence de l'isoforme SM-B chez l'Humain, puis 
j'ai quantifié son expression dans différents organes humains au niveau de l' ARNm et 
des protéines. J'ai observé que l'isoforme SM-B est principalement exprimé dans les 
muscles lisses rapides dits phasiques. J'ai ensuite purifié la myosine de plusieurs organes 
de rats et j'ai trouvé que vmax augmentait de façon croissante et corrélative avec le 
contenu du muscle lisse en SM-B. 
De plus, j'ai mesuré l'expression de gènes codant pour SM-B ainsi que pour 
d'autres protéines contractiles du muscle lisse dans des biopsies endobronchiales de 
patients normaux et asthmatiques. Le SM-B, la kinase des chaînes légères de myosine 
(MLCK), ainsi que la transgeline (SM-22), sont surexprimées dans les biopsies des 
patients asthmatiques. La MLCK ayant pour rôle d'activer la myosine, l'augmentation de 
SM-B combinée avec celle de la MLCK contribuent à augmenter la vitesse de contraction 
du muscle lisse décrite chez les asthmatiques. De plus, j'ai aussi montré que la MLCK 
pouvait accélérer V rnax par un mécanisme supplémentaire et indépendant de la 
phosphorylation des chaînes légères de myosine. Nous avons aussi trouvé que la SM-22 
ne change pas V rnax, malgré qu'elle s'attache à l'actine; son rôle exact reste donc inconnu. 
Enfin, vu que le muscle lisse a la capacité unique de maintenir une force élevée 
tout en consommant peu d'A TP (propriété appelée 'latch-state'), j'ai étudié les propriétés 
mécaniques permettant de comprendre le latch-state au niveau moléculaire. Ce 
phénomène est surtout observé dans les muscles lisses lents, dit toniques, qui contiennent 
surtout l'isoforme de myosine SM-A. J'ai utilisé une trappe au laser pour mesurer les 
forces d'attachement des isoformes de myosine SM-A et SM-B non phosphorylés (non-
activés) avec des filaments d'actine. J'ai trouvé que les deux isoformes de myosine non 
phosphorylée peuvent s'attacher aux filaments d'actine et qu'ils peuvent maintenir une 
force similaire. J'ai aussi mesuré V max lors de concentrations croissantes d'ADP, et j'ai 
ainsi montré que SM-A a une plus grande affinité pour l'ADP. Vu que la relâche d'ADP 
est le facteur limitant avant que la myosine ne se détache de l'actine, mes résultats 
suggèrent que l'isoforme SM-A reste attache plus longtemps, lui laissant plus 
d'opportunité pour être dephosphorylé alors qu'il est encore attaché à l'actine. Ces 
résultats expliquent la plus grande tendance du muscle lisse tonique à entrer en état de 
latch-state. 
IX 
. .,---
Contribution of authors 
Chapter 2 consists of a manuscript that has been published and is reproduced with 
permission from the publisher: "(+)Insert (SMB) Smooth Muscle Myosin Heavy Chain 
Isoform Expression in Human Tissues ", by Renaud Léguillette, Fulvio R. Gïl, Nedjma 
Zitouni, Stéphane Lajoie-Kadoch, Apolinary Sobieszek, Anne-Marie Lauzon, from 
American Journal ofPhysiology, Cell physiology (2005) vol. 289, 5:pCI277-1285. 
This study was performed by the frrst author (Renaud Léguillette) under the 
supervision of Dr. Anne-Marie Lauzon (Department of Physiology, Meakins-Christie 
Laboratories, Mc Gill University). Fulvio R. Gil was a Masters student under the 
supervision of Dr. Lauzon. He generated the PCR products to sequence most of the 
smooth muscle myosin heavy chain SM-B isoform and assembled the sequence of the 
gene. Dr. Nedjma Zitouni is the research assistant in Dr Lauzon's laboratory and purified 
the functional myosin from the tissues. She also performed the Western blots to assess 
the SM-B content in the human tissues. Stéphane Lajoie-Kadoch is a PhD student from 
Dr. Hamid's group, at the Meakins-Christie Laboratories, who tought me the PCR, real-
time PCR, cloning and sequencing techniques. Dr. Apolinary Sobieszek is a renowned 
biochemist from the Institute for Biomedical Aging Research, Austrian Academy of 
Sciences, who helped us troubleshoot the myosin purification technique from small 
organs. l (R. Léguillette) performed (+ )insert myosin isoform sequencing in humans, 
real-time PCR in human tissues, Western blot on rat tissues, in vitro motility assays of rat 
tissues, and manuscript redaction. 
Chapter 3 consists of the manuscript "Overexpression and function of the myosin 
SM-B isoform, SM22, and MLCK in mi Id asthmatic endobronchial biopsies" by R. 
Léguillette, M. Laviolette, C. Bergeron, N. Zitouni, P. Kogut, J. Solway, A.-M. Lauzon, 
which has been submitted to the American Journal of Respiratory and Critical Care 
Medicine. This study was performed by the frrst author (Renaud Léguillette) under the 
supervision of Dr. Anne-Marie Lauzon (Department ofPhysiology, Meakins-Christie 
Laboratories, McGill University). Dr. Laviolette, a pneumologist from the Centre de 
x 
---
Recherche de l'Hôpital Laval at Université Laval, obtained endobronchial biopsies from 
asthmatic and normal patients. Dr. Bergeron was a fellow at the Meakins-Christie 
Laboratories and tought me the immuno-histochemistry technique. She also performed 
the immuno-histochemistry analysis for SM22. Dr. Nedjma Zitouni purified myosin from 
the rat tissues studied and performed Western blots analysis. P. Kogut, a technician in Dr. 
Sloway's laboratory, in the Department of Medicine at The University of Chicago, 
generated recombinant SM22. Dr. Solway edited the manuscript. 1 performed real-time 
PCR analysis of contractile protein genes in endobronchial biopsies, adsorption tests for 
immuno-histochemistry, immuno-histochemistry ofMLCK and SM-B, in vitro motility 
assays with rat tissues, with MLCK, and with SM22, SM-22 cosedimentations and 
immunoprecipitations and Western blot analysis, and manuscript redaction. 
Chapter 4 consists of the manuscript "Tonie and phasic smooth muscle myosin 
affinity for adenosine diphosphate and unbinding force from actin ", by_Renaud 
Léguillette, Nedjma B. Zitouni, Karuthapillai Govindaraju, Anne-Marie Lauzon. The 
manuscript is under final editorial preparation for submission to the Journal of Cell 
Science. This study was performed by the first author (Renaud Léguillette) under the 
supervision of Dr. Anne-Marie Lauzon (Department ofPhysiology, Meakins-Christie 
Laboratories, McGill University). Dr. Nedjma Zitouni purified myosin from the tissues 
and performed Western blot analysis. Dr. Karuthapillai Govindaraju, a research associate 
at the Meakins-Christie Laboratories, helped with the troubleshooting of the myosin 
purifications. 1 performed the laser trap alignment and stiffness calibration, dichroic 
mirror testing for imaging, , laser trap and in vitro motility assay measurements, and 
manuscript redaction. 
XI 
Chapter 1: Introduction: 
Smooth muscle is found in the wall of all hollow organs of the body and performs 
a variety of functions. Its contraction can result in content propulsion, increase in fluid 
pressure and opening or closing of sphincters. Smooth muscle has been identified in the 
early 1900s, when individual cells have been viewed after maceration of fixed tissues. 
These muscle cells were called smooth because, in contrast to skeletal muscle, no 
intracellular transverse divisions could be seen. Despite efforts from several groups, the 
exact intracellular organization and mechanics of the smooth muscle contractile apparatus 
are still poody understood. 
Structurally, smooth muscle cells can be divided into the cytoskeleton and the 
contractile apparatus. The cytoskeleton is mainly composed of microtubules, cytoplasmic 
actin, dense bodies, vimentin and desmin. Vimentin and desmin are also called 
intermediate filaments because of their diameter of 10nm, which is intermediate between 
the thick filaments (l4-18nm) and thin filaments (7-8nm) from the contractile apparatus. 
The cytoskeleton is thought to resist compressive forces and therefore to have a critical 
role in cellular pre-stress and mechanotransduction (Wang, Butler et al. 1993; 
Stamenovic, Mijailovich et al. 2002; Wang, Tolic-Norrelykke et al. 2002). The 
interactions between compressive forces generated by the contractile apparatus and the 
cytoskeleton have been studied in a tensegrity model where the stiffness of the 
cytoskeleton structure increases proportionally to the stress applied to the cells (Wang, 
Butler et al. 1993). 
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The contractile apparatus is composed of thick and thin filaments. Thin filaments are 
made of a and y smooth muscle actin, the regulatory proteins tropomyosin, caldesmon 
and calponin, and potentially, SM22. Calponin is also found in the cytoskeleton (North, 
Gimona et al. 1994). Thick filaments are assemblies of myosin molecules but their exact 
structure and distribution is still unknown and subject to controversy. The contraction 
generated by smooth muscle cells results from the interactions between regulatory 
proteins, myosin and actin filaments. Of all the proteins participating in the contraction of 
smooth muscle cells, only myosin is a molecular motor that can generate force and 
motion. 
A smooth muscle myosin knockout mouse has been generated in which only the 
expression of non-muscle myosin was possible (Morano, Chai et al. 2000). These mice 
showed abnormaIities in gastrointestinal tract contraction and ductus arteriosus closure, 
dilated cardiomyopathy, enlarged thin-walled bladder, as well as neonataI mortality. 
Interestingly, their smooth muscle tissues could still contract when stimulated with KCI, 
but the rapid fIfst phase of contraction, observed in wild type animais, had disappeared. 
Thus, this model showed that smooth muscle myosin is necessary for vital functions. In 
this sense, altered smooth muscle mechanics may lead to health-related issues. For 
example, smooth muscle mechanics is altered in asthma (Ma, Cheng et al. 2002). 
This thesis will therefore focus on the expression of smooth muscle contractile 
proteins in humans, their molecular mechanics, and their potentiaI role in airway smooth 
muscle in the context of asthma. My hypothesis is that contractile protein expression is 
altered in asthma, leading to abnormalities in airway smooth muscle function. 
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1- EXPRESSION AND FUNCTION OF SMOOTH MUSCLE 
MYOSIN HEA VY AND LIGHT CHAIN ISOFORMS: 
The shortening velocity of smooth muscle from different organs can vary by as much 
as 20-fold (Malmqvist and Amer 1991; Murphy, Walker et al. 1997). Interestingly, the 
molecular basis behind this phenomenon has not yet been established. Because myosin 
isoform content has been shown to have a direct impact on striated muscle performance 
(Lutz and Lieber 2002), it is reasonable to assume that the same may be true for smooth 
muscle. This section will focus on the different smooth muscle myosin heavy and light 
chain isoforms and their contractile role in the different types of smooth muscle. 
A- Tonie and phasie smooth muscle: 
Smooth muscle contractility is heterogeneous even from cell to cell within one organ, 
e.g. blood vessels. Despite this heterogeneity, smooth muscle has been classified, based 
on electrophysiological properties, as either tonic or phasic (Somlyo and Somlyo 1968; 
Kroeger and Stephens 1975; Kuriyama, Mishima et al. 1975; Himpens, Matthijs et al. 
1988; Somlyo and Somlyo 1990; Somlyo and Somlyo 1994). When activated by KCI 
depolarization, phasic smooth muscle contracts rapidly, showing an initial transient peak 
in force that quickly declines (Somlyo and Somlyo 1968). Conversely, tonic smooth 
muscle contracts much more slowly and maintains tension for long periods of time 
(Somlyo and Somlyo 1968). Phasic and tonic smooth muscles also differ in their 
membrane activity. Phasic smooth muscle can generate action potentials. Phasic smooth 
muscle cells have a large number of gap junctions that allow intercellular propagation of 
electrical potential waves generated by pacemakers. This is why they are also called 
single unit muscles (Kannan and Daniel 1980; Daniel, Kannan et al. 1986). To the 
contrary, tonic muscle does not respond to electrical stimulation with action potentials, 
but does respond to pharmacological or humoral agents (Somlyo and Somlyo 1994). 
Tonic smooth muscle cells have very few gapjunctions (2.7 ±0.3 per 100 cells) (Daniel, 
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Kannan et al. 1986) but have more nerve contacts, thus functioning as distinct units with 
individual neuronal control. Tonie smooth muscle is therefore called multi-unit. 
Parallel to these functional differences tonie and phasic smooth muscles have a 
distinct distribution among organs. Typically, phasic smooth muscle is found in the 
rapidly contracting organs like the intestine, the bladder, the portal vein, and small 
arterioles. Tonie smooth muscle is found in slowly contracting, tone-maintaining organs 
like the uterus, large veins and arteries, the fundus region of the stomach, and sphincters. 
Evidence is accumulating to suggest that the content in regulatory and contractile proteins 
between phasic and tonie smooth muscle also differs (Szymanski, Chacko et al. 1998). 
The next sections will focus on the expression and function of the different smooth 
muscle myosin heavy and light chain isoforms. 
B- Myosin: 
Molecular motors, such as myosin, kinesin and dynein, constitute a superfamily of 
mechanoenzymes that can transform the chemical energy liberated from ATP hydrolysis 
into mechanical work. Sequence analysis allowed to differentiate Il classes of motor 
proteins (Sellers and Goodson 1995). Among those motor proteins, myosin molecules 
represent several classes, which differ in their structure and function. Comparative 
sequence analysis of most of the myosin classes showed that the motor domain has many 
weIl conserved regions with basic structural elements, namely an actin- and a nucleotide-
binding sites (Cheney, Riley et al. 1993; Goodson and Spudich 1993; Spudich 1994). 
AlI vertebrate cells contain non-muscle (or cellular) myosin, which plays a role in cell 
division, cell shape, cell motility, intracellular movement and cell secretion. This non-
muscle myosin is a class II myosin. The two isoforms of non-muscle myosin heavy 
chains (NMMHC-A and NMMHC-B) are products oftwo different genes, have a tissue-
specific expression, and have also been found in humans (Katsuragawa, Yanagisawa et 
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al. 1989; Simons, Wang et al. 1991). The nomenclature is unfortunate because smooth 
muscle myosin heavy chain isoforms (described later in this thesis) were also named as A 
andB. 
Skeletal, cardiac, and smooth muscle cells share the same basic molecular structure, 
suggesting that they diverged from a common ancestor (Nagai, Larson et al. 1988). 
Skeletal, cardiac, and smooth muscle myosin are different isoforms of myosin class II. 
They are all hexamers composed oftwo heavy chains (~200 kDa) noncovalently 
associated with two pairs of light chains of 17 and 20 kDa, respectively. The three-
dimensional structure of skeletal myosin has been described by crystallography and is a 
good model for all myosins (Rayment, Rypniewski et al. 1993). The light chains are 
attached to the "IQ motifs" (described in section C-3) which are well conserved between 
myosin classes (Espreafico, Cheney et al. 1992; Xie, Harrison et al. 1994). The four 
known isoforms of smooth muscle myosin heavy chains are generated by alternative 
splicing ofa single gene located on chromosome 16p13.13-13.12 in humans (Deng, Liu 
et al. 1993) . 
c- Structure of smooth muscle myosin heavv and light chain isoforms: 
There are four isoforms of smooth muscle myosin heavy chain described in the 
literature that show variations at the N- and the C- terminal portions of the prote in, as 
well as two isoforms of each ofthe regulatory (LC2o) and essential (LC17) light chains. 
The catalytic portion (or head) ofthe myosin heavy chain is at the N-termÏnus and the 
elongated coiled-coil a-helix (or tail) is at the C-terminus (Figure 1). The head is mostly 
responsible for the enzymatic activity and binding to actin, whereas the tail is involved in 
self-association and filament formation (Figure 1) (Rovner, Fagnant et al. 2002). It has 
also been suggested that the tail has a direct effect on cross-bridge cycling (Martin, Bhatti 
et al. 1997). The function of the various myosin heavy and light chain isoforms will be 
discussed in detail in this chapter. 
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Figure: 1 
Functional regions: 
SMMHC Head and Neck: 
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1 1 
1 1 
Rod 1 1 
1 1 
LMM 
Proteolytic cleavage frag ments: 
Figure 1: Schematic illustrating the structure of the smooth muscle myosin heavy and 
light chains: The functional regions and the fragments obtained by two distinct 
proteolytic cleavages are shown. SMMHC: Smooth muscle myosin heavy chain, LC2o: 
Regulatory light chain (20 kDa), LC 17: Essentiallight chain (17 kDa), HMM: Heavy 
meromyosin, LMM: Light meromyosin. 
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1- Carboxy-terminus smooth muscle myosin heavy chain isoforms: 
discovery, nomenclature and structure: 
Separation of the 200kDa and the 204kDa proteins on SDS-polyacrylamide gels 
allowed the identification of the tail isoforms in turkey gizzard (Kawamoto and Adelstein 
1987) and in swine carotid and stomach smooth muscle (Rovner, Thompson et al. 1986; 
Eddinger and Murphy 1988). The longer tail isoform was called SMI and the shorter one 
was called SM2 (Figure 2) (Eddinger and Murphy 1988). Their distinct amino acid 
sequences have been determined using cDNA clones (Figure 2) (Babij and Periasamy 
1989; Nagai, Kuro-o et al. 1989). Their sequence is identical through amino acid 1928 
but from this point, SM1 contains a sequence of 43 amino acids whereas SM2 contains a 
different sequence of only 9 amino acids (Figure 2). The shorter sequence of SM2 results 
from the insertion of a 39 nucleotide exon that encodes a stop codon at the beginning of 
its sequence (Figure 2) (Babij and Periasamy 1989; Nagai, Kuro-o et al. 1989). Of note, 
the SMI (204kDa) isoform has a serine residue in an acidic environment which can be 
phosphorylated in vitro and in intact cells by case in kinase II (Kelley and Adelstein 
1990). The amino acid sequence of this phosphorylation site is well conserved among 
smooth muscle SM1 and non-muscle myosin from a variety oftissues and species (Babij 
and Periasamy 1989; Shohet, Conti et al. 1989; Murakami, Healy-Louie et al. 1990; Saez, 
Myers et al. 1990) which suggests that it probably has an important function. The role of 
this phosphorylation is not known, but it does not affect myosin conformation (extended 
6S vs folded lOS), filament formation, ATPase activity, nor velo city of actin filament 
propulsion (vrnax) in the in vitro motility assay (Kelley and Adelstein 1990). 
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Figure 2: Schematic illustrating the alternative splicing of the mRNA that occurs in 
SMMHC at the 5' and 3' ends. Inclusion of exon 5b generates the (+)insert isoform, 
whereas inclusion of exon 41, encoding a stop codon, generates the shorter (200kDa) 
SM2 isoform. The 7 amino acid insert of the N-terminus is shown in red and is 
underlined. The amino acid sequence of the insert is identical in human and rat but differs 
by one amino acid in the chicken. From (Low, Leguillette et al. 2006) 
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Myosin molecules are assembled as di mers and there is controversy in the literature 
regarding whether or not, SMI and SM2 form homodimers or heterodimers (Kelley, 
Sellers et al. 1992; Tsao and Eddinger 1993). Kelley and coworkers showed, by 
immunoprecipitating SMI from bovine aortic smooth muscle, that only homodimers 
were present (Kelley, Sellers et al. 1992). However, others have reported that porcine and 
rabbit SMI and SM2 light meromyosin (LMM; Figure 1) could cross-link either as 
homodimers or heterodimers (Tsao and Eddinger 1993). The fact that sorne smooth 
muscle tissues have a non-stoichiometric SMlISM2 ratio is consistent with both views. 
More recently, baculovirus-transfected insect cells were used to produce pure populations 
of SMI or SM2 (Rovner, Fagnant et al. 2002). The cross-linking of SMl with SM2 was 
then asessed, and although SMl and SM2 heterodimers could be formed in vitro, cells 
were found to preferentially contain homodimers of each isoform (Rovner, Fagnant et al. 
2002). 
2- Amino-terminus smooth muscle myosin heavy chain isoforms: 
discovery, nomenclature and structure: 
Because of its important catalytic function, extensive research has addressed the 
role of individual sections of the myosin head. There are two flexible surface loops in the 
head region (Figures land 3). Loop-l is located above the nucleotide binding site at the 
junction of the 25-50 kDa proteolytic domains, whereas 100p-2 is the actin binding site. 
There are two myosin heavy chain isoforms that differ by an insert in loop 1 (Figures 2 
and 3). 
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loop 2: Actin bindlng cleft 
Figure 3: Model of the (+) and (-)insert N-terminus SMMHC isoforms. The insert is 
shown in red. The (-)insert loop is shown in blue like the rest of the heavy chain. The 
regulatory light chain (LC20) is shown in yellow and the essentiallight chain (LC17) is 
shown in pink. The model was generated using the coordinates of Rayment (Rayment, 
Rypniewski et al. 1993) using Insight 2, v. 95.0 (MSI). Modified from (Low, Leguillette 
et al. 2006). 
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Sequence divergence in the N-terminal region of the smooth muscle myosin heavy chain 
was first observed in rabbit and chicken tissues (Hamada, Yanagisawa et al. 1990; Babij, 
Kelly et al. 1991). Both studies identified a short 21 base pair exon that was inserted or 
not, between exon 5a and exon 6 (Figures 2 and 3). Based on the crystal structure of the 
skeletal myosin head, this region is part ofloop 1 (Figure 3). Interestingly, several 
species share the same alternative splicing site, and the work presented in Chapter 2 of 
this the sis reveals the sequence of the insert in human myosin (Figure 2) (Leguillette, Gil 
et al. 2005). 
The nomenclature is still not standardized in the field of myosin isoforms. The N-
terminal inserted smooth muscle myosin heavy chain II is referred to as SM-B or 
(+ )insert whereas the non-inserted isoform is referred to as SM-A or (-)insert. As 
mentioned at the beginning of the section on myosin, an isoform of vertebrate non-
muscle myosin heavy chain is also called the B isoform, i.e. non-muscle myosin lIB. This 
non-muscle myosin isoform also has an insert in loop 1 but of 10 amino acids (Takahashi, 
Kawamoto et al. 1992). Non-muscle myosin lIB should not be mistaken with the smooth 
muscle SM-B isoform. 
3- Ligth chain isoforms: nomenclature and structure: 
LC20 and LC17 noncovalently bind to the "IQ motif' of the heavy chain, which 
has the consensus sequence is IQXXXRGXXRXXY (or W) (Espreafico, Cheney et al. 
1992; Xie, Harrison et al. 1994). LC20 can be phosphorylated and is responsible for 
smooth muscle myosin activation (Figure 3). The existence oftwo isoforms of the LC20 
has been reported in vascular smooth muscle. These isoforms originate from separate 
genes and differ by an Il amino acid substitution (Mougios and Barany 1986); However, 
there is no known functional difference between these two isoforms. LC l7, on the other 
hand, is known to enhance the molecular mechanical properties of the myosin heavy 
chain (VanBuren, Waller et al. 1994) but how it exerts this function remains obscure 
(VanBuren, Waller et al. 1994). Two isoforms of the LC17 (LC l7a and LCl7b) are also 
generated by alternative mRNA splicing from a single gene, and differ by the substitution 
of 5 of the last 9 amino acids in their carboxyl terminus (Nabeshima, Nabeshima et al. 
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1987; Hasegawa, Deno et al. 1988; Helper, Lash et al. 1988; Lenz, Lohse et al. 1989; 
Lash, Helper et al. 1990; Hasegawa and Morita 1992). LC17a has a more acidic isoelectric 
point (pl == 4.13) than LC17b (pl = 4.19) (Helper, Lash et al. 1988). The carboxyl terminal 
sequence ofLC17b (in gizzard) is identical to that of the non-muscle LC 17 (Nabeshima, 
Nabeshima et al. 1987; Hasegawa and Morita 1992). Both LC17a and LC17b can bind to 
SM-l or SM-2 and SM-A and SM-B (Figure 3). 
D- Expression and function of the carboxyl terminal myosin isoforms: 
1- Expression in normal tissues and in diseases: 
The content of SMI and SM2 is tissue specific (Cavaille, Janmot et al. 1986; 
Mohammad and Sparrow 1988). Depending on the species, the SMl/SM2 protein ratio 
can be as low as 0.6 to as high as 4 in tonic and phasic tissues (Mohammad and Sparrow 
1988; Sparrow, Mohammad et al. 1988). Pig carotid artery (Rovner, Thompson et al. 
1986) and bovine aorta smooth muscle (Kelley, Sellers et al. 1992) contain as much SM1 
as SM2. Furthermore, there is a good correlation between mRNA and protein content for 
SM1 and SM2, suggesting that little post-transcriptional regulation occurs (Meer and 
Eddinger 1996). 
The expression of SM1 and SM2 changes with the proliferative state of smooth 
muscle cells. The SMl/SM2 ratio increases when smooth muscle cells are actively 
dividing, as shown in embryonic development of the vascular system, in arteriosclerotic 
vessels, or in cell culture (Rovner, Murphy et al. 1986; Kawamoto and Adelstein 1987; 
Kuro-o, Nagai et al. 1991; Babij, Kawamoto et al. 1992). The SMl/SM2 ratio shifts 
during maturation, as observed in pig airway smooth muscle where the ratio is 0.95 in 
adults and 2.1 in neonates (Mohammad and Sparrow 1988). Human airway may be an 
exception as the same group did not find any difference between adult and human infant 
bronchial and tracheal tissue, where the SMl/SM2 ratio was 0.69 (Mohammad and 
Sparrow 1989). Interestingly, other investigators found a similar SMl/SM2 ratio ( 0.72) 
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in trachea and bronchus of adult asthmatics, suggesting that the expression in these 
isoforms is not altered in asthma (De Marzo, Di Blasi et al. 1989). The distribution of 
SMI and SM2 in tissues can however be complex in other diseases. For example, SM2 is 
significantly decreased in arteries from hypertensive rats, whereas the SMlISM2 ratio 
does not change in the portal vein from the same animaIs (Sparrow, Mitchell et al. 1990). 
The rabbit model of bladder obstruction further increased the complexity by revealing 
that, in addition to differences in SMlISM2 content between organs (Cher, Abemathy et 
al. 1996), there are also regional differences in the expression of these isoforms within 
one tissue (Mannikarottu, Hypolite et al. 2005). Indeed, it seems that even cells from one 
region can show heterogeneity in their SMI and SM2 content (Meer and Eddinger 1996). 
Lastly, the SM1/SM2 ratio also appears to be at least partially under hormonal control in 
reproductive organs. The uterus is frequently studied because of the quick and dramatic 
changes occurring in weight, force, and velocity of contraction after a few days of 
estrogen treatment or during pregnancy (Hewett, Martin et al. 1993). An increased 
SM1/SM2 ratio has been reported in rat uterine smooth muscle treated with estrogen 
(Hewett, Martin et al. 1993) as well as during pregnancy (Sparrow, Mohammad et al. 
1988; Morano, Erb et al. 1993). 
2- Function of the carboxyl terminus isoforms: 
The function of SM1 and SM2 is not clear. The tissue-specific expression of SM1 
and SM2 as well as the presence of a phosphorylation site by casein kinase in SM1 but 
not in SM2 suggest that the se two isoforms function differently. However, no differences 
in their molecular mechanics have been reported so far in vitro (Kelley, Sellers et al. 
1992; Rovner, Fagnant et al. 2002). Ikebe and coworkers used proteolysis to remove the 
SM1 tailpiece from chicken gizzard myosin and found that it enhances myosin filament 
formation (Ikebe, Hewett et al. 1991). This was later confirmed using the baculovirus and 
insect cell system to express three different smooth muscle myosin rods that either had 
the same tail as SM1 or SM2, or that were lacking the non-helical C-terminal tail 
(Rovner, Fagnant et al. 2002). The tendency to form filaments followed the following 
order: No tail> SM1> SM2. Furthermore, electron microscopy images ofparacrystals of 
the rods of SM1 and SM2 homodimers showed that they have a very different 
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conformation (Rovner, Fagnant et al. 2002). Altogether these results suggest that, 
although there are no differences observable in their molecular mechanics in vitro, the 
myosin filaments assembly may differ between the SMI and SM2 isoforms in vivo, 
which may confer functional differences at the whole muscle level (Rovner, Fagnant et 
al. 2002). 
Furthermore, it has been suggested that the C-terminal portion of the myosin heavy chain 
can alter the function ofthe N-terminus. Indeed, the proteolytic removal of the SMI 
tailpiece increases the A TPase activity at low Mg2+ concentrations, although the 
maximum ATPase activity is not different from intact myosin (Ikebe, Hewett et al. 1991). 
Others used peptides that mimick the tail regions of SMI or SM2 to show that they can 
interact with the hinge region (S2-LMM region) of neighboring myosin molecules in 
thick filaments (Cai, Ferguson et al. 1995). The SMI peptide permanently decreased the 
velocity of shortening by 60% and enhanced the Ca2+ sensitivity of smooth muscle fibers, 
while the SM2 peptide had effects oflower magnitude that were reversible (Cai, 
Ferguson et al. 1995). As a control, the investigators used an antibody that could bind 
myosin rods in the same region as the SMI peptide and found that the antibody binding 
can also decrease the velocity of shortening. This suggests that perturbations of the 
structure in the S2-LMM region affects contractility (Cai, Ferguson et al. 1995). 
The possible relationship between smooth muscle tissue shortening velocity and 
SMlISM2 content is still controversial. Studies using uterine smooth muscle from rats 
reported a small positive correlation between SMI content and the rate of shortening 
(Sparrow, Mohammad et al. 1988; Hewett, Martin et al. 1993), but this relationship was 
not maintained in many other smooth muscle tissues (Schildmeyer and Seidel 1989; 
Packer, Griffith et al. 1991; Upadhya, Samuel et al. 1993; Sherwood and Eddinger 2002). 
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E- Expression and function of the amino terminal myosin isoforms: 
1- Expression in normal tissues: 
Differences in myosin SM-A and SM-B expression were first described at the 
mRNA level in rat and rab bit visceral and vascular smooth muscle tissues. Phasic smooth 
muscle from the bladder and the intestine were reported to contain a large proportion of 
mRNA encoding for SM-B (White, Martin et al. 1993; DiSanto, Cox et al. 1997). 
Conversely, the SM-B mRNA was shown to be absent in large arteries (aorta) but it was 
found in small distal arteries (White, Martin et al. 1993; DiSanto, Cox et al. 1997). It is 
now well accepted that SM-A and SM-B are differentially expressed in a tissue-specific 
manner. Subsequent studies using a 7 amino acid insert-specific antibody corroborated 
the mRNA results and confirmed that tonic smooth muscle contains less SM-B than 
phasic smooth muscle (White, Zhou et al. 1998; Low, Mitchell et al. 1999). The stomach 
shows a mixed expression of myosin isoforms, with an increased content in SM-B going 
down from the fundus to the antrum, which parallels the secretory vs propulsive roles of 
these regions, respectively (Pari si and Eddinger 2002). Large tonic arteries contain little 
SM-B while it is expressed in smaller resistance phasic blood vesseis and in the portal 
vein (Di Santo, Cox et al. 1997; Low, Mitchell et al. 1999; Sherwood and Eddinger 2002; 
Stiebellehner, Frid et al. 2003). 
2- Expression of the SM-B isoform in diseases: 
Interestingly, the expression of the SM-B isoform is altered in diseases. This has 
been shown for both visceral and vascular smooth muscles. First, in models of lung 
hypertension, the vascular smooth muscle of the venous and arterial microvasculature 
expresses the SM-B isoform, whereas it is rare in normotensive Iungs (Stiebellehner 
1998; Jones, Steudel et al. 1999). Furthermore, in rat spontaneous systemic hypertension, 
cardiac pre-capillary arterioles contain less SM-B than the normotensive controis 
(Wetzel, Lutsch et al. 1998). Studies of the expression ofSM-B in visceral tissue in 
disease states have focused on the bladder smooth muscle after urinary obstruction 
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(reviewed in (Chacko, DiSanto et al. 1997; Chacko, DiSanto et al. 1999)), whereas 
studies on other organs are rare (Lofgren, Fagher et al. 2002; Gil, Zitouni et al. 2006). 
Urinary bladder hypertrophy caused by urethral obstruction decreases the bladder SM-B 
expression to 50% (Sjuve, Haase et al. 1996; Chacko, DiSanto et al. 1999; DiSanto, Stein 
et al. 2003). The changes in SM-B expression are due to shifts in existing cells, showing 
the ability of smooth muscle cells to adapt to their environmental conditions (DiSanto, 
Stein et al. 2003). In this sense, treatment of rabbits with Tanedan, which returns the 
hypertrophied bladder detrusor smooth muscle contractility to normal, also reverses the 
myosin isoform content to normal (Gomes, Disanto et al. 2000). Furthermore, SM-B 
expression decreases much more at the base of the bladder than at the dome 
(Mannikarottu, Hypolite et al. 2005), which correlates with the dome and the base of 
hypertrophied bladder being subjected to different expansion pressures (Schroder, 
Uvelius et al. 2002; Mannikarottu, Hypolite et al. 2005). Similarly to bladder obstruction, 
intestinal obstruction induces a decrease in rate of shortening concomitant with a 
decrease in SM-B myosin isoform expression (Lofgren, Fagher et al. 2002). Although 
both myosin isoforms are expressed in rat airways, we recently showed that the SM-B 
isoform expression is increased in a rat model of airway hyperresponsiveness (Gil, 
Zitouni et al. 2006). Furthermore, using primers specifically designed for human SM 
myosin, 1 demonstrated unequivocally the presence of the SM-B isoform in various 
human tissues (Leguillette, Gil et al. 2005) (Chapter 2) and 1 showed that its expression is 
increased in asthmatic bronchial biopsies ((Leguillette, Laviolette et al. 2006) (see 
chapter 3). 
3- Regulation of the SM-B isoform expression: 
The control of smooth muscle myosin heavy chain isoform expression is still 
poorly understood, but hormonal regulation in normal smooth muscle tissues has been 
reported (Calovini, Haase et al. 1995; Haase and Morano 1996; White 1997; Lofgren, 
Fagher et al. 2002). In the uterus, a tonic organ, estradiol decreases the SM-B content to 
undectectable levels and alters its distribution in the various smooth muscle layers 
(Calovini, Haase et al. 1995; White 1997). To the contrary, testosterone can increase the 
expression of the SM-B isoform in the uterus (Calovini, Haase et al. 1995). Visceral and 
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vascular smooth muscle expression of the SM-B isoform is also rnodulated by thyroxine. 
Exposure to thyroxine increased by 25% the SM-B mRNA levels for which baseline 
expression was quite high, and increased by 70% the SM-B levels in the aorta, for which 
baseline expression was low (Lofgren, Fagher et al. 2002). Multiple other stimuli, yet to 
be studied, most certainly also alter myosin isoform expression. Major advances in the 
field will certainly come from a better understanding of the precise mechanisms that 
control the alternative splicing of the myosin rnRNA. 
4- Function of the SM-B isoform in vitro: 
The fIfst study to investigate the function of the inserted and non-inserted myosin 
isoforms was performed in avian smooth muscle (Kelley, Takahashi et al. 1993). Kelley 
and collaborators purified myosin from gizzard,and aorta and found a positive correlation 
between the SM-B content and Vrnax as measured in the in vitro motility assay. They 
found that gizzard myosin, which contained mostly the SM-B isoform had a 2.5-fold 
faster V rnax and has an ATPase activity 2-fold greater than aorta, which contained mostly 
the SM-A isoform. In addition, they ruled out the role of the light chain isoforms in 
inducing these differences in motility and activity by repeating the measurements after 
exchanging the light chains between gizzard and aorta myosins. This suggests, as 
proposed before (Spudich 1994), that the 7 amino acids in loop 1 are critical for the 
function of myosin. Similar results were later obtained using the baculovirus/insect cell 
system to express myosin protein constructs that only differed by the presence or absence 
of the seven amino acid insert (Rovner, Freyzon et al. 1997). Changes in ATPase activity 
were coupled to changes in Vrnax, suggesting that alterations in the amino acid sequence of 
the loop can affect the rate-limiting steps common to both the ATPase activity and the 
unloaded shortening velocity. 
So how does the 7 amino acid insert alter the cross-bridge cycle? This has been 
dissected out at the molecular level using a laser trap assay with SM-A and SM-B 
myosin constructs (Lauzon, Trybus et al. 1998). Although the two isoforms generate 
similar unitary force and displacement, the presence of the insert decreases the 
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atiachment time to actin following the power stroke by shortening both the time of 
MgADP release and the time of MgATP binding (Lauzon, Tyska et al. 1998). This is in 
agreement with the three-fold difference in MgADP dissociation rate constant between 
the two isoforms measured using enzymatic assays (Sweeney, Rosenfeld et al. 1998). 
The rate of MgADP release had been shown to be sufficiently slow to be the limiting step 
of the unloaded shortening velocity (Siemankowski, Wiseman et al. 1985; Spudich 1994). 
It had further been hypothesized that loop 1 controls the rate of MgADP release, whereas 
loop 2 contraIs the inorganic phosphate release and thus, the A TPase activity (Spudich 
1994). This view has however been challenged by the results of the functional studies, 
where addition of the insert changed both the ATPase activity and V rnax (Kelley, 
Takahashi et al. 1993; Rovner, Freyzon et al. 1997), while alterations in the actin binding 
loop affected myosin's regulatory praperties (Rovner, Freyzon et al. 1995). It should, 
however, be kept in mind that the biochemical and molecular mechanics measurements 
may in fact underestimate the effect of the insert in vivo. Indeed, isolated single smooth 
muscle cells containing 95% of SM-B can contract three times faster than cells 
containing 38% of SM-B (Eddinger and Meer 2001). This is much faster than what in 
vitro studies would have predicted, and suggests that other factors, in addition to the 
insert, may also contribute to differences in the rate of shortening of smooth muscle cells. 
5- In vivo function, knockout mice studies: 
Targeted deletion of exon 5B of the smooth muscle myosin gene allowed the 
generation of an SM-B knockout mouse (Babu, Loukianov et al. 2001). Unfortunately, it 
was later discovered that concomitant with the (+ )insert deletion, the expression of other 
contractile proteins was also altered, rendering impossible the attribution, solely to the 
insert, of alterations found in their smooth muscle mechanics (Babu, Pyne et al. 2004). 
An increased expression ofLCl7b (2-fold) and calponin (1.4-fold) was observed in the 
aorta, whereas the expression of caldesmon was decreased (50% in the aorta and 30% in 
the bladder) (Babu, Pyne et al. 2004). This decrease in caldesmon expression suggests 
that it may be co-expressed with the SM-B isoform in the intact animal and potentially 
alters its function. Nevertheless, mechanical data from tonic and phasic smooth muscle 
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from the se knockout mice unequivocally show that the velocity of shortening is reduced 
(up to 3.1-fold in the bladder). This suggests that, similarly to the in vitro data, the 
presence of the SM-B isoform accelerates the acto-myosin interactions in vivo (Babu, 
Loukianov et al. 2001). However, a decrease in velocity of shortening was also observed 
in the knockout mouse aorta, which was surprising given that the aorta expresses little 
SM-B isoform (Babu, Pyne et al. 2004). This may potentially be attributable to the 
increased expression of Le17 and/or to the decreased expression of caldesmon (Babu, 
Pyne et al. 2004). 
The results of the studies addressing the effect of the SM-B isoform suppression 
on force measurements are unclear (Babu, Loukianov et al. 2001; Karagiannis, Babu et 
al. 2003; Babu, Pyne et al. 2004). Depending on the activation system and on the type of 
smooth muscle studied, the maximal tension may be increased, decreased or unaltered in 
the knockout mice tissues (Babu, Loukianov et al. 2001; Karagiannis, Babu et al. 2003; 
Babu, Pyne et al. 2004). Furthermore, upon addition of exogenous MgADP, the knockout 
smooth muscle develops a greater increase in force than in stiffness, suggesting that more 
myosin heads are attached to actin, thus slowing the cross-bridge cycle (Karagiannis, 
Babu et al. 2003). It was suggested that in the absence of the SM-B isoform, there could 
either be an additional step in the cross-bridge cycle immediately prior to the MgADP 
release, or that the ADP off-rate is slower, prolonging the attachment time of myosin to 
actin. A siower MgADP off-rate is supported by moiecular mechanics studies «Lauzon, 
Tyska et al. 1998); section 4 above). 
Our group has aiso measured pulmonary mechanics in these knockout mice (Tuck, 
Maghni et al. 2004). After a bolus of methacholine, the time to reach maximal airway 
resistance was prolonged by 18% in the knockout animaIs (Tuck, Maghni et al. 2004). 
However, the actual maximal airway resistance was not altered, potentially because this 
knockout was generated in a hyporesponsive background mice strain, making it difficult 
to reduce airway responsiveness any further. 
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F - Expression and function of the myosin light chains isoforms: 
There is no known pattern of expression nor functional difference between the two 
LC20 isoforms. T 0 the contrary, many studies focused on the expression and function of 
the LCl7 isoforms and many controversies are found in the literature concerning their role 
in smooth muscle contraction. We will therefore concentrate on the distribution and 
function of the LC17 isoforms in smooth muscle. 
1- Expression in smooth muscle tissues: 
It has been reported that the LCl7a/LCl7b ratio tends to be greater in phasic than in 
tonic smooth muscle (Helper, Lash et al. 1988; Malmqvist and Amer 1991; Fuglsang, 
Khromov et al. 1993). However, exceptions have also been reported (Sobieszek and 
Jertschin 1986). Certain phasic smooth muscles only contain one LCl7 isoform. For 
example, porcine jejunum and stomach and chicken gizzard contain only the LC17a 
isoform (He1per, Lash et al. 1988; Kelley, Takahashi et al. 1993). Similarly to the myosin 
heavy chain isoforms, the expression of the essentiallight chains varies during hormonal 
changes; LCl7a increases in uterus during pregnancy (from 46% to 65%) and decreases 
post-partum (Morano, Erb et al. 1993). However, the relationship between LCl7 isoforms 
and myosin heavy chain isoform expression is unclear. Indeed, we (Gil, Zitouni et al. 
2006) and others (Mannikarottu, Hypolite et al. 2005) reported uncorrelated changes in 
LCl7a content and the SM-B SMMHC isoform in airway hyperresponsiveness and in 
bladder hypertrophy, respectively. The expression of essentiallight chain isoforms is also 
well correlated with mRNA levels in rabbit tissues, suggesting that there is little post-
transcriptional regulation (Eddinger, Korwek et al. 2000). 
2- Function of the essentiallight chains isoforms: 
The interest for the LC 17 isoforms started when a correlation was tirst described 
with the kinetics properties of smooth muscle. The ATPase activity declines with 
increasing LCl7b content in multiple bovine tissues (Helper, Lash et al. 1988) and in 
different segments of the porcine aorta (Hasegawa and Morita 1992). Investigators also 
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reported in the same study that myosin with LC I7b has a good affinity for filamentous 
actin, while LC17a cannot bind actin (Hasegawa and Morita 1992). Maximal muscle strip 
shortening velocity showed the same positive correlation with LC17a content as the 
ATPase activity (Malmqvist and Amer 1991; Hasegawa and Morita 1992). This 
correlation was also maintained in the pregnant rat model (Morano, Erb et al. 1993). 
These studies were however performed at the whole tissue level and other parameters 
could have biased the results. Indeed, as mentioned in section E- 4), the molecular 
mechanics of myosin molecules with different LCI7 isoforms is not different, as 
measured in the in vitro motility assay (KeIley, Takahashi et al. 1993; Rovner, Freyzon et 
al. 1997). Furthermore, studies performed at the single cell level, found no correlation 
between the LC17 isoform expression levels and the unloaded shortening velocity 
(Eddinger, Korwek et al. 2000; Sherwood and Eddinger 2002). Altogether these results 
suggest that LC17 isoforms are not the major contributor to the differences in smooth 
muscle mechanics of contraction. 
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11- THE LAT CH STATE: 
It has been approximately 40 years since were obtained the fIfst electron microscopy 
images of the smooth muscle cell contractile apparatus. In spite of that, the intracellular 
organization and dynamics of the thick and thin filaments during contraction are still 
speculative and subject to controversy. In vitro and in vivo biochemical and 
biomechanical studies have improved our understanding of the function of the smooth 
muscle contractile molecules. However, more work needs to be done to shine light on the 
mechanisms behind the high efficiency of smooth muscle. Indeed, the most out standing 
physiological feature of smooth muscle is its ability to maintain force for long periods of 
time at low energy cost. This unique property of smooth muscle is called the latch state 
and will be the focus ofthis section. However, before elaborating on the latch state, a 
thorough review of the activation system of smooth muscle myosin is required. 
A- Smooth muscle activation system: 
A transient increase in myoplasmic Ca2+ concentration is observed after electrical 
stimulation of smooth muscle, which is attributable to Ca2+ release from the sarcoplasmic 
reticulum (Deth and Casteels 1977). When Ca2+-chelating agents are used, contraction is 
inhibited in single smooth muscle cells and muscle strips (Fay 1977). Even if the 
intracellular Ca2+ rises instantaneously, there is a 200 ms delay (compared to less than 
2ms in skeletal muscle) before the onset of active force development (Fay 1977). The 
release of Ca2+ induces phosphorylation of LC20 (Ratz and Murphy 1987). The delay in 
contraction is thus, due to the activation of the LC20 and to the attachment of myosin to 
actin. However, it is still unclear if intracellular activation of myosin results in 
reorganization of the thick filaments, which would also contribute to this delay. It has 
been shown that MLCK activity parallels both the ATPase activity and tension 
development (Gorecka, Aksoy et al. 1976; Sherry, Gorecka et al. 1978), and that MLCK 
phosphorylation of the LC20 is both necessary and sufficient for the ATPase activation 
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and contraction (Sobieszek and Bremel 1975). Furthermore, MLCK was found in many 
smooth muscle tissues, supporting again its essential role in smooth muscle activation 
(Chacko, Conti et al. 1977; Small and Sobieszek 1977; Small and Sobieszek 1977). When 
contraction is initiated in single cells or smooth muscle strips, the Ca2+ -calmodulin 
complex activates MLCK, which phosphorylates myosin LC20 (Driska, Damon et al. 
1978; Cassidy, Hoar et al. 1979; Hoar, Kerrick et al. 1979). 
It is believed that LC20 phosphorylation is not the only regulatory mechanism of 
contraction in smooth muscle. Contrary to skeletal muscle, the smooth muscle A TPase 
activity is independent of Ca2+ (it is only indirectly dependent on Ca2+ because of its 
activation of MLCK) (Stull, Silver et al. 1983; Stull, Kamm et al. 1988). Indeed, several 
studies have described the development of contraction in the absence of any increase in 
Ca2+ which led to the discovery of a dephosphorylation enzyme, namely phosphatase 
(MLCP), which is again Ca2+-independent (Etter, Eto et al. 2001). Thus, LC20 
phosphorylation results from the competitive effects ofMLCK and MLCP. Inhibition of 
MLCP results in an augmented contractile response, a process known as Ca2+ 
sensitization (Ni shimura, Kolber et al. 1988; Kitazawa, Kobayashi et al. 1989; Somlyo 
and Somlyo 1994). For example, prote in kinase C (PKC), a kinase that inhibits 
phosphatase activity, leads to slow Ca2+-independent contraction or Ca2+ sensitization 
(Morgan and Morgan 1984; Rasmussen, Takuwa et al. 1987; Rembold and Murphy 
1988). 
An actin-linked regulatory system similar to that observed in skeletal muscle had also 
been proposed in smooth muscle, where Ca2+ would interact with leiotonin (potentially 
an actin regulatory protein) and tropomyosin to regulate the state ofthin filaments 
(Mikawa, Nonomura et al. 1978; Haeberle 1999). This would allow actin, in presence of 
Ca2+, to trigger myosin ATPase activity (Mikawa, Nonomura et al. 1978; Haeberle 1999). 
However, it is now believed that technical difficulties biased those early studies (Seidel 
1979). Therefore, it is well accepted that activation of smooth muscle contraction is not 
regulated at the thin filament level, as in skeletal muscle, but rather at the level of 
myosm. 
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B- What is latch? 
Once it was established that Ca2+ was initiating smooth muscle contraction via 
phosphorylation of the LC20 by a Ca2+-calmodulin dependent kinase, the relationship 
between myosin phosphorylation and muscle contraction generated a lot of interest. Early 
studies reported that maximum smooth muscle tension can be produced even when only a 
small percentage of the LC20 is phosphorylated (Driska and Hartshome 1975). However, 
it is Dillon and coworkers who first demonstrated the correlation between LC20 
phosphory lation levels and rate of shortening and the intriguing relationship between 
LC20 phosphorylation levels and force development (Figure 4) (Dillon, Aksoy et al. 
1981). 
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Figure 4: Load-bearing capacity (black circles), shortening velocity at an afterload of 
O.12F 0 (black squares) and fractional phosphory lation of tissue LC20 (open circles) as a 
function of time on a log scale after K+ stimulation of a carotid media preparation. The 
mechanical data points are averaged from a series offive preparations (± 1 SEM), with 
extensions of the curves based on time course studies in other tissues. Each 
phosphorylation determination represents a single tissue, frozen at the indicated times 
(n=30), and C designates unstimulated tissues. From (Dillon, Aksoy et al. 1981). 
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Dillon and coworkers stimulated pig carotid arteries with KCI and measured the resulting 
LC20 phosphorylation level, velocity of shortening, as well as the load bearing capacity 
(Figure 4) (The load bearing capacity is defined as the total stress minus passive stress at 
optimallength at which the activated muscle yields when subjected to a quick stretch). 
Despite the fact that the readings of phosphorylation at such low levels were erroneous 
due to technical difficulties, the general aspect of the LC20 phoshorylation curve was later 
confirmed (Rembold, Wardle et al. 2004). LC20 phosphorylation, rate of shortening and 
load bearing capacity, increase over approximately 30 s. At this point, LC20 
phosphorylation and the rate of shortening had reached a maximum and decreased back 
towards baseline at about 20 min after stimulation. Conversely, the load bearing capacity 
kept on increasing and reached a plateau at about 2 min, which was maintained for at 
least 50 min after stimulation. Dillon and coworkers have therefore shown that, even if 
LC20 phosphorylation is necessary for force development, the relationship between 
phosphorylation levels and load bearing capacity is not linear but hyperbolic. (Dillon, 
Aksoy et al. 1981; Dillon and Murphy 1982; Rembold and Murphy 1988; Rembold and 
Murphy 1988). In fact, force can be supra maximal even ifLC2ophosphorylation levels 
are as low as 30%, providing a very non-linear force-phosphorylation relationship 
(Dillon, Aksoy et al. 1981; Rembold, Wardle et al. 2004). This high force maintenance 
state at a low LC20 phosphorylation level and low velocity of shortening has been termed 
the latch-state. This term was chosen to compare with the catch state, that was previously 
described in molluscan smooth muscle (Ishii, Mitsumori et al. 1989). However, the latch-
state is different from the catch state, because cross-bridges are believed to still be 
actively cycling during latch, while they are not during catch (Ishii, Mitsumori et al. 
1989). 
The latch-state is specific to smooth muscle and is not found in skeletal muscle. 
However, this relationship is not the same in all smooth muscles and also varies with 
experimental conditions. While the function of the latch-state in tonic smooth muscle is 
most likely to maintain force for long periods of time, the latch-state has also been 
described in phasic smooth muscle (Fischer and Pfitzer 1989; Kwon, Melandri et al. 
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1992). Yet, the forces measured in phasic muscle were usually not maintained at peak 
value as measured in tonic smooth muscle (Himpens, Matthijs et al. 1988). 
Since the experiments of Dillon in 1981 (Dillon, Aksoy et al. 1981), many theories 
have been suggested to explain the latch-state but to this day, the phenomenon remains 
unexplained. However, because the latch-state has also been described in skinned smooth 
muscle, and because during latch the ATPase activity is extremely low, the latch state is 
believed to be a property of the contractile apparatus itself (Guth and Junge 1982; 
Chatterjee and Murphy 1983). Investigators have proposed two main theories that involve 
the contractile apparatus. The tirst one, suggested by Dillon and coworkers (Dillon, 
Aksoy et al. 1981) states that dephosphory lation of LC20 while myosin is attached to actin 
creates non-cycling cross-bridges that are capable of maintaining force, but which create 
a load on the other cycling cross-bridges and thereby decrease velo city . The second 
theory suggests that dephosphorylated myosins can reattach to actin and maintain force 
(Siegman, Butler et al. 1985; Himpens, Matthijs et al. 1988; Somlyo, Goldman et al. 
1988; Vyas, Mooers et al. 1992; Vyas, Mooers et al. 1994). 
1- TheOl)' 1: Dephosphorylation ofmyosin while attached to actin 
creates latch-bridges: 
Hai and Murphy proposed a model to explain the latch state (Hai and Murphy 1988; 
Hai and Murphy 1988). The basis ofthis model is that myosin is activated by 
phosphorylation of its LC20, but dephosphorylation of myosin molecules that are attached 
to actin induces the formation of latch bridges. Thus, the model proposes that 
dephosphorylated myosins can maintain force and detach very slowly from actin. The 
existence of non-cycling attached cross-bridges had been suggested even before the 
discovery of latch, to explain the high resistance to stretch at rest of certain smooth 
muscle at intermediate intracellular Ca2+ levels (Siegman, Butler et al. 1976). However, 
the contribution of these slowly cycling or non-cycling latch bridges to the decrease in 
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.---. rate of shortening remains controversial. Molecular mechanics demonstrated that 
unphosphorylated myosin exerts a load on faster cycling phosphorylated myosin 
(Warshaw, Yamakawa et al. 1989; Warshaw, Desrosiers et al. 1990), whereas energetic 
measurements showed the opposite (Butler, Siegman et al. 1986). Nevertheless, there are 
two populations of myosin molecules in the model of Hai and Murphy: phosphorylated 
and dephosphorylated myosin. Each one could be attached, or not, to actin but it was 
postulated that latch bridges could only be generated by dephosphorylation of attached 
cross-bridges. The assumptions of the model were as follows: 1) Ca2+-dependent MLCK 
activation of myosin was the only regulatory mechanism (ML CP activity was not 
regulated but constitutive), 2) myosin molecules can cycle independently from each 
other, and 3) unphosphorylated myosin cannot attach to actin (Haï and Murphy 1988). 
The fit of the model to data was very good provided that basal values ofphosphorylation 
were considered as experimental artifacts (Hai and Murphy 1988). The model even 
allowed predictions of MgA TP consumption (Hai and Murphy 1988). Because in this 
model cross-bridge cycling is determined only by the ratio of MLCK to MLCP activity, 
the authors concluded that myosin phosphorylation, by a Ca2+-dependent regulatory 
mechanism, is both necessary and sufficient to obtain latch. 
This model was later refined by the addition of regulated MLCP (Rembold and 
Murphy 1990; Walker, Wingard et al. 1994; Etter, Eto et al. 2001). Lastly, because their 
model did not fit weIl the newer and more precise LC20 phosphorylation data, Rembold 
and coworkers improved it by incorporating cooperative activation of dephosphorylated 
myosin by phosphorylated myosin and actin filaments (Rembold, Wardle et al. 2004). 
2- Theory 2: Reattachment of dephosphorylated myosin to actin and 
force maintenance: 
Multiple models of the latch-state proposed that detached dephosphorylated 
myosin is capable of reattaching to actin and thus contributes to force maintenance. The 
first model suggested that dephosphorylated myosin can reattach to actin and cycle under 
the control of a yet to be identified Ca2+ -dependant regulatory mechanism, other than 
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phosphorylation of the LC20 (Siegman, Butler et al. 1985). Then, many models suggested 
the existence of cooperativity between dephosphorylated myosin and other contractile 
proteins. Several models proposed cooperativity between phosphorylated and 
dephosphorylated myosin (Somlyo, Goldman et al. 1988; Vyas, Mooers et al. 1992; 
Vyas, Mooers et al. 1994). One of the se models suggested that the rate ofattachment of 
dephosphorylated myosin was dependent on the number of attached phosphorylated 
cross-bridges (Vyas, Mooers et al. 1992; Vyas, Mooers et al. 1994). Another model based 
on the cooperativity princip le between phosphorylated and unphosphorylated myosin was 
also proposed to explain the complex relationship between Ca2+ and LC20 
phosphorylation levels and the existence of the latch state in phasic smooth muscle 
(Himpens, Matthijs et al. 1988). However, none ofthese models proposed precise 
molecular mechanisms to explain how phosphorylated and dephosphorylated myosin 
molecules cooperate. 
One possibility is that cooperativity between dephosphorylated myosin and 
phosphorylated myosin occurs through communication across the myosin thick filament 
(Butler, Siegman et al. 1986). However, such a communication system between myosin 
molecules is unlikely because there is no difference in the relationship of V rnax versus 
percentage ofphosphorylated myosin in the in vitro motility assay between filamentous 
and monomeric myosin molecules (Warshaw and Trybus 1991). A better understanding 
of myosin filaments assembly in vivo may suggest further cooperativity mechanisms 
through the thick filaments. Nevertheless, communication mechanisms via the actin 
filament-associated proteins have also been suggested (Somlyo, Goldman et al. 1988; 
Vyas, Mooers et al. 1992; Rembold, Wardle et al. 2004) and are discussed below. 
The function of caldesmon, a thin filament regulatory protein, has been studied in 
the context of the latch-state. Caldesmon has an amino acid sequence that is very similar 
to the actin-binding sequence of MLCK, and is closely associated with actin in a ratio of 
1 caldesmon to14 actin. Caldesmon inhibits the ATPase activity ofactomyosin by 
reducing the transition from weak to strong binding, probably by competition for the 
actin binding sites (Chalovich, Cornelius et al. 1987; Horiuchi, Samuel et al. 1991; 
Marston and Redwood 1992). Furthermore, caldesmon can also bind specifically to 
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smooth muscle myosin, thus cross-linking thick and thin filaments (Marston, Pinter et al. 
1992). When put in the in vitro motility assay at high concentration, caldesmon can slow 
the velocity of actin filaments, probably by exerting a drag effect (Haeberle, Trybus et al. 
1992; Horiuchi and Chacko 1995). In the view of these data, it has been proposed that 
caldesmon may be responsible for force maintenance in latch (Marston 1989; Walsh and 
Sutherland 1989). However, to date force maintenance in presence of caldesmon has 
never been measured. It is nonetheless difficult to conceptualize that caldesmon cross-
linking may be regulated at the same time by a system that also controls active 
shortening. Further studies are thus necessary to elucidate a possible role of caldesmon in 
the latch-state. 
Most recently, Rembold and coworkers refined the Hai & Murphy model (Hai 
and Murphy 1988) by incorporating a cooperativity parameter that is a function of 
myosin phosphorylation (Rembold, Wardle et al. 2004). In this new model, the number of 
myosin binding sites on the actin filament is a critical parameter. Moreover, the number 
of myosin binding sites yielding the best fit to the experimental data, is seven. 
Coincidently, tropomyosin, another actin regulatory protein, is linked to seven actin 
monomers, and increases cross-bridge cycling rate in vitro (Haeberle, Trybus et al. 1992), 
suggesting that it may play a role in cooperativity (Rembold, Wardle et al. 2004). 
Although aH these cooperativity models propose attractive mechanisms to explain 
the latch-state, they also imply the existence of a system that monitors the number of 
phosphorylated myosin heads and their phosphorylation status. Such a monitoring system 
has not been shown to date (Rembold and Murphy 1993). Furthermore, many theories of 
the latch-state were generated from muscle strip level measurements and extrapolation to 
the molecular level. However, there are no molecular level data available that showany 
mechanism to explain the latch state. In chapter 4 of this thesis, 1 report mechanics 
measurements addressing at the molecular level, various theories of the latch-state. 
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3- The role of the affinity of smooth muscle myosin for MgADP in the 
latch-state: 
Whereas the latch state was first described in vascular tonic smooth muscle (Dillon, 
Aksoy et al. 1981), it became apparent that depending on the experimental conditions and 
methods of stimulation, it could also be reproduced in phasic smooth muscle (Siegman, 
Butler et al. 1985; Himpens, Matthijs et al. 1988; Fischer and Pfitzer 1989; Kwon, 
Melandri et al. 1992). It is however weIl accepted that tonic smooth muscle has a greater 
propensity to enter into latch than phasic smooth muscle. One of the mechanisms 
suggested to explain the different susceptibility oftonic and phasic muscle to enter into 
latch is their different affinity for MgADP. Indeed, it has been shown that MgADP 
decreases the rate of relaxation of tonic smooth muscle much more than for phasic 
smooth muscle (Fuglsang, Khromov et al. 1993). This behavior has been suggested to be 
due to a greater affinity oftonic smooth muscle for MgADP. Because MgADP release 
from myosin is necessary for its detachment from actin, such a high affinity for MgADP 
would allow tonic muscle myosin to remain attached to actin longer and thereby, have 
more chances of getting dephosphorylated while attached, i.e getting into latch. It has 
even been suggested that dephosphorylation simply reduces the rate of MgADP release 
from cross-bridges and thus slows myosin detachment (Hai and Murphy 1988). However, 
none of these mechanisms have been tested at the molecular level. The role of the affinity 
of different myosin isoforms for MgADP is addressed in Chapter 4 of this thesis. 
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111- MECHANICS OF AIRWAY SMOOTH MUSCLE IN AIRWAY 
HYPERRESPONSIVENESS AND ASTHMA: 
Asthma was already described in 1776 as a recurrent respiratory difficulty without 
fever, with crises that were called paroxysm (Lieutaud and D'artois 1776). Asthma was 
also described as frequently occurring in people who worked in a dusty environment, and 
post-mortem macroscopic abnormalities of the lungs were also reported (Lieutaud and 
D'artois 1776). More than two centuries later, asthma is now described as a chronic 
inflammatory disease of the bronchi, clinically characterized by airway obstruction, 
enhanced bronchial responsiveness, and airway inflammation (Holgate 1999; Busse and 
Lemanske 2001). Although the role of airway smooth muscle in asthma bas been 
challenged, and despite the fact that the synthetic and secretory function of smooth 
muscle may play a role in the regulation of local inflammation, it is now well accepted 
that airway smooth muscle is the key effector of asthma because of its ability to contract. 
The following section will focus on the mechanics of smooth muscle in airway 
hyperresponsiveness and asthma. 
A- Function of airway smooth muscle: 
Airway smooth muscle has a common embryologic origin with gastrointestinal 
smooth muscle. Whereas smooth muscle has an obvious function in the gastro-intestinal 
system, it is not evident in the lung. If airway smooth muscle was removed, airway tone 
and diameter might be altered slightly, but the se changes do not have obvious physiologic 
consequences. Conversely, smooth muscle plays a critical role in respiratory diseases 
such as asthma. Therefore, this led researchers to suggest that airway smooth muscle is a 
vestigial remnant tissue that has no essential physiologic function but that can lead to 
serious medical problems (Seow and Fredberg 2001). 
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Historically, possible roles for airway smooth muscle have been proposed, but 
availability of new data has invalidated those theories. The first role of airway smooth 
muscle that cornes to mind is protection from noxious particles by bronchoconstriction. 
Although many particles and gases induce smooth muscle contraction (Nadel 1973; 
Wright, Sun et al. 1999), a local reduction in one region of the lung would lead to a more 
peripheral deposition in non-constricted regions, thereby negating any beneficial effect of 
bronchoconstriction (Macklem, Hogg et al. 1973). It was recently suggested that airway 
smooth muscle may assist exhalation by a peristalsis mechanism using bronchial 
rhythmic constriction (Kondo, Kobayashi et al. 2003). However, gas exchange also 
occurs normally even when bronchi are fully relaxed, meaning that this function would 
be far from essential to respiration. Similarly, it does not seem that airway peristalsis 
helps to clear mucus significantly compared to the efficiency of ciliated epithelium and 
coughing. Peristaltic contractions have been observed in rabbit and pig fetallung 
explants, and it was suggested that perhaps, they play a role in the differentiation and 
branching of airways (Schittny, Miserocchi et al. 2000). Another role of peristaltic airway 
contractions was suggested by physiologists who noted an enlargement of venous and 
lymphatic vessels around constricted airways. They hypothesized that peristaltic airway 
contractions play a role in blood and lymph return, but the absence of valves in these 
vessels and the rhythmic variations in interstitial pressure due to ventilation, invalidated 
this hypothesis (Albelda, Hansen-Flaschen et al. 1986). The role of airway resistance in 
ventilation/perfusion matching is far less important than the regionallung distensibility, 
thus decreasing the interest for airway smooth muscle in this matter (West 2000). In this 
sense, the distribution of ventilation was not affected by relaxation after administration of 
isoproterenol (Siegler, Fukuchi et al. 1976). The observation that airway narrowing 
occurs during coughing, which increases velocity of air movement and mucus removal 
(Mead, Turner et al. 1967), suggests that airway smooth muscle may be activated during 
coughing, but there is no direct evidence to support this roie. To the contrary, it was 
suggested that bronchodilators may actually improve the effectiveness of coughing by 
increasing expiratory flow rates (McCool and Leith 1987). Recent developments in 
treatments like thermoplasty, which destroys airway smooth muscle, were shown to be 
promising in avoiding the negative effects ofbronchoconstriction during asthma crises 
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-(Cox, Miller et al. 2004). Altogether, these results support a vestigial role ofairway 
smooth muscle (Seow and Fredberg 2001). 
B- Altered smooth muscle mass in asthma: Static alterations: 
The increase in smooth muscle thickness in asthma has been described in a 
morphometric study performed in 1922, when investigators compared the thickness of the 
airway smooth muscle layer in 5 cases of fatal asthma, and in 4 patients who died from 
other causes (Huber and Koessler 1922). They had already addressed the issue of finding 
a good reference measurement to compare airway layers thickness and used the external 
diameter of the airway as a reference. Indeed, this was an issue because the internaI and 
external diameters of the airways were decreased in constricted bronchi, and asthmatic 
airways were constricted more often and with a greater magnitude than normal airways. It 
was later shown, however, that the basal membrane perimeter is a better reference 
because it is quite constant even at different lung volumes or when smooth muscle is 
contracted (James, Hogg et al. 1988; James, Pare et al. 1988). Another advantage of using 
the basal membrane perimeter as a reference is that smooth muscle area from asthmatic 
and control groups from different studies can be compared by using the square root of the 
airway smooth muscle area versus the airway size (basal membrane perimeter) or the 
value of the intercept ofthe airway smooth muscle area versus the airway size (James, 
Pare et al. 1989). Many morphometric studies have shown that the airway smooth muscle 
layer is either thickened, of greater area, or of increased mass in asthmatic airways 
(Dunnill, Massarella et al. 1969; Heard and Hossain 1973; Saetta, Di Stefano et al. 1991; 
Carroll, Elliot et al. 1993; Ebina, Takahashi et al. 1993; Benayoun, Druilhe et al. 2003; 
Woodruff, Dolganov et al. 2004). It is now weIl accepted that airway smooth muscle 
mass is increased in fatal asthma, but the increase is not as significant in non-fatal asthma 
(Carroll, Elliot et al. 1993; Kuwano, Bosken et al. 1993). Indeed, using a special 
technique that allowed to distinguish smooth muscle cells from their matrix, Thomson 
and coworkers found that airway smooth muscle was not increased in the se cases 
(Thomson, Bramley et al. 1996). 
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Altogether these results raise questions regarding the mechanisms explaining the 
increase in airway smooth muscle mass, notably if it results from hyperplasia or 
hypertrophy of smooth muscle cells. This last issue may be of importance, because 
studies in vascular remodeling, where smooth muscle mass is increased, suggest that the 
contractility of remodeled smooth muscle cells is not equivalent to that of normal tissues 
(Coflesky, Jones et al. 1987). Unfortunately, studies on hypertrophy and hyperplasia of 
airway smooth muscle in human tissues are rare and conclusions are controversial (Heard 
and Hossain 1973; Ebina, T akahashi et al. 1993; Benayoun, Druilhe et al. 2003; 
Woodruff, Dolganov et al. 2004). Nonetheless, one study suggested that hyperplasia is 
present in central airways, while hypertrophy may be more pronounced in peripheral 
airways (Ebina, Takahashi et al. 1993). Furthermore, Woodruffand coworkers recently 
used precise stereomorphometric measurements and also reported hyperplasia in airway 
smooth muscle of endobronchial biopsies of large airways in patients with mild asthma 
(Woodruff, Dolganovet al. 2004). 
c- Altered smooth muscle mechanics in asthma: Force and rate of 
shortening: 
Even if it is now weIl accepted that the smooth muscle mass is increased in asthma, 
its relative contribution to bronchoconstriction is still subject to controversy. Regardless 
of the mechanisms responsible for the increased smooth muscle mass, it has been 
suggested that it leads to altered smooth muscle mechanics and thus bronchoconstriction 
(James, Pare et al. 1989). Bronchoconstriction is the result of the contractile force 
generated by airway smooth muscle, and the impedance of the parenchymal tissues 
attached to the airways. The elastic recoil of the lung parenchyma and the stiffness of the 
airway wa1l1imit the contraction of airway smooth muscle and explain the lower degree 
of contraction of smooth muscle observed in vivo than in vitro (Macklem 1987). Despite 
the fact that parenchymal tissue may also be an important restriction to 
bronchoconstriction in asthma, several investigators have generated models predicting 
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that the most powerful parameter to obtain exaggerated airway narrowing is an increase 
in smooth muscle mass ,because it leads to an increase in smooth muscle force (Lambert, 
Wiggs et al. 1993; Macklem 1996). 
In addition to the increased force production secondary to the increased muscle mass, the 
question was also raised by many investigators, whether airway smooth muscle is 
intrinsically different in asthma, either by generating more force and/or by contracting 
faster. Another possibility is also that asthmatic airway smooth muscle may have 
different mechanics when subjected to variations in length. 
1- Plasticity theory of smooth muscle contraction: 
Skeletal muscle is subjected to the Frank-Starling Law, which means that in the 
limits of normal physiological conditions, the force it generates increases linearly with 
the pre-contraction fiber length. Skeletal muscle can thus only generate maximal force at 
a precise optimallength. Conversely, the relationship between force and length is not 
fixed in ASM. If given enough time to recover (of the order of minutes (Naghshin, Wang 
et al. 2003)), smooth muscle can generate the same maximal force after length 
perturbations (Pratusevich, Seow et al. 1995). For example, ASM is capable ofa 
complete readjustment of its length-tension relationship when subjected to chronic 
shortening (Wang, Pare et al. 2001; Naghshin, Wang et al. 2003). This shift in length-
tension relationship has been referred to as plasticity of smooth muscle contraction 
(Pratusevich, Seow et al. 1995). It has been proposed that smooth muscle plasticity relies 
on contractile filament rearrangements. Two main theories on the formation of contractile 
filaments have been suggested. The first possibility is that myosin filaments 
polymerization is labile and subject to rapid turnover (Seow, Pratusevich et al. 2000; 
Kuo, Wang et al. 2001; Herrera, Kuo et al. 2002). The second possibility is that actin 
filament length is dynamic and regulated (Gunst, Meiss et al. 1995). The two theories are 
discussed in the following paragraphs in light of the available data. 
Because of the limitations in intracellular imaging techniques, there is no 
experimental evidence available characterizing the assembly and disassembly of myosin 
filaments in smooth muscle cells. However, experimental data indirectly suggest that the 
number of myosin filaments, as well as their structure can change with celliength or 
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during activation (Kuo, Wang et al. 2001; Smolensky and Ford 2005; Smolensky, Gilbert 
et al. 2006). The theory of dynamic myosin filaments has been used to explain the lack of 
relaxation of asthmatic ASM after deep inspirations. That is, because asthmatic ASM 
remains in a shortened state for long periods of time, it adapts to shorter lengths, thus 
generates more force at shorter lengths and is more difficult to stretch (Wang, Pare et al. 
2001). However, this view has been challenged by recent results showing that asthmatic 
airways dilate when subjected to deep inspirations, but then re-constrict faster than those 
ofnormals (Brown, Scichilone et al. 2001; Jackson, Murphy et al. 2004). 
The second theory to explain smooth muscle plasticity of contraction is based on 
dynamic actin remodeling and suggests that mechano-transduction processes regulate 
actin filament length. Variable actin length would allow for a better acto-myosin overlap 
at different celliengths, thus optimizing force production (Dulin, Fernandes et al. 2003). 
The polymerizing end of the actin filaments is made up of capping proteins (HSP27, 
tropomodulin, CapZ) (Hart, Korshunova et al. 1997; Bamburg 1999; Yamboliev, Hedges 
et al. 2000). Regulation at the level of the capping proteins can thus lengthen or shorten 
actin filaments. The dynamic actin length theory has also been applied to asthma: It has 
been speculated that longer actin filaments in asthmatic ASM cells may contribute to 
their elastic behavior by allowing cells to generate more force even after being stretched 
(Dulin, Fernandes et al. 2003). 
2- Force 
It is interesting to note that, although there is conflicting information between 
different laboratories, it is generally agreed that isometric force generation is similar 
between normal and asthmatic airways (Roberts, Rodger et al. 1985; Goldie, Spina et al. 
1986; Whicker, Armour et al. 1988; Cerrina, Labat et al. 1989; Bai 1991; Bjorck, 
Gustafsson et al. 1992). Sorne studies reported increased force generation by asthmatic 
smooth muscle (Schellenberg and Foster 1984; de Jongste, Mons et al. 1987; Bai 1990; 
Bramley, Thomson et al. 1994; Thomson, Bramley et al. 1996) but, none except for one 
(Bramley, Thomson et al. 1994) also evaluated the airway smooth muscle content. The 
difficulty of reporting force results relative to the optimallength and normalized to 
48 
volume or mass of the smooth muscle present in the tissue should however be taken into 
account. 
3- Velocity of shortening: 
The velocity of shortening is another mechanical property of airway smooth 
muscle that might be altered in asthma. Evidence that it may be important in asthma came 
from studies addressing the mechanics of airway smooth muscle when subjected to tidal 
stretches, i.e. in a dynamic environment. That is, tidal inflation and deep breaths have 
been shown to decrease airway resistance in normallungs (Skloot, Permutt et al. 1995). 
However, this effect was not observed in asthmatic patients (Fish, Ankin et al. 1981; 
Skloot, Permutt et al. 1995). Recent studies using high-resolution CT sc ans demonstrated 
that central and peripheral airways from asthmatics do dilate during deep inspiration, but 
they quickly narrow back to their initial diameter values, whereas in non-asthmatics the 
airways remain dilated (Brown, Scichilone et al. 2001). Furthermore, applying tidal 
oscillatory stretches of only 2% of the muscle length in vitro decreases the force 
generated by activated airway smooth muscle by 50% in normal airways (Fredberg, 
Inouye et al. 1997). Altogether these findings suggest that a critical abnormality of 
asthmatic airways lies in the dynamic events that follow airway tidal stretching. It has 
been suggested that the degree of airway narrowing is an equilibrium state that depends 
on the rate of acto-myosin cross-bridges interaction vs the rate of stretch imposed to 
airway smooth muscle by tidal breathing (Fredberg, Inouye et al. 1999). A greater rate of 
smooth muscle shortening is likely to compensate for the disruption of cross-bridges 
induced by oscillatory stretches, thus generating more force under oscillations (Gunst 
1983; Fredberg, Inouye et al. 1997; Solway and Fredberg 1997; Fredberg, Inouye et al. 
1999). While numerous studies concentrated on force measurements in the context of 
asthma and airway hyperresponsiveness, fewer studies reported airway smooth muscle 
rate of shortening. However, the few studies that have addressed the question reported a 
greater rate of airway smooth muscle shortening in various animal models of asthma 
(Antonissen, Mitchell et al. 1979; Fan, Yang et al. 1997; Duguet, Biyah et al. 2000), in 
sensitized human bronchi (Mitchell, Ruhlmann et al. 1994), and even in asthmatic human 
single airway smooth muscle cells (Ma, Cheng et al. 2002). The general agreement is 
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thus that hyperresponsive airway smooth muscle exhibits increased rate of shortening. 
The cause for this phenomenon is not known yet, but it may be due to increased 
activation of myosin and/or to differences in the content of myosin isoforms with 
different mechanics or kinetics. Sorne studies have reported that myosin light chain 
phosphorylation levels are increased in hyperresponsive airways, secondary to increased 
expression of MLCK (Jiang, Rao et al. 1992; Jiang, Rao et al. 1992). In chapter 3, we 
demonstrate that the fast cycling SM-B myosin isoform expression is increased in 
asthmatic airway smooth muscle suggesting a molecular mechanism behing the increased 
rate of shortening observed in asthma. 
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IV- GOAL OF THIS THE SIS 
The goal of this thesis was to investigate the role of myosin isoforms in asthma 
and to understand their molecular mechanics, particularly in the latch-state. 
ln chapter 2, 1 determined the nuc1eotide sequence of the SM-B myosin isoform in 
human smooth muscle and studied its distribution in various tissues. 1 also compared 
Vrnax for rat myosin purified from multiple tonic and phasic organs. 
ln chapter 3, 1 studied the mRNA expression of smooth muscle myosin isoforms 
and other contractile proteins in endobronchial biopsies from asthmatic and normal 
patients. 1 then investigated the molecular mechanics of the contractile proteins for which 
the mRNA was upregulated in asthma. 
ln chapter 4, 1 used the in vitro motility assay and the laser trap to investigate, at 
the molecular level, fundamental mechanical properties of smooth muscle myosin, in 
order to gain more information about the mechanisms responsible for the latch-state. 
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Chapter 2: 
(+)Insert Smooth Muscle Myosin Heavy Chain (SM-B) Isoform 
Expression in Human Tissues 
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1- Prologue: 
Smooth muscle myosin heavy chain isoforms are generated by alternative splicing of a 
single gene. The SM-B and SM-A isoforms have distinct mechanics and differ by the 
presence or absence of a seven amino acid insert in the surface loop above the nucleotide 
catalytic site. These isoforms are expressed in a tissue-specifie manner. That is, SM-B is 
found in greater content in phasic smooth muscle whereas SM-A is mostly found in tonie 
smooth muscle. In spite of numerous studies on myosin isoforms, the sequence of the 
human SM-B was unavailable in databanks. Thus, 1 sequenced the human SM-B isoform 
and investigated its expression at the mRNA and prote in levels in a panel of several 
human tissues. To assess the functional significance of the differential myosin isoform 
expression among organs, 1 developed a protocol to purify myosin from small tissue 
samples and measured V rnax for myosin from multiple rat organs. 
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II - Abstract 
Two smooth muscle myosin heavy chain isoforms differ in their amino-terminus by the 
presence «+)insert) or absence «-)insert) ofa 7 amino acid insert. Animal studies show 
that the (+ )insert isoform is predominantly expressed in rapidly contracting phasic muscle 
and the (-)insert isoform is mostly found in slowly contracting tonic muscle. The 
expression of the (+ )insert isoform has never been demonstrated in human smooth 
muscle. We hypothesized that the (+ )insert isoform is present in human and that its 
expression is commensurate with the organ's functional requirements. We report, for the 
first time, the sequence of the human (+ )insert isoform, and quantification of its 
expression by real-time PCR and Western blot analysis in a panel ofhuman organs. The 
(+ )insert isoform mRNA and protein expression levels are significantly greater in small 
intestine compared to all organs studied except for trachea, and are significantly greater 
in trachea compared to uterus and aorta. T 0 assess the functional significance of this 
differential myosin isoform expression between organs, we measured the rate of actin 
filament movement (vrnax) when propelled by myosin purified from rat organs, because 
the rat and human inserts are identical and their remaining sequences show 93% identity. 
Vrnax exhibits a rank correlation from the most tonic to the most phasic organ. The 
selective expression of the (+ )insert isoform observed among human organs suggests that 
it is an important determinant of tissue shortening velocity. A differential expression of 
the (+ )insert isoform could also account for altered contractile properties observed in 
human pathology. 
Key words: Phasic and tonie smooth muscle, real-time PCR, in vitro motility assay 
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111- Introduction 
Smooth muscle is found in aU hoUow organs of the mammalian organism and its function 
ranges from tone maintenance to content propulsion. Many studies are pointing to the 
smooth muscle myosin heavy chain (SMMHC) as an important element contributing to 
these diverse contractile properties (see (Karagiannis and Brozovich 2003) for review). 
SMMHC is made up of a globular head, containing an ATPase site and an actin binding 
domain, and an alpha-helical tail to which regulatory and essentiallight chains are bound. 
SMMHC isoforms are generated by alternative splicing from a single gene (Eddinger and 
Murphy 1988; Nagai, Kuro-o et al. 1989; Babij 1993; White, Martin et al. 1993). Four 
SMMHC isoforms have been described in various animal species. The fust two isoforms 
identified differ in the carboxyl-terminus by distinct sequences of 43 (SMI) or 9 (SM2) 
amino acids (Babij and Periasamy 1989; Nagai, Kuro-o et al. 1989). The next two 
isoforms differ in the amino-terminus by the presence ((+)insert) or absence ((-) insert) of 
a 7 amino acid insert in a surface loop above the ATPase site (Kelley, Takahashi et al. 
1993; White, Martin et al. 1993). The (+) and (-)insert isoforms are also commonly 
referred to as SM-B and SM-A, respectively. AlI combinations ofthese isoforms are 
possible, i.e. (+)insert SM1, (+)insert SM2, (-)insert SM1, and (-)insert SM2. No 
difference in molecular mechanics has been observed between SMI and SM2 but as 
shown using myosin constructs, the sole presence of the amino-terminal insert doubles 
the actin-activated ATPase activity and the rate ofactin filament movement (vmax) in the 
in vitro motility assay (Kelley, Sellers et al. 1992; Rovner, Freyzon et al. 1997; Lauzon, 
Tyska et al. 1998). Because of these properties, there is considerable interest in the 
possibility that the selective expression of the (+) or (-)insert isoforms could contribute to 
the wide range of smooth muscle contractile properties. 
The expression of the (+) and (-)insert SMMHC isoforms is tissue-specifie (Babij 1993; 
Kelley, Takahashi et al. 1993; White, Martin et al. 1993; DiSanto, Cox et al. 1997; 
Eddinger and Meer 2001). Rapidly contracting phasic muscle is predominantly composed 
of the (+ )insert isoform whereas slowly contracting, tone maintaining tonie muscle is 
mostly composed of the (-)insert isoform (Hamada, Yanagisawa et al. 1990; White, 
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Martin et al. 1993). This pattern of expression suggests that the (+) and (-)insert isoforms 
contribute to the different mechanical properties of phasic and tonic muscles. 
Furthermore, animal model studies have reported alterations in myosin isoform 
expression during development, pregnancy, and pathologies (Babij 1993; Morano, Erb et 
al. 1993; Haase and Morano 1996; Sjuve, Haase et al. 1996; Siegman, Butler et al. 1997; 
Wetzel, Lutsch et al. 1998; White, Zhou et al. 1998; Lofgren, Fagher et al. 2002; 
DiSanto, Stein et al. 2003). Significantly, positive correlations between mechanical 
performance and the presence of the (+ )insert isoform are seen in an hypertrophied rat 
urinary bladder model (Sjuve, Haase et al. 1996), in an hypertrophied guinea-pig small 
intestine model (Lofgren, Fagher et al. 2002), and in a rat model of airway 
hyperresponsiveness (Lauzon 2001). A (+)insert SMMHC knockout mouse (Babu, 
Loukianov et al. 2001) confirmed the critical role of the insert in smooth muscle 
contractility. Notably, we showed alterations in the time-course ofbronchoconstriction in 
these knockout mi ce (Tuck, Maghni et al. 2004). While the presence of the fast (+)insert 
isoform and its role in animal models of disease have received enormous attention, its 
expression in human smooth muscle has never been demonstrated. 
In this study, we identified a human (+)insert SMMHC and sequenced both the (+) and (-
)insert isoforms. We showed that the human (+)insert isoform is expressed both at the 
mRNA and protein levels, in proportion to the organ's functional requirements. This was 
independently confirmed in our in vitro motility assay of myosin purified from multiple 
organs. Thus, our study is not only the first report of the presence of the (+ )insert 
SMMHC isoform in humans, but also provides essential information for our 
understanding of human smooth muscle function in normal and pathological conditions. 
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IV- Methods: 
Sequencing o(the human SMMHC insert cDNA: To determine the sequence of the human 
SMMHC insert, the region hypothetically coding for the insert was amplified by 
conventional PCR and the products were sequenced. Briefly, 1 !-tg ofhuman bladder total 
RNA (BD Clontech), in a total reaction volume of 20JlI, was reversed transcribed using 
oligo( dT)12-18 primer, Superscript II, and RNAguard ribonuclease inhibitor (Amersham 
Pharmacia). Primers flanking the hypothetical region containing the code for the insert 
were designed from human (-)insert SMMHC (Genbank accession #NM-002474): sense 
primer: 5'-CCGAAAACACCAAGAAGGTC-3' (642-661 nucleotides), antisense primer: 
5'-GTTGGCTCCCACGATGTAAC-3' (849-868 nucleotides). These primers amplified 
both myosin isoforms «+) and (-)insert). Note that we designed the se primers to bind to 
two different exons, separated by two large introns (4kb and 3.5kb). This strategy 
rendered amplification of genomic DNA unlikely while making it easily noticeable by the 
large difference in size of amplicons. The PCR mixture consisted of 1.5 mM MgCh, 10X 
PCR buffer (lnvitrogen), 0.2 mM of each dNTP, 2 units of Platinum Taq DNA 
polymerase (lnvitrogen), 004 JlM of each of the sense and antisense primers, and 1 JlI 
cDNA. The samples were amplified in a Programmable Thermal Controller (PTC-1 00, 
Ml Research Inc. Watertown, MA) for 40 cycles (45 s denaturation at 94°C, 45 s 
annealing at 58°C, 45 s of extension at 68°C) and 8 min final extension at 68°C. The PCR 
amplification products were resolved by 4% T AE-agarose gel electrophoresis and 
visualized by ethidium bromide. The two amplicons obtained were purified (Qiagen 
QIAquick kit), and ligated into pGEM-T Easy (Promega) according to the manufacturer's 
instructions. Ligation products were transformed into Dh5a competent cells. Plasmids 
were extracted using a miniprep kit (Qiagen). Plasmids were commercially sequenced to 
verify their identity and integrity. 
Sequencing o(the Complete SMMHC cDNA: To determine the sequence of the complete 
SMMHC isoform, the cDNA generated as above was amplified in 4 segments (-1.8 kb 
each) by conventional PCR and the products were sequenced. The entire (+)insert 
SMMHC transcript was amplified and the product was then used in nested and hemi-
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nested PCR to yield 4 overlapping segments. The prim ers were designed from human ( -
)insert SM1 SMMHC (Genbank accession #NM-002474). The PCR mixture consisted of 
2 mM MgS04, IX High Fidelity PCR buffer (Invitrogen), 0.2 mM of each dNTP mixture, 
1 unit of High-Fidelity Platinum Taq (Invitrogen), 0.2 !-lM of each of the sense and 
antisense primers for the SMMHC gene, and 1 !-lI of the above cDNA strand. 
Amplification was performed for 35 cycles (1 min denaturation at 94°C, 1 min annealing 
at 55°C, 80 s of extension at 68°C per kb of amplification target) and 40 min final 
extension at 68°C. The PCR amplification products were resolved on 0.8% T AE-agarose 
gel electrophoresis and visualized by ethidium bromide. Fragments were cloned and 
commercially sequenced. 
Quantitative Rea/-Time peR Ana/ysis: 
To quantify human tissue total SMMHC as weIl as the (+) and (-)insert SMMHC 
isoforms, human total RNA was obtained commercially (BD Clontech) for the following 
tissues: skeletal muscle, bladder, aorta, heart, trachea, lung parenchyma, stomach, small 
intestine, uterus, placenta, testis, kidney, spleen, thyroid, salivary glands, spinal cord, 
brain, bone marrow, fetalliver, and fetal brain. The company pooled the RNA from 5 to 
59 Caucasian subjects (depending on the organ) aged from 15 to 75 years, with the 
exception of fetal tissues that were pooled from 22 to 40 weeks old fetuses. The company 
also assessed the RNA by electrophoresis on denaturing gel and certified its quality and 
quantity. 1 !-lg of RNA from each of the se tissues was reverse transcribed simultaneously 
to minimize variability, in a total reaction volume of 20 !-lI. Total SMMHC was first 
quantified in absolute terms using standard curve analysis to determine which organs 
contained sufficient smooth muscle to pursue a relevant investigation of the (+) and (-
)insert isoforms. Quantification of splice variants in absolute terms is however very 
difficult due to the additive errors introduced in generating two reliable standard curves 
for two sets ofprimers (Vandenbroucke, Vandesompele et al. 2001). The (+) and (-)insert 
isoforms were therefore quantified in relative terms for the selected organs, using a 
previously validated algorithm (Livak and Schmittgen 2001; Liu and Saint 2002; Liu and 
Saint 2002) that expresses the content of each isoform normalized to total SMMHC, with 
respect to a calibrator organ. The calibrator organ was chosen to be the one that contained 
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the greatest amount of each isoform. Primers for total SMMHC were designed by 
targeting a region common to aIl SMMHC isoforms as follows: total SMMHC: sense 
primer 5'-AGCAGCTACAGGCTGAAAGG-3' (2904-2923 nucleotides) and antisense 
primer: 5'- TGGAGGATGAGATCCTGGTC -3' (3036-3055 nucleotides). Because total 
SMMHC was quantified in absolute terms, we generated standard curves as follows. 
Total SMMHC PCR products were extracted from several amplicons and pooled. cDNA 
concentration was measured by spectrophotometry and was considered accurate only 
when the OD was greater than 0.1 (relative units). Ten dilutions were then assayed by 
real-time PCR and the best five contiguous dilutions were chosen for the standard curve. 
For the (+) and (-)insert SMMHC isoforms relative quantification, primers were designed 
using the insert sequence determined above and the human ( -)insert SMMHC sequence 
(Genbank accession #NM-002474). The 21bp insert sequence itself served as the 
(+)insert sense primer. The (-)insert sense primer spanned the insertjunction. The 
sequence of the primers was as follows: (+ )insert isoform: sense primer 5'-
CAAGGCCCATCTTTTGCCTAC-3' (703-723 nucleotides) and antisense primer 5'-
GTTGGCTCCCACGATGTAAC-3' (849-868 nucleotides), (-)insert isoform: sense 
primer 5'- CAAGAAAGACACAAGTATCACGG-3' (700-722 nucleotides) and 
antisense primer: same as for (+)insert isoform. Note that to keep efficiencies close, the 
primers were designed to obtain amplicons ofsimilar length (lbp difference) and the 
same antisense primer was used. PCR reactions were performed in a volume of 20 f.tl, 
containing 1 f.tl cDNA, 10 f.tL 2x QuantiTect SYBR® Green PCR (Qiagen), 7 f.tL of 
nuclease-free H20, and 1 f.tl ofboth the forward and reverse primers (final concentration 
0.1 f.tmol each). The samples were amplified in a LightCycler® system (Roche 
Diagnostics).The real-time PCR conditions consisted of a denaturation step of 15 minutes 
at 95°C followed by an amplification of 45 cycles (denaturation at 95°C for 15s, 
annealing at 60°C for 20s and extension at 72°C for 20s) and 1 melting curve cycle. PCR 
reactions were performed in triplicate, Le. 3 repeats on the same RNA samples pooled 
from several subjects. Each primer set generated oruy one peR product and the identity 
and integrity of these products was confirmed by commercial sequencing. PCR reaction 
efficiencies were calculated for each reaction following a previously described method 
(Liu and Saint 2002; Liu and Saint 2002), and were used in the quantitative analysis that 
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was performed using LightCycler® software (v 3.5). The results are reported as mean 
±SE. 
(+ )Insert and Total SMMHC Semi-Quantitative Protein Analysis: Western blot analysis 
was performed to determine the (+ )insert SMMHC isoform and total SMMHC protein 
expression in human and rat tissues. 
Human: Human small intestine, stomach, trachea, bladder, uterus, aorta, and brain 
(negative control) prote in MedleyTM were obtained from BD Biosciences (Clontech). The 
company pooled the proteins from 16 to 49 Caucasian subjects (depending on the organ) 
aged from 16 to 65 years. Electrophoresis was done through 6% SDS polyacrylamide gel 
using a Laemmli buffer system. Protein concentration was determined by a standard 
Bradford assay. For detection of total SMMHC, 60 Ilg ofprotein was loaded on the gel 
whereas for the (+ )insert isoform, gels were loaded with either 100ilg or with 160 Ilg. 
Proteins were then electroblotted onto nitrocellulose membrane (Bio-Rad). The 
membrane was probed with the polyclonal (+)insert antibody, kindly provided by Dr. A. 
Rovner, that specificaBy recognizes the 7 amino acid insert QGPSF A y (White, Zhou et 
al. 1998), or with the polyclonal BT-562 (Biomedical Technologies Inc.) that recognizes 
aB SMMHC isoforms. Antibody detection was done by Enhanced Chemiluminescence 
(Amersham). Six Western blot repeats were done on the same protein samples pooled 
from several subjects. Because different organs contain different amounts of muscle, it is 
important to normalize the myosin isoform content to the total amount of myosin in a 
given organ. However, to overcome the inevitable differences in affinities ofthe 
antibodies for the (+ )insert isoform and total myosin, we normalized the densitometric 
values with respect to a calibrator organ in the following way: 
( + )insert in target organ 
( ). ( + )insert in reference organ + lUsert content = _'-----'--______ --=---1._ 
( 
Total myosin in target organ ) 
Total myosin in reference organ 
(1) 
The results are reported as mean ±SE. 
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Rat: Four Lewis female rats, ~16 weeks of age, were purchased from Harlan (IN, USA). 
AlI experiments were conducted in compliance with the animal ethics committee of 
McGill University. AnimaIs were sacrificed with an overdose of sodium pentobarbital 
(lOOmg/kg, i.p.). The small intestine, stomach, trachea, bladder, uterus, and aorta were 
harvested and powdered in liquid nitrogen and homogenized at 4°C in sodium 
pyrophosphate extraction buffer (lOmM sodium pyrophosphate, O.3M KCI, 3mM MgCh, 
2mM DTT, pH=6.8). Electrophoresis was performed as above except that 50 )lg of total 
protein were loaded onto the gel. Organs from the 4 rats were pooled and measurements 
were repeated 3 times. The quantification was performed as described above for the 
human Western blots. 
(+) and (-)Jnsert SMMHC In Vitro Rate ofMovement: 
To quantify at the molecular level the differences in mechanics between tonic and phasic 
smooth muscle, we measured using the in vitro motility assay the rate of actin filament 
movement (vrnax) when propelled by smooth muscle myosin purified from rat organs. 
Sixteen Lewis rats were sacrificed as described above and their small intestine, stomach, 
trachea, bladder, uterus, and aorta were rapidly harvested and frozen in liquid nitrogen. 
(Note that the motility of stomach myosin was not assessed because of the difficulty in 
purifying functional myosin from that organ). Myosin extraction was carried out in 
folding conditions (90mM KCI, 2mM Na2ATP) followed by filament formation at 50mM 
MgCh. Separation of myosin from actin was performed by ammonium sulfate 
fractionation. Myosin fractions were then dissolved and dialyzed against low salt buffer 
(40mM KCI, pH 6.7) to precipitate myosin filaments. The purified myosin was then 
thiophosphorylated with 0.6mM ATPyS, 7.5)lM calmodulin, 5)lM MLCK (kindly 
provided by Dr. J. R. Haeberle), 0.2mM CaCh and 2mM MgCh. Unregulated actin was 
purified from chicken pectoralis acetone powder (Pardee and Spudich 1982) , 
fluorescently labelled with tetramethylrhodamine isothiocyanate phalloidin (Sigma), and 
diluted in actin buffer: 25mM KCI, 25mM imidazole, 1mM EGTA, 4mM MgCh, 25mM 
DTT (pH 7.4) with an oxygen scavenger system: O.1mg/ml glucose oxidase, 0.018mg/ml 
catalase, 2.3mg/ml glucose. The in vitro motility assay was performed as previously 
described (Warshaw, Desrosiers et al. 1990). Briefly, inactive myosin molecules were 
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removed by ultracentrifugation. Myosin was then diluted to a concentration of 0.25mg/ml 
in a myosin buffer: 300mM KCI, 25mM imidazole, 1mM EGTA, 4mM MgCh, 25mM 
DTT (pH 7.4). The myosin in solution was flushed through a chamber (Warshaw, 
Desrosiers et al. 1990) and allowed to attach randomly onto the nitrocellulose-coated 
glass. Inactive myosin heads were further inhibited by adding monomeric unlabeled actin 
in actin buffer. Labeled actin filaments in actin buffer were then added to the chamber, 
followed by motility buffer: 0.5% methylcellulose, 2mM MgATP, 25mM KCI, 25mM 
imidazole, 1mM EGTA, 4mM MgCh, 25mM DIT, and oxygen scavenger as above. 
Measurements were made at 30 oc. Actin movement was recorded by a SIT camera, 
digitized and analyzed (Scion-Image software). Vrnax measurements were repeated 5 times 
with myosin pooled from each of the various organs from 16 rats. V rnax was reported in 
Dm/sec ± SD. 
Statistical Analysis: 
Statistical analysis of the replicated measurements on the pooled samples was performed 
as follows: differences between tissues in total SMMHC cDNA, (+)insert isoform cDNA 
and proteins, (-)insert isoform cDNA, and V rnax were tested using one-way ANOV As 
followed by tests for normal and rank correlations. Differences between human and rat 
(+)insert protein expression were tested by a two-way ANOV A. 
63 
v- ResuUs: 
Sequencing the human SMMHC insert cDNA: 
The region of human SMMHC mRNA hypothetically coding for the 7 amine acid insert 
was identified by cDNA sequence comparisons with other species. Amplification ofthat 
region from human bladder cDNA was performed and two distinct products were 
obtained (Fig. lA). Sequencing of the clones derived from these amplicons confirmed that 
the two products differed by 21 nucleotides. Comparisons with other species' sequences 
showed that the cDNA amplified was indeed the region co ding for the inserted surface 
loop (Fig.lB). Interestingly, the human and rat nucleotide sequences co ding for the insert 
are identical (Fig. lB). The human sequence differs from the mouse by 1 bp, from the 
rabbit by 2bp, and from the chicken by 3 base pairs (Fig. lB). To our knowledge, this is 
the first report of the (+ )insert SMMHC isoform in human smooth muscle. 
Sequencing the Complete (+ )Insert SMMHC cDNA: 
The sequence of the complete human (+)insert SMMHC (~7 kb) was accomplished by 
RT -PCR using human bladder RNA. Compilation of the sequences obtained for the 
complete (+ )insert SMMHC transcript revealed two isoforms of 6882 bp and 6921 bp 
(see Supplementary Information SI). Comparison with the available human (-)insert 
isoform sequence (Genbank accession #NM-002474) revealed identical sequences, 
except for the 21 nucleotides coding for the 7 amino acid insert. This comparison also 
showed that the shorter mRNA product (6882 bp) generates the longer SM1 protein and 
the longer mRNA product (6921 bp) generates the shorter SM2 protein, due to the 
insertion of a short exon encoding a stop codon. Furthermore, there are no differences in 
the RNA encoding the carboxyl-terminal amino acids, i.e. the (+) and (-)insert SM1 and 
the (+) and (-)insert SM2 isoforms. These human (+)insert SM1 and (+)insert SM2 
SMMHC cDNA sequences have been deposited to Genbank (Accession numbers: 
A Y520816-A Y520817). 
Quantitative Rea/-Time PCR Ana/ysis: 
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Quantitative real-time PCR was performed in triplicate on commercial human RNA 
pooled from several subjects. A panel ofhuman organs were initially screened for their 
total SMMHC content. Total SMMHC includes the four isoforms, Le. (+)insert SM! and 
SM2, and (-)insert SM! and SM2, because the primers targeted a region not subject to 
alternative splicing. SMMHC cDNA was found in aU tissues studied (Fig.2). Tissues 
containing very low amounts of total SMMHC «2XIO-5 ng/~g RNA) were not analyzed 
any further because such a low content was presumably a reflection of the ubiquitous 
vascular smooth muscle and not of the organ itself. The (+) and (-)insert SMMHC 
isoform analysis was therefore pursued only for the bladder, aorta, smaU intestine, 
stomach, uterus, and trachea. Relative quantification was performed by normalizing the 
content of each isoform with respect to total SMMHC, a good marker of total smooth 
muscle content in each tissue, and with respect to a calibrator organ. The calibrator organ 
for a given isoform was chosen to be the tissue that contains the greatest amount of that 
isoform. The small intestine is the organ that contains the greatest amount of (+ )insert 
isoform so was set to 100% (Fig.3). AU other organs express significantly less (+ )insert 
cDNA than the small intestine (stomach expresses 58 ± 4% (+)insert cDNA with respect 
to the small intestine and normalized to total SMMHC, the trachea 19 ± 3%, the bladder 
10 ± 2%, the uterus 5 ± 2%, and the aorta 0 ± 0% (p<0.05) (Fig.3)). Statistically 
significant differences are also found between the stomach and aIl other organs, and 
between the trachea and aorta or uterus (p<0.05) (Fig.3). The organ that contains the 
greatest amount of ( -)insert isoform is the uterus and was set to 100% (Fig.4). Thus, with 
respect to the uterus and normalized to total SMMHC, the stomach (99 ±15%) and aorta 
(98 ± 13%) express significantly more of the (-)insert isoform than the bladder (56 ± 13%) 
and small intestine (53 ±11%) (p<0.05) (Fig.4). The trachea expresses an intermediate 
level of ( -)insert isoform (72±9%). Because comparisons amongst different sets of 
primers is invalid and because the reference organs are not the same for the (+) and (-
)insert isoforms, figures 3 and 4 should not be directly compared. 
(+ )/nsert Protein Analysis in Human Tissues: 
The expression of the (+ )insert SMMHC isoform was also determined at the prote in level 
by Western blot analysis repeated 6 times on commercial samples pooled from several 
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subjects. The (+)insert SMMHC isoform protein is expressed in aH hurnan tissues studied 
but is not detected in the brain (negative control) (Fig.5A). The small intestine has the 
greatest (+ )insert isoform prote in expression and so was set to 100%. The results were 
therefore expressed with respect to the content in the small intestine and normalized to 
total SMMHC (Fig.5B). AIl organs except the trachea (74.0±16.7%) show statistically 
less (+ )insert prote in expression than the small intestine; the stomach expresses 
47.7±12.9% of the (+)insert prote in in the small intestine, the bladder 42.7±6.3%, the 
uterus 36.6±8.4%, and the aorta 33.0±8.3% (p<0.05) (Fig.5B). Interestingly, the trachea 
also shows statistically more (+)insert than the aorta and uterus (p<0.05) (Fig.5B). 
(+ )Insert Protein Analysis in Rat Tissues: 
The expression of the (+)insert SMMHC isoform was also determined at the protein level 
in samples pooled from 4 rats by Western blot analysis performed in triplicate (Fig.6A). 
A semi-quantitative analysis was performed as for human (+)insert protein (Fig.6B). No 
significant differences in the pattern of expression were observed between the rat and 
hurnan organs (p=0.45). 
(+) and (-)Jnsert SMMHC Rate ofMovement 
To assess at the molecular level the physiological significance of the differential 
expression of the (+) and ( -)insert isoforms, we used the in vitro motility assay to 
measure V rnax for actin filaments propelled by myosin molecules purified from rat organs. 
Rat myosin was used as a model for human because the insert sequence is identical, the 
rest of the myosin sequence is 93% identical, and its expression of the (+)insert isoform 
is similar to hurnan among organs (see Figs. 5 and 6). Measurements ofvrnax were 
repeated 5 times with myosin pooled from 16 rat organs. V rnax was significantly different 
between aU organs: small intestine (O.64±O.Ol ,"unis), bladder (O.58±O.03J.1m1s), trachea 
(0.44±O.OlJ.1m1s), uterus (0.35±O.OIJ.1m1s) and aorta (O.23±O.OlJ.1m1s) (Fig.7A, p<O.05). 
We expected a linear regression between (+)insert protein expression and V rnax but 
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because we tested only a selected number of organs, we have very few points and thus, 
the test for r=0 is not significant. However, from the most tonic to the most phasic organ 
there is a rank correlation that is almost perfect between the (+ )insert prote in expression 
and vmax, and a test with Kendall K is significant at the criticallevel of 0.05 (Fig.7B). 
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VI- Discussion: 
In this study we demonstrated, for the first time, that the (+ )insert SMMHC isoform is 
expressed in human smooth muscle at the mRNA and protein levels. We also performed 
quantitative real-time PCR and semi-quantitative protein analyses that showed 
differential expression of the (+) and (-)insert isoforms between human organs, 
suggesting a role for the se isoforms in determining the rate of shortening of phasic and 
tonie smooth muscle. Furthermore, we showed that rat myosin is a good model of human 
myosin. Finally, using the in vitro motility assay, we observed a greater Vrnax for myosin 
purified from phasie than from tonie rat smooth muscle, whieh correlated with the 
(+ )insert isoform expression. 
Mapping the Complete (+ )Insert SMMHC on the Human Genome: 
Using the cDNA sequence obtained for the complete (+)insert SMMHC isoform, we used 
UCSC's BLAT tool (Kent, Sugnet et al. 2002) and identified 42 exons spanning 6.9 kb 
on the reverse strand of human chromosome 16. The 21 bp sequence encoding the 7 
amino acid insert, starting and ending at nucleotides 15845014 and 15844994, constitutes 
a complete exon in itself. By analogy with previous publications in other species (Babu, 
Warshawet al. 2000; Babu, Loukianov et al. 2001) we called this exon 5b, because it is 
located between exons 5 and 6 (Fig.8). Exon 5b is flanked by the classical splice donor 
and acceptor sites AG and GT, respectively (Fig.8). The expression of the (+) or (-)insert 
isoform results from alternative splicing of exon 5b (Babij 1993; White, Martin et al. 
1993). (Note that this exon is also located on chromosome 16 in the mouse, while it is on 
chromosome lOin the rat.) Also, our cDNA sequence demonstrates that the human 7 
amino acid insert is identical to that of the rat and mouse (QGPSF A Y), whereas it differs 
by one amino acid in the chicken (QGPSFSY) and rabbit (QGPSLA Y) (Fig. lB). 
The tail of human SMMHC is also subject to alternative splicing, yielding the SM1 and 
SM2 isoforms. Our sequencing results confirmed that the SM1 and SM2 isoforms only 
differ in their tail region, with the rest of the sequence remaining the same. In agreement 
with a previous report (Nagai, Kuro-o et al. 1989), nucleotide sequence analysis also 
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revealed, that a 39 bp exon that is spliced into the myosin sequence encodes a stop codon 
that prematurely arrests translation, thus generating the SM2 isoform. Furthermore, this 
short exon (39 bp) is located on chromosome 16 between exons 40 and 42 (between 
nuc1eotides 15769099 and 15769l37), and was caUed exon 41 (Fig.8). 
(+ )Jnsert Isoform and Contractile Properties: 
SMMHC was detected in aU tissues studied. As real-time PCR is exquisitely sensitive 
(Bustin 2000), it is likely that myosin from the vasculature of an examined organ is also 
detected, thereby explaining the weak positive signal in non-contractile organs. This 
could explain why mRNA coding for the (+ )insert SMMHC was found in all human 
tissues tested except for the bone marrow. It has been shown previously that the (+)insert 
SMMHC is the dominant isoform in rat and rabbit small vessels and arterioles (DiSanto, 
Cox et al. 1997; Wetzel, Lutsch et al. 1998; Jones, Steudel et al. 1999) and blood vessels 
could also explain the signal detected for this isoform in all human tissues. Our data 
showed, as expected, that the greatest amount of SMMHC was found in contractile 
organs (Fig.2). Correspondingly, only the organs that showed the greatest SMMHC 
mRNA expression were followed up at the protein level. The main purpose of this 
analysis was to verify whether or not the (+ )insert isoform was also expressed at the 
protein level. This was confirmed and a relative quantification of the (+)insert SMMHC 
isoform protein was carried out. 
The (+)insert isoform mRNA and prote in expression levels were significantly greater in 
the small intestine compared to all other organs studied except for trachea, and were 
significantly greater in the trac he a compared to uterus and aorta. This myosin isoform 
distribution in human smooth muscle is in general agreement with the rate of shortening 
assigned to phasic and tonic smooth muscles in previous animal studies, i.e. rapidly 
contraeting phasie muscle eontaining mostly the (+)insert isoform while the (-)insert 
isoform being predominantly present in slowly eontraeting tonie muscle. 
Correspondingly, the small intestine is deseribed in the guinea-pig as a typieal phasic 
muscle that eontracts rapidly to propel its content (Lofgren, Fagher et al. 2002). The 
rabbit stomach has two distinct regions in which the contractile function correlates with 
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the myosin isoform content: the antrum, which contains mostly the (+ )insert isoform, and 
the fundus, which contains mostly the ( -)insert isoform (Eddinger and Meer 2001). The 
total RNA we purchased came from whole human stomach which probably explains why 
we observed a relatively high content of both (+) and (-)insert isoform mRNA. At the 
protein level, however, we cannot be sure ofthe exact region from which the samples 
were taken which may explain why we observed a lower content in (+ )insert isoform. 
Although the urinary bladder is usually viewed as aphasie smooth muscle, it does not 
contract as frequently as the small intestine (Lofgren, Fagher et al. 2002). A lower 
amount of (+ )insert isoform than in the small intestine was therefore anticipated. 
Conversely, the aorta (Rhee and Brozovich 2000) and uterus (Haase and Morano 1996 ; 
Morano, Koehlen et al. 1997) are well characterized tonic muscles, and we showed here 
that in humans they express almost exclusively the (-)insert isoform mRNA. The rabbit 
trachealis, on the other hand, has been referred to as either a tonic (Horiuti, Somlyo et al. 
1989) or a phasic (Malmqvist and Amer 1991) smooth muscle. Topographical differences 
have also been reported in rat tracheal contractile properties; the segment closer to the 
main carina contracts more in response to an agonist (Florio, Styhler et al. 1996). Our 
results show that the human trachea contains mid-range levels of the (+ )insert isoform 
mRNA and high levels of (+)insert protein, but again we cannot be sure of the exact 
segments from which our samples were taken. It is worth noting that a previous study 
reported that the (+ )insert isoform mRNA was absent in human airways (Ma, Cheng et al. 
2002). However, using primers specific to human smooth muscle myosin, we selectively 
quantified each isoform and demonstrated unequivocally that the (+ )insert isoform 
rnRNA is expressed in human airways and we confirmed its presence at the protein level. 
While the regulation of the (+) and (-)insert isoforms by alternative splicing is still poorly 
understood, a reasonable correlation was observed between the rnRNA and prote in data 
(Figs. 3 & 5) suggesting minor post-transcriptional regulation. Furthermore, our 
quantitative rnRNA data suggest that tonic smooth muscle (uterus, aorta) is characterized 
by its lack of (+ )insert isoform. Together with our in vitro motility data that dernonstrate 
a rank correlation between the (+ )insert isoform expression and vrnax, this organ' s specifie 
(+ )insert myosin isoform expression strongly suggests a role for this isoform in 
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determining the rate of shortening of the whole muscle or even the whole organ. To our 
knowledge, this is the first study addressing the molecular mechanics of myosin purified 
from different organs from the same animaIs. Our conclusions, therefore, reflect the 
effects of the 7 amino acid insert and not other potential inter-species variability in the 
SMMHC sequence. 
Effects oflnsert on Contractilty: 
While the kinetic properties of smooth muscle are partially determined by the regulatory 
pathways leading to phosphorylation of the regulatory light chains, the differences in 
contraction kinetics between tonic and phasic smooth muscle remain even after complete 
phosphorylation, achieved either with ATPyS or ATP plus okadaic acid (Horiuti, Somlyo 
et al. 1989). Thus, it is likely that the acto-myosin complex plays an important role in 
conferring the kinetic differences between tonic and phasic smooth muscle. Indeed, in the 
present study we measured, in the in vitro motility assay, Vmax when actin was propelled 
by fully phosphorylated myosin purified from phasic and tonic muscle. The phasic 
muscle contained up to Il times more of the (+ )insert isoform than the tonic muscle 
(Fig.6) and propelled actin with an ~3-fold greater vmax. Previous studies have also 
measured V max in baculovirus expressed constructs differing only by the 7 amino-acid 
insert and similar results were reported (Rovner, Freyzon et al. 1997; Lauzon, Tyska et al. 
1998). Something intrinsic to the insert therefore alters the kinetics of muscle contraction 
and evidence is accumulating to suggest that the insert affects the release of MgADP 
(Fuglsang, Khromov et al. 1993; Khromov, Somlyo et al. 1995; Lauzon, Tyska et al. 
1998; Sweeney, Rosenfeld et al. 1998) which is the rate limiting step in shortening 
velo city (Siemankowski, Wiseman et al. 1985). Tuning of the myosin molecule to alter 
the release of MgADP is therefore an attractive mechanism to explain the differences in 
smooth muscle rate of shortening. Indeed, Somlyo and coworkers (Fuglsang, Khromov et 
al. 1993; Khromov, Somlyo et al. 1995) showed, at the tissue level, a greater affinity for 
MgADP of tonic rabbit femoral artery than phasic rabbit bladder and guinea pig portal 
vein. U sing the laser trap at saturating MgA TP levels, we showed a 2-fold faster rate of 
MgADP release for (+)insert isoform constructs (Lauzon, Tyska et al. 1998). 
Furthermore, we recently found a greater affinity for MgADP of purified tonic calf aorta 
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myosin compared to phasic chicken gizzard myosin in the in vitro motility assay 
(Leguillette 2004). This is perhaps not surprising because the 7 amino acid insert is 
strategically located in surface 100p-1, right above the nucleotide binding pocket, 
potentially altering the MgADP binding site. 
According to our in vitro motility measurements, as well as those from previous studies 
(Kelley, Takahashi et al. 1993; Rovner, Freyzon et al. 1997; Lauzon, Tyska et al. 1998), 
the expression of the (+)insert SMMHC isoform can on1y explain a two to three-fold 
difference in rate of shortening. Considering that at the tissue level, greater differences in 
rate of shortening have been reported between tonie and phasic smooth muscles (Murphy, 
Walker et al. 1997), other mechanisms must also contribute to the kinetics of the whole 
muscle. The three-dimensional arrangement of the myosin filaments and their 
interactions with regulatory and other contractile proteins are alllikely to contribute to 
the rate of smooth muscle shortening. These factors will require further investigation. 
(+ )insert SMMHC Isoform in Pathology: 
Alterations of the (+ )insert SMMHC isoform expression has been studied in many 
models ofpatho10gy. Expression of the (+)insert SMMHC isoform decreases by 50% in 
the hypertrophied rat urinary bladder while the maximal shortening velocity and rate of 
force development decreases by 20% and 25%, respectively (Sjuve, Haase et al. 1996). 
The maximal shortening velocity of the guinea-pig hypertrophie small intestine decreases 
by 50% and is accompanied by a significant decrease in (+ )insert SMMHC isoform 
expression and an increased MgADP sensitivity (Lofgren, Fagher et al. 2002). An 11-fold 
greater expression of the (+ )insert SMMHC isoform is measured in the hyperresponsive 
rat of a genetic model of asthma (Lauzon 2001). The rate of contraction of explanted 
airways was aiso shown to be greater in airways of these hyperresponsive animaIs 
(Wang, Aimirall et al. 1997). Other studies have also shown alterations in the (+ )insert 
SMMHC isoform expression in pregnancy or in models of diseases, though the 
correlation to muscle function is not as clear (Morano, Erb et al. 1993; Siegman, Butler et 
al. 1997). The results of our study, demonstrating the presence of the (+ )insert SMMHC 
isoform in human organs, are therefore timely in supporting the increasing interest in the 
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investigation of the expression and function of the (+)insert SMMHC isoform in various 
models ofhuman pathology. 
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VII- Figures: 
Fig. 1 A: PCR amplification products from cDNA derived from hum an bladder 
RNA. The primers were designed to amplify both the (+) and (-)insert SMMHC 
isoforms. Results presented in duplicate. B: Nucleotide sequence encoding for the 
(+)insert amino acid sequence in human, rat, mouse, chicken, and rabbit mRNA. 
The 21 bp sequences are identical in the human and rat, but differ by 1 bp in the mouse, 2 
bp in the rabbit, and 3 bp in chicken. 
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Fig. 2: Total SMMHC. Absolute quantification of human total SMMHC cDNA in a 
panel of organs (mean±SE). Measurements were performed in triplicate on commercial 
RNA pooled from 5-59 individuals. The inset shows the standard curve used. 
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Fig. 3: (+)insert isoform cDNA analysis: Relative quantification of the human (+)insert 
SMMHC isoform with respect to the content in the calibrator organ, smaU intestine, and 
normalized to total SMMHC (mean±SE). Measurements were performed in triplicate on 
commercial RNA pooled from 5-59 individuals. Statistical differences were found 
between the smaU intestine and aU other organs (p<O.05), between the stomach and an 
other organs (p<O.05), and between the trachea and uterus or aorta (p<O.05). 
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Fig. 4: (-)insert isoform cDNA analysis: Relative quantification of the human (-)insert 
SMMHC isoform with respect to the content in the calibrator organ, uterus, and 
normalized to total SMMHC (mean±SE). Measurements were performed in triplicate on 
commercial RNA pooled from 5-59 individuals. The uterus, stomach and aorta express 
statistically more (-)insert than the bladder and small intestine (p<O.05). 
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Fig.5 A: Western blot ofhuman SMMHC and (+)insert protein: Western blot of total 
SMMHC and (+)insert isoform prote in in the aorta, uterus, bladder, trachea, stomach, 
small intestine and brain. In these representative western blots, 160 and 60 Ilg of total 
protein were loaded onto the gel for detection of the (+ )insert SMMHC isoform and total 
SMMHC, respectively. B: Human (+)insert isoform protein analysis: Relative 
quantification of the human (+)insert SMMHC isoform with respect to the small 
intestine, and normalized to total SMMHC (mean±SE). The Western blots were repeated 
6 times on commercial samples pooled from severa! subjects. AlI organs except the 
trachea express statistically less (+ )insert prote in than the small intestine and the aorta 
and uterus express statistically less (+)insert than the trachea (p<0.05). 
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Fig. 6 A: Western blot of rat SMMHC and (+)insert protein: Western blot of total 
SMMHC and (+)insert isoform protein in the aorta, uterus, bladder, trachea, stomach and 
small intestine. 50 Ilg of total protein were loaded onto the gel. B: Rat (+)insert isoform 
protein analysis: Relative quantification of the rat (+ )insert SMMHC isoform with 
respect to the small intestine, and normalized to total SMMHC (mean±SE). The Western 
blots were performed in triplicate on samples pooled from 4 rats. The pattern of 
expression of the (+)insert isoform was not different to that in human p=0.45). 
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Fig.7 A: Rate of actin filament movement in the in vitro motility assay: Rate of actin 
filament movement (vmax) when propeUed by myosin purified from rat aorta, uterus, 
bladder, trachea, and smaU intestine (mean±SD). V rnax measurements were repeated 5 
times with myosin pooled from 16 rat organs. Statistical differences were found between 
aU organs (p<O.05). B: Rate of actin filament movement vs (+)insert protein 
expression: A significant rank correlation was observed (p<O.05). 
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_.,r- Fig. 8: Alternative splicing at the 5' and 3' ends of the SMMHC: Schematic 
illustrating the proposed mechanism for the alternative splicing of the mRNA that occurs 
in the human SMMHC at the 5' and 3' ends. Inclusion ofexon 5b generates the (+)insert 
isoform, whereas inclusion of exon 41, encoding a stop codon, generates the shorter 
(200kDa SM2 isoform). The insert is shown in bold and underlined. 
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Chapter 3: 
Myosin SM-B isoform, SM22, and MLCK are upregulated in mild 
asthmatic endobronchial biopsies 
83 
1- Prologue: 
Asthma is characterized by airway obstruction, enhanced bronchial responsiveness, and 
airway inflammation. It is now well accepted that smooth muscle hypercontractility is a 
major contributor to the symptoms observed in asthma. Tidal breathing and deep 
inspiration have a bronchodilating effect in normal subjects but not in asthmatics. One 
hypothesis to explain this phenomenon is that airway smooth muscle from asthmatics 
contracts faster, thus catching back the dilatation induced by tidal stretch. An increase in 
airway smooth muscle rate of shortening has already been described in animal models of 
hyperresponsiveness and in human asthma. Thus, 1 investigated the expression of 
contractile protein genes in endobronchial biopsies from asthmatic and control subjects 
and tested their function in the in vitro motility assay. 
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II - Abstract: 
Airway smooth muscle (SM) exhibits a greater velocity of shortening (Vmax) in 
asthmatics than in normals. This increase in V max is believed to counteract the relaxing 
effect of tidal breathing, thus maintaining asthmatic airways constricted. A greater V max 
can result from increased myosin activation. This has been reported in sensitized human 
airway SM and in models of asthma. A faster Vmax can also result from the expression 
of specifie contractile protein genes that promote faster cross-bridge cycling. This 
possibility has never been addressed in asthma. We hypothesized that the expression of 
SM genes is altered in asthmatic airways, thus contributing to their increased Vmax. We 
quantified the expression of several SM genes in human airway endobronchial biopsies 
and found that the fast SM myosin heavy chain isoform (SM-B), transgelin (SM22), and 
myosin light chain kinase (MLCK), are increased in mild allergic asthmatics. 
Furthermore, we showed by immunohistochemistry that the se genes are expressed at the 
protein level in both normals and asthmatics. To address the functional significance of 
this overexpression, we purified tracheal myosin from Fisher and Lewis rats, a model of 
innate airway hyperresponsiveness, and found a faster rate of actin filament propulsion 
(vrnax) in the in vitro motility assay for myosin from the hyperresponsive rats. Moreover, 
we showed that, beyond its enzymatic effects, MLCK can mechanically increase vrnax• 
Conversely, SM22 did not alter Vrnax• Our findings suggest that selective overexpression 
of SM genes in asthmatic airway leads to increased Vmax, thus contributing to the airway 
hyperresponsiveness observed and asthma. 
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111- Introduction: 
The primary features of asthma are airway inflammation, bronchial hyperresponsiveness 
and intermittent airway obstruction. Altered airway smooth muscle (SM) function is 
considered to be an important contributor to airway hyperresponsiveness and asthma 
(Martin, Duguet et al. 2000). As suggested by mathematical models, airway narrowing 
results from a balance between the contraction produced by airway SM and the 
impedance of the surrounding tissues (Lambert, Wiggs et al. 1993; Macklem 1996). 
Asthmatic airway SM exhibits enhanced contractility (Bjorck, Gustafsson et al. 1992; 
Mitchell, Ruhlmann et al. 1994). This could be due to an increased SM mass and/or 
increased power of the contractile apparatus. Although still controversial, it is now 
believed that increased SM mass alone does not account for airway hyperresponsiveness 
(Eidelman, DiMaria et al. 1991; Thomson, Bramley et al. 1996; Thomson and 
Schellenberg 1998). Conversely, a greater velocity of airway SM shortening (Vmax) has 
been observed in many animal models of asthma (Antonissen, Mitchell et al. 1979; Fan, 
Yang et al. 1997; Duguet, Biyah et al. 2000), in sensitized human bronchi (Mitchell, 
Ruhlmann et al. 1994), and in single SM cells from asthmatic human airways (Ma, Cheng 
et al. 2002). A greater Vmax is likely to counteract the relaxing effect oftidal breathing 
and could therefore maintain asthmatic airway SM in a more constricted state (Gunst 
1983; Solway and Fredberg 1997). While a greater force generating capacity would also 
contribute to an increased muscle power, several studies have reported that there was no 
difference in isometric force generation between asthmatic and control airway SM 
(Whicker, Arrnour et al. 1988; Bai 1991). 
The contractile apparatus is responsible for muscle force and movement production. 
Vmax depends on the proteins involved and their level of activation. Myosin is the 
molecular motor that drives muscle contraction. Alternative splicing of the SM myosin 
heavy chain (SMMHC) gene generates four isoforms. Splicing in the 5' region results in 
the expression oftwo isoforms that differ by the presence (SM-B) or the absence (SM-A) 
of a seven amino acid insert in the surface loop above the nucleotide binding pocket 
(Babij 1993; White, Martin et al. 1993). The SM-B and SM-A isoforms are also referred 
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to as (+) and (-) insert isoforms, respectively. Splicing in the 3' region leads to the 
expression oftwo isoforms that differ by distinct sequences of 43 (SM-l) or 9 (SM-2) 
amino acids at the carboxy terminal (Eddinger and Murphy 1988; Nagai, Kuro-o et al. 
1989). Although no differences in the molecular mechanics of SM-l and SM-2 have been 
reported, SM-B propels actin filaments at two times the velocity (vrnax) of SM-A, in the in 
vitro motility assay (Kelley, T akahashi et al. 1993; Rovner, F reyzon et al. 1997; Lauzon, 
Tyska et al. 1998). The expression and function of these SMMHC isoforms in airway SM 
hypercontractility has never been thoroughly addressed. 
It is weIl established that smooth muscle contraction is mainly regulated by 
phosphorylation ofthe myosin regulatory light chains (LC20) by myosin light chain 
kinase (MLCK) (Sobieszek 1977). Recently, it has been shown that MLCK can bind 
simultaneously to myosin and actin, and that this binding stimulates the ATPase activity, 
independently of the phosphory lation activity (Sellers and Pato 1984; Okagaki, 
Hayakawa et al. 1999; Ye, Kishi et al. 1999). Increased expression of MLCK has been 
described in models of asthma and in human airway SM (Jiang, Rao et al. 1992; Ammit, 
Armour et al. 2000; Benayoun, Druilhe et al. 2003) but its mechanical role in the 
enhancement of Vmax has never been addressed. Actin binding proteins are also known 
to alter SM cross-bridge kinetics. For example, caldesmon decreases both the ATPase 
activity and Vrnax (Okagaki, Higashi-Fujime et al. 1991; Haeberle, Trybus et al. 1992) 
whereas tropomyosin increases Vrnax (Okagaki, Higashi-Fujime et al. 1991). However, the 
expression of actin binding proteins has never been addressed in airway 
hyperresponsiveness and asthma. 
In this study, we hypothesized that the expression of genes that code for contractile 
proteins is altered in asthmatic airway SM, thus contributing to their increased Vmax. We 
found that the expression of SM-B, transgelin (SM22) and MLCK is increased in 
endobronchial biopsies from humans affected with mild asthma. Furthermore, we found 
that the myosin purified from airways of the Fisher rats, an animal model of innate 
bronchial hyperresponsiveness that overexpresses SM-B in airway SM, has a greater Vrnax 
than myosin from controls. We also found that MLCK, in addition to its enzymatic 
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activity, can mechanically enhance vrnax • Conversely, SM22 had no effect on cross-bridge 
cycling rate. Our findings suggest that the selective contractile protein gene expression in 
asthmatic airway SM leads to increased velocity of shortening, thus contributing to the 
airway hyperresponsiveness observed in asthma. 
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IV - Material and methods: 
Selection of subjects for endobronchial biopsies: 
Eight asthmatic subjects, whose diagnoses were made according to the definition of the 
American Thoracic Society and eight healthy subjects without allergy history, asthma, 
nor occupational exposure to sensitizing agents were recruited. The clinical 
characteristics of the subjects are provided in Table 1. Evaluation included a medical 
history, physical examination, skin prick tests to common allergens (Omega, Montreal, 
Canada), spirometry, and measurements of airway responsiveness to inhaled 
methacholine according to standardized procedures (ATS 1987). AlI subjects were 
nonsmokers and had not had respiratory infection within the last 2 months. Asthmatics 
were stable and were receiving a treatment of inhaled f32-agonist on demand, but no 
inhaled corticosteroid therapy. Control subjects had no systemic disease, were not 
receiving any medication, and had negative skin prick tests. The study was approved by 
the Laval Hospital and the Montreal Chest Institute Research Ethics Board of McGill 
University Health Center and all subjects provided written informed consent for their 
participation. 
Bronchoscopy and endobronchial biopsy process: 
Oxygen was administered at 5 Llmin by a nasal catheter, and vital signs, 
electrocardiogram, and oxymetry data were monitored during the bronchoscopy. Local 
anesthesia of the airways was done with 2 or 4% lidocaine, up to a total dose of 400 mg. 
A flexible bronchoscope (Olympus OES 10 fiberscope; Olympus, Markham, Canada) and 
alligator forceps (Olympus FB-15C-l) were used for the procedure. Six to seven 
specimens were taken from the origins of sub-segmental, segmental or lobar bronchial 
carinae and kept in RNA-Iater® solution (Qiagen Inc., Mississauga, Canada) for mRNA 
extraction. In 1 control and 2 asthmatics, additional biopsies were taken and fixed in 4% 
paraformaldehyde for immunohistochemistry. 
Relative quantification of contractile mRNA by real-time peR analysis: 
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We quantified by real-time PCR the mRNA expression ofmyosin isoforms (SM-l, SM-2, 
SM-A, SM-B), actin isoforms (a, y), SM myosin light chain kinase (MLCK), 
tropomyosin isoforms (a, 13), SM caldesmon, and transgelin (SM22) in the endobronchial 
biopsies of five asthmatic and five healthy subjects. AIl primer sets spanned at least one 
intron. The sequence of the primers is shown in Table 2. The primer set called "Total 
SMMHC" amplifies the four SMMHC isoforms because it targets a region not subject to 
alternative splicing. The six to seven biopsies from each patient were pooled and 
homogenized in RNAlater® buffer and total RNA was extracted using a commercial kit 
(Mini Prep, Qiagen) following the manufacturer's recommendations. l!lg of RNA from 
each of these subjects was reverse transcribed simultaneously to minimize variability. 
PCR reactions were performed in a volume of 20!l1, containing 1 !lI cDNA, 10 !lL 2x 
QuantiTect SYBR® Green PCR (Qiagen), 7 !lL ofnuclease-free H20, and 1 !llofboth 
the forward and reverse primers (final concentration 0.1 !lmol each). The samples were 
amplified in a LightCycler® system (Roche Diagnostics). The real-time PCR conditions 
consisted of a denaturation step of 15 minutes at 95°C followed by an amplification of 50 
cycles (denaturation at 95°C for 15 s, annealing at 60°C for 20 s and extension at noc 
for 20s) and 1 melting curve cycle. PCR reactions were performed in triplicates, i.e. 3 
repeats on the same RNA sample pooled from each subject. Each primer set generated 
only one PCR product. PCR reaction efficiencies were ca1culated for each reaction 
following a previously described method (Liu and Saint 2002; Liu and Saint 2002) and 
were used for relative quantification with REST© software (v2) (Pfaffl, Horgan et al. 
2002). Results were expressed in fold increase in asthmatics compared to controls, using 
the ribosomal protein S9 as a reference gene and a correction was made for the 
differences in primer efficiency. 
Immunohistochemistry on biopsies: 
Protein expression ofthe SM-B SMMHC isoform, SM22, and MLCK was verified by 
immunohistochemistry in five asthmatic and five control subjects (sorne of the subjects 
were tested both at the mRNA and protein levels, see table 1). The paraformaldehyde-
fixed biopsy specimens were dehydrated in a1cohol, incubated in xylene and embedded in 
blocks of fresh molten paraffin wax. Sections of 5 !lm were made with the cutting angle 
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in the axis of the bronchial mucosa. For general assessment of the tissue, three slides 
were deparaffinized, rehydrated and stained with hematoxylin-eosin. Only biopsies with 
smooth muscle bundles and preserved morphology were used. A peroxidase protocol for 
paraffin embedded sections was used for immunohistochemistry. For each target prote in, 
aIl procedures were performed simultaneously and in the same conditions for asthmatics 
and normals. Slides were deparaffinized in xylene and in decreasing concentrations of 
a1cohol. Tissues were permeabilized with Triton 0.2% and incubated with 5% peroxide 
except for MLCK, where they were initially incubated in citrate buffer (10 mM citric 
acid, pH= 6.0). After blocking with universal blocking solution for 30 min (Dako, 
Carpinteria, CA), sI ides were incubated overnight with the following anti-human primary 
antibodies against the SM-B SMMHC isoform (SM-B7, gift from Dr. A. Rovner, U. 
Vermont) (Low, Mitchell et al. 1999), SM22 (ablO135, ABCam), and MLCK (M7905, 
Sigma). Subsequently, the slides were incubated with biotinylated secondary antibody 
(E0453, Dako) and with ABC complex (Dako), and were then stained with DAB 
(diaminobenzidine)-chromogen (Dako) and counterstained with hematoxylin. 
To control for non-specific binding, a competitive pre-adsorption test was performed. A 
synthetic peptide of the seven amino acid insert sequence (QGPSF A Y), purified smooth 
muscle MLCK (generous gift from Dr. 1. Heaberle), and recombinant SM-22 (see below) 
were incubated for 2 hours at room temperature with their respective antibodies at a 
molar ratio of 1: 1 00. Incubation of slides with the se antigen-antibody complexes were 
then performed, in the same conditions as described above. 
Mo/ecu/ar mechanics: 
We used the in vitro motility assay to quantify the rate of actin filament movement (vrnax) 
when propelled by myosin molecules. The in vitro motility assay was described before 
(Lauzon, Tyska et al. 1998; Leguillette, Gil et al. 2005). The buffers were as follows: 
myosin buffer (300mM KCI, 25mM imidazole, ImM EGTA, 4mM MgCh, 25mM DTT, 
pH 7.4); actin buffer (25mM KCI, 25mM imidazole, ImM EGTA, 4mM MgCh, 25mM 
DTT, pH 7.4); and motility buffer (0.5% methy1cellulose, 2mM MgATP, 25mM KCI, 
25mM imidazole, ImM EGTA, 4mM MgCh, 25mM DTT, pH 7.4) combined with an 
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oxygen scavenger (O. 1 mg/ml glucose oxidase, 0.018mg/ml catalase, 2.3mg/ml glucose). 
Myosin regulatory light chains were thiophosphorylated with 0.6mM ATPyS, 7.5IJ.M 
calmodulin, 5IJ.M MLCK, 0.2mM CaCh and 2mM MgCh. Inactive myosin molecules 
were removed by ultracentrifugation (Lauzon, Tyska et al. 1998). Myosin (0.25mg/ml) 
was then perfused into a flow-through chamber (Warshaw, Desrosiers et al. 1990) and 
allowed to attach randomly onto the nitrocellulose-coated glass. Inactive myosin 
molecules were further inhibited by the addition of monomeric uniabelled actin dissolved 
in actin buffer. Actin fluorescently labeled with tetramethylrhodamine isothiocyanate 
phalloidin (TRITC P1951, Sigma) in actin buffer was then perfused into the chamber, 
followed by motility buffer. Actin movement was recorded by a SIT camera, digitized 
and analyzed (Scion-Image software). Measurements were made at 30 oC. V rnax was 
reported in IJ.m/sec ± SD. V rnax was measured for three separate purifications from each rat 
strain. For each in vitro motility assay, the movement of a minimum of ninety filaments 
was analyzed. 
Protein purification for the in vitro motility assay: 
Tracheal SM myosin was purified from 8 Fisher and 8 Lewis rats, following our 
previously described protocol for small samples (Leguillette, Gïl et al. 2005). AlI 
experiments were conducted in compliance with the animal ethics committee of Mc Gill 
University. Chicken gizzard SM myosin was purified following a standard protocol 
(Sellers, Pato et al. 1981). Skeletal myosin was a generous gift from Dr. P. VanBuren (u. 
of Vermont). Unregulated actin was purified from chicken pectoralis acetone powder 
following the Pardee and Spudich protocol (Pardee and Spudich 1982). Recombinant 
SM22 was generated in Escherichia coli as previously described (Fu, Liu et al. 2000). 
Briefly, cDNA containing the full-iength SM22 coding region was ligated in frame into 
BamH 1- and Hind Ill-digested pQE-30 bacterial expression vector (Qiagen) containing 
an NH2-terminal MRGHHHHHHGS "His" tag. Recombinant His-tagged SM22 was 
expressed in Escherichia coli and batch purified under native conditions using nickel [Ni-
nitrilotriacetic acid (NTA)] beads (Qiagen). Transformed E. coli were grown to optical 
density of 0.6-1.0 at 600 nm, and then recombinant protein expression was induced for 
6 h with 1 mM isopropyl-j3-D-thiogalactopyranoside. Bacteria were lysed on ice for 30 
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min in buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCI, 10 mM 
imidiazole, and 1 mg/ml lysozyme followed by sonication on ice using a microtip. Lysate 
was centrifuged to remove cell debris, and then Ni-NT A beads were added and allowed 
to bind at 4°C for 30 minutes. Bound proteins and beads were washed 4 times with 
50 mM sodium phosphate pH 8.0, 300 mM NaCI and 50 mM imidiazole. The retained 
proteins were eluted and stored in buffer containing 50 mM sodium phosphate pH 
8.0,300 mM NaCI, 250 mM imidazole, and protease (serine, cysteine, calpain, and 
metalloprotease) inhibitors (Roche). Two purifications of SM22 recombinant protein 
were done and tested in the in vitro motility assay. 
Incubation, cosedimentation and immunoprecipitation of SM22 with actin for the in vitro 
motility assay: 
SM22 was bound to unregulated actin following a previously described protocol (Fu, Liu 
et al. 2000) with slight modifications. Briefly, recombinant SM22 (3I-lM) was incubated 
in presence ofunregulated monomeric actin (IOI-lM) and tetramethylrhodamine 
isothiocyanate phalloidin (lOI-lM) (Sigma) for 12 hours at 4°C in a buffer containing 
12mM KPi (pH=6.8), 20mM imidazole, 24mM NaCI, 2mM MgCh, ImM ATP, ImM 
EGTA. To ascertain that only SM22-bound actin was used in the in vitro motility assay, 
co sedimentation of actin with SM22 was performed, and the pellet was washed twice and 
resuspended in actin buffer before use in the in vitro motility assay. For cosedimentation, 
the actin-SM22 solution was spun at 100,000g for 21 minutes. We further verified that 
the pellet contained mostly actin-bound SM22 using immunoprecipitation. The acto-
SM22 mixture was incubated with an actin-specific antibody (#4700, Sigma) at 4°C. 
Protein-A sepharose beads (Amersham) were then incubated with the acto-SM22 solution 
for one hour before being spun down at 15000rpm for 2 minutes. The supernatant and the 
pellet were then boiled in Leammli buffer and loaded onto a gel for SDS-PAGE, 
followed by Western blotting (described below), with a primary antibody that targeted 
SM22 (ablO135, ABCam). To ascertain the sepharose beads were not non-specifically 
pulling down actin or SM22, control experiments were performed using different primary 
and secondary antibodies as shown in figure 8B. 
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MLCK incubation with skeletal myosin: 
To bind MLCK to skeletal myosin, MLCK (l ~M) was incubated for 1 hour at 4°C with 
skeletal myosin (l ~M) in myosin buffer. 
SDS-P A GE and Western Blotting of purified myosin: 
The relative content of the SM-B myosin isoform with respect to total myosin in the 
Fisher and Lewis rat trachealis purifications was determined by Western blot analysis. 
Proteins were separated by SDS-PAGE using a 7% acrylamide gel. Equal volumes of 
myosin solutions were loaded onto a single gel. Protein concentration was estimated by a 
standard Bradford assay, and 1 OO~g of proteins were loaded in each weIl. Proteins were 
transferred electrophoretically onto nitrocellulose membranes (Bio-Rad). Membranes 
were blocked with 5% nonfat milk and probed with the polyclonal SM-B6 antibody that 
specifically recognizes the 7 amino acid insert QGPSF A y (White, Martin et al. 1993; 
Low, Mitchell et al. 1999), or with the polyclonal BT-562 antibody (Biomedical 
Technologies Inc.) that recognizes aIl SMMHC isoforms. Antibody detection was done 
by Enhanced Chemiluminescence (Amersham) and quantification was performed with a 
Fluorchem 8500 imaging system using AlphaEase software (Alpha Innotech). 
Quantification was performed for three separate purifications, and loaded in duplicate for 
each rat strain, on six nitrocellulose membranes (Fig. 5B). The results are reported as 
mean±SE. 
Statistica! Analysis: 
Differences in mRNA expression between biopsies from asthmatics and controls were 
tested using Pair Wise Fixed Reallocation Randomisation Test© in REST© software (v 
2). Differences in the SM-B tracheal protein content and in V max between Fisher and 
Lewis rats, between actin bound SM22 and no SM22, and between myosin incubated 
with MLCK and no MLCK, were aIl tested using Student' st-tests. Significance was 
considered for values of p<0.05. 
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v- Results: 
Contractile gene expression in asthmatic and control endobronchial biopsies: 
We quantified, by real time PCR, the expression of SM-specifie contractile genes in 
endobronchial biopsies from asthmatic and control subjects (Fig. 1 ). The housekeeping 
gene ribosomal S9 unit was very stable and had similar levels in asthmatic and control 
biopsies (Asthmatic/control: + 1.03, p= 0.78). Thus, ribosomal S9 was an adequate 
housekeeping gene. There was no significant difference between asthmatics and controls 
mRNA expression in the SMMHC SM-l isoform, tropomyosin (3, caldesmon, and 
a-actin. The expression oftropomyosin a (Asthmatic/control: 0.78, p<0.03) and y-Actin 
(Asthmatic/control: 0.53, p<O.OI) was significantly lower in asthmatics compared to 
controls. Conversely, the mRNA expression of total SMMHC, SM-2, SM-A, SM-B 
isoforms was significantly upregulated in asthmatics, along with significant upregulation 
of SM22 and MLCK. The increase in SM-A expression (Asthmatic/control: 1.63, 
p<0.002) and SM-2 (Asthmatic/control: 1.53, p<0.005) was of similar magnitude as that 
of total SMMHC (Asthmatic/control: 1.69, p<O.OOI). SM-B (Asthmatic/control: 2.41, 
p<0.007) showed the greatest upregulation among SMMHC isoforms, and was the only 
myosin isoform with a significant upregulation in asthmatics relatively to total SMMHC. 
SM22 (Asthmatic/control: 2.18, p<0.005) was also highly upregulated, whereas the 
upregulation ofMLCK (Asthmatic/control: 1.21, p<0.05) was modest. Thus, these results 
show that the mRNA encoding for the SM-B SMMHC isoform, SM22, and MLCK is 
upregulated in mild asthmatic endobronchial SM. 
SM-B isoform, SM22 and MLCK immunohistochemistry: 
To confrrm that SM-B, SM22 and MLCK are also expressed at the protein level in human 
airways, we performed immunohistochemistry on the endobronchial biopsies. The 
positive staining for the SM-B SMMHC isoform had a granular pattern (Figs. 2A and B). 
At high magnification the staining was intracellular and had an elongated spindle shape 
when the muscle bundle was eut longitudinally (Figs. 2A and B). Interestingly, the SM-
B-positive cells were usually dispersed homogeneously in the SM tissue although they 
were seldom grouped (Figs.2A and B). The positive staining for SM22 was also granular 
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and intracellular (Figs. 3A and B). The SM22-positive cells were also dispersed 
homogeneously in the SM tissue (Figs. 3A and B). The staining for MLCK also 
confirmed its expression in the airway SM cells at the protein level (Figs. 4A and B). The 
absence of staining after competitive pre-adsorption (Figs. 2C, 3C, 4C) confirmed that 
the signal was specific in aIl cases. 
Fisher and Lewis rat tracheal smooth muscle molecular mechanics and isoform 
expression: 
To verify if overexpression of the SM-B isoform contributes to muscle hypercontractility, 
we measured the rate of actin filament propulsion (vmax) in the in vitro motility assay of 
purified Fisher and Lewis rat trachealis myosin. V max was significantly faster for the 
myosin purified from Fisher rat tracheae (0.61 !Amis ±0.01) than from Lewis rat tracheae 
(0.47 !Amis ±0.01) (p<O.OOl; Figure 5A). To then verify that myosin purification did not 
alter the previously reported SM-B content in Fisher and Lewis rat trachealis (Gil, 
Zitouni et al. 2006), we performed Western blot analysis. The hyperresponsive Fisher rat 
trachealis had 1.8 ±0.2 fold more of the SM-B isoform (p<O.OOI) than the 
hyporesponsive Lewis rat (Fig. 5B). The difference between Fisher and Lewis rats is of 
the same magnitude as what we observed between the asthmatic and control biopsies 
(Fig. 1). Altogether, these data suggest that the overexpression of the SM-B isoform 
results in a faster myosin cycling velocity, thus a faster velocity of SM contraction. 
Molecular mechanics of MLCK-bound skeletal myosin: 
To verify if, in addition to its enzymatic role, MLCK could also mechanically enhance 
myosin function, we measured V max in the in vitro motility assay for skeletal myosin 
before and after incubation with MLCK. The MLCK-bound skeletal myosin propelled 
actin filaments significantly faster (3.96 !Amis ±0.12) than the myosin free of MLCK 
(2.96 !Amis ±0.21) (p:S0.001; Fig. 6). Because skeletal myosin is not activated by MLCK, 
this increase in velocity was not due to MLCK enzymatic activity. These data suggest 
that, in addition to phosphorylating SM LC2o, MLCK enhances the rate of SM shortening 
by a direct mechanical effect on myosin. 
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Mo/ecu/ar mechanics ofSM22-bound actinji/aments: 
To verify if the over-expression ofSM22 observed in the asthmatic subjects might 
contribute to muscle hypercontractility, the molecular mechanics of SM22-bound actin 
filaments, when propelled by myosin molecules, was assessed in the in vitro motility 
assay. No difference in Vmax was observed when SM22 was completely absent (O.79f.unls 
±O.Ol) or when it was bound to actin (O.79~m1s ±O.02) (Fig. 7). The binding ofSM22 to 
actin was verified by immunoprecipitating the cosedimented actin-SM22 with an actin-
specifie antibody, and analyzing by Western blotting with an SM22-specific antibody 
(Fig. 8A). SM22 was mostly found in the pellet obtained after immunoprecipitation of 
actin, showing that actin was effectively bound to SM22 (Fig. 8A). Specificity of the 
immunoprecipitation procedure was verified by control experiments with antibodies 
against P44 MAP kinase and the chemokine CCR5 (Fig. 8B). These data show that, at the 
molecular level, SM22-bound actin does not directly alter cross-bridge cycling rate. 
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VI- Discussion: 
ln this study, we found that the expression of specific genes encoding for SM contractile 
proteins is upregulated in asthrnatic bronchial biopsies. Significantly, we showed from a 
rat model of airway hyperresponsiveness that the upregulation of the SM-B myosin 
isoform leads to a faster rate of actin filament propulsion (vrnax) in the in vitro motility 
assay. Because V rnax correlates with unloaded shortening velocity (Sheetz, Block et al. 
1986; Umemoto and Sellers 1990), a greater expression of the SM-B isoform contributes 
to the faster rate of airway SM shortening. We also found that SM22 is overexpressed in 
asthrnatic bronchial biopsies. However, we did not elucidate its function at the molecular 
level. Finally, we demonstrated that in addition to its enzymatic properties, MLCK has a 
direct mechanical effect on myosin, also increasing its Vrnax, thereby contributing to the 
faster rate of asthrnatic airway SM shortening. 
Smooth muscle rate of shortening and airway hyperresponsiveness 
There is ample evidence suggesting that airway diameter increases with each inspiration 
(see (Solway and Fredberg 1997) for a review). AIso, ifprevented from taking deep 
inspirations, normal humans respond similarly to asthrnatic subjects when challenged 
with bronchoconstrictive agents (Skloot, Permutt et al. 1995; Moore, Verburgt et al. 
1997). From those observations, Gunst (Gunst 1983) and Solway and Fredberg (Solway 
and Fredberg 1997) suggested that the kinetics of muscle contraction play a crucial role 
in bronchial hyperresponsiveness. That is, tidal breathing and especially deep inspirations 
putatively allow for detachrnent of cross-bridges. This must have a more pronounced 
relaxing impact on slowly contracting muscles than on fast ones, i.e. rapidly contracting 
muscle probably constricts to a greater extent between each breath or after deep 
inspirations (Gunst 1983; Solway and Fredberg 1997). Indeed, there is evidence that 
airway re-narrowing occurs faster in asthrnatics than controls (Jackson, Murphy et al. 
2004). Our results ofalterations in expression ofrnRNA from the contractile machinery, 
along with our in vitro motility data, offer molecular mechanisms to explain the increased 
rate of airway SM shortening observed in airway hyperresponsiveness and asthrna. 
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,- The raIe of SM-B in asthma: increased velocity of shortening of airway SM 
The rate of shortening of airway SM is increased in human asthmatic SM cells (Ma, 
Cheng et al. 2002), human sensitized airways (Mitchell, Ruhlmann et al. 1994), and 
animal models of bronchial hyperresponsiveness (Antonissen, Mitchell et al. 1979; Fan, 
Yang et al. 1997; Duguet, Biyah et al. 2000; Blanc, Coirault et al. 2003). In the current 
study, we showed that the mRNA expression of SM-B doubles in airway SM from mild 
asthmatics compared to normals. Furthermore, we demonstrated that an increased SM-B 
isoform content in airway SM has a functional impact by measuring Vmax for myosin 
purified from Fisher and Lewis rat trachealis muscle. We chose this animal model 
because fresh human airway SM is not readily available, and because the Fisher rats are 
hyperresponsive (Eidelman, DiMaria et al. 1991; Gil, Zitouni et al. 2006) and express 
more SM-B than the Lewis rats (Gil, Zitouni et al. 2006), as also shown in figure 5B. 
Interestingly, the difference in SM-B isoform expression between Fisher and Lewis rats 
is of the same magnitude as what we observed between asthmatic and control human 
biopsies. 
Myosin is a mechano-enzyme: the breaking of MgATP leads to actin binding and a 
conformational change that results in the translational movement of actin. Structural 
differences between the SM-B and SM-A SMMHC isoforms explain the differences in 
their contractile kinetics. The 7 amino acid insert is strategically located to alter the in 
and out movement of the nucleotide (Kelley, Takahashi et al. 1993; White, Martin et al. 
1993) (For review cf (Low, Leguillette et al. 2006)). Indeed, it has been shown that the 
presence of the insert increases the flexibility of the loop above the nucleotide binding 
pocket, and as a consequence, facilitates the binding of MgA TP and the release of the 
hydrolysis product, MgADP (Sweeney, Rosenfeld et al. 1998). This was confrrmed in our 
previous study(Lauzon, Tyska et al. 1998) in which we used a laser trap to demonstrate 
that the time of attachment of SM-B to actin is half that of SM-A, thereby explaining the 
2-fold faster Vmax for SM-B measured in the in vitro motility assay (Kelley, Takahashi et 
al. 1993; Rovner, Freyzon et al. 1997). In the same study, we also showed that there was 
no difference in molecular force generating capacity between these two isoforms 
(Lauzon, Tyska et al. 1998). It is interesting to note the striking similarities between the 
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molecular mechanical properties of this myosin isoform (Lauzon, Tyska et al. 1998) and 
the airway SM mechanical properties reported in asthma, namely, an increased rate of 
shortening yet no force enhancement (Bjorck, Gustafsson et al. 1992; Ma, Cheng et al. 
2002). 
The presence of the myosin SM-B isoform is also known to affect SM kinetics at the 
whole organ level. We previously purified myosin from multiple rat organs and showed a 
rank correlation in Vrnax from the slowest contracting tonic organ to the fastest contracting 
phasic organ (Leguillette, Gil et al. 2005). Furthermore, by measuring the pulmonary 
mechanics of the SM-B isoform knockout mouse (Babu, Loukianov et al. 2001), we 
showed the impact of the 7 amino acid insert at the whole animallevel (Tuck, Maghni et 
al. 2004). We observed an 18% increase in the time to peak airway resistance in the 
knockout compared to the wild type mi ce (Tuck, Maghni et al. 2004). It is also 
noteworthy that the expression of the SM-B isoform has been shown to be altered in 
several models of disease. For example, bladder or intestinal obstruction causes a 
reduction in mRNA encoding for SM-B, with concurrent reductions in maximal 
shortening velo city (Sjuve, Haase et al. 1996; Lofgren, Fagher et al. 2002; DiSanto, Stein 
et al. 2003). Hormones (Calovini, Haase et al. 1995) as well as stages of development 
(Low, Mitchell et al. 1999) also alter the expression of the SM-B myosin isoform. 
Immunohistochemistry showed intercellular heterogeneity in the distribution of SM-B in 
biopsies from both normals and asthmatics. Positive SM-B cells were not usually 
observed in clusters but individually dispersed. Similar results have been reported in 
swine stomach SM and rat lung airway SM (Low, Mitchell et al. 1999; Pari si and 
Eddinger 2002). Parisi and Eddinger (Pari si and Eddinger 2002) have previously 
suggested that such heterogeneity might be critical in conferring a wider range of 
shortening velocity to SM. For example, they suggested that cells expressing high levels 
of the SM-B isoform could, by contracting rapidly, stretch and activate SM-B-deprived 
neighborhood cells via mechano-transduction. Such a mechanism could explain how 
heterogeneity in cell phenotype would lead to amplification of the rate of SM cell 
activation. 
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Total SMMHC in asthma: 
Although still controversial, it is rather widely accepted that airway SM mass is increased 
in asthma (Ebina, Takahashi et al. 1993; Lambert, Wiggs et al. 1993; James and Carroll 
2000; Benayoun, Druilhe et al. 2003; Woodrutf, Dolganov et al. 2004). Our results of a 
1.7-fold upregulation ofSMMHC mRNA (Fig. 1) in the asthmatic biopsies may indirectly 
reflect an increase in airway SM mass. However, the mRNA data were normalized to a 
ubiquitously expressed ribosomal S9 gene, so our results do not allow for distinction 
between a greater number of SM cells expressing SMMHC (hyperplasia) and a similar 
number of SM cells each expressing more SMMCH (hypertrophy). Nevertheless, if more 
SMMHCs are present in the biopsies from asthmatics they potentially contribute to the 
hypercontractility of airway SM observed in asthma. 
The role of MLCK in asthma: increased velocity of shortening of airway SM 
Previous studies have reported significant increases of MLCK expression in asthma and 
in models of asthma. MLCK protein content was increased in human bronchial SM 
sensitized ex-vivo (Ammit, Armour et al. 2000) and in a dog model of allergie airway 
hyperresponsiveness (Jiang, Rao et al. 1992; Jiang, Rao et al. 1994). Our data show an 
upregulation ofMLCK mRNA in asthmatics compared to controls. Our data agree with 
those of Ma and coworkers (Ma, Cheng et al. 2002) who also studied whole tissue 
biopsies from a similar subject population but using conventional RT-PCR. Others used 
laser capture to dissect out the SM portion of biopsies, along with mRNA amplification 
techniques, and did not find significant changes in MLCK expression between asthmatic 
and control bronchial biopsies (Woodrutf, Dolganov et al. 2004). At the protein level, a 
morphometric analysis in patients with severe and moderate asthma, showed a significant 
increase in MLCK in the severe asthmatics (Benayoun, Druilhe et al. 2003). 
Discrepancies between studies may be due to differences in patient populations and 
quantification techniques. 
Increased MLCK expression may accelerate SM shortening by two possible mechanisms. 
First, MLCK is the key activator of SM contraction by phosphorylation of the LC20, 
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-thereby initiating the cross-bridge cycling (Kamm and Stull 1985). The maximal velocity 
of SM contraction is tightly dependent on the acto-myosin cross-bridge cycling rate 
(Sheetz, Block et al. 1986; Umemoto and Sellers 1990). Many studies have suggested 
that cross-bridge cycling rate is proportional to the amount ofMLCK and the resulting 
LC20 phosphorylation levels (Gerthoffer and Murphy 1983; Stephens and Jiang 1997); 
however this direct link remains controversial (Gerthoffer 1987; Merkel, Gerthoffer et al. 
1990; Mitchell, Seow et al. 2001). It has also been suggested that in addition to its 
enzymatic activity, MLCK may have mechanical effects on the cross-bridge cycling rate 
(Sato, Ye et al. 1995). This may contribute to the uncoupling between myosin 
phosphorylation levels and SM velocity of shortening, observed at the tissue level early 
in the contraction process (Mitchell, Seowet al. 2001). Indeed, it has been described in 
the skeletal muscle literature that MLCK binds to myosin via a telokin-like site, and that 
this attachment modifies the conformation of myosin filaments, moving them closer to 
the actin thin filaments (Levine, Kensler et al. 1996). In SM, it has been shown that 
MLCK also has actin-binding capabilities (Sellers and Pato 1984) and that this binding 
increases the myosin ATPase activity in a phosphorylation-independent manner (Ye, 
Kishi et al. 1999). In the CUITent study, we verified if SM MLCK could also mechanically 
potentiate the cross-bridge cycling rate. We addressed this question, by incubating 
skeletal myosin with MLCK, because contrary to SM, skeletal myosin is not 
enzymatically activated by MLCK. We found a greater V rnax for skeletal myosin in 
presence of SM MLCK. To our knowledge this enzymatic-independent increase in cross-
bridge cycling rate by SM MLCK has never been described. Therefore, our data suggest 
that upregulation of MLCK in asthmatic airway SM biopsies increases cross-bridge 
cycling rate by both an enzymatic and a mechanical effects, thus contributing to the 
increased rate of shortening of airway SM. 
The role ofSM22 in asthma: 
Although SM22 has been fIfst purified from SM more than a decade ago (Shapland, 
Lowings et al. 1988), its function remains unknown. SM22 binds to filaments of actin in 
SM cells, both in vitro and in vivo (Shapland, Hsuan et al. 1993; Fu, Liu et al. 2000; 
Zhang, Kim et al. 2001), and is not essential for life and SM development (Zhang, Kim et 
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al. 2001). We hypothesized that SM22 would behave as several other actin-binding 
proteins and directly alter the cross-bridge cycling rate and/or ATPase activity (Haeberle 
1994). Our results demonstrate no difference in V rnax when SM22 is bound to actin. It is 
possible that SM22 has a role in actin filament remodeling. In this sense, actin elongation 
has been suggested to play a role in bronchial hyperresponsiveness (Dulin, Fernandes et 
al. 2003). It is also possible that the effect ofSM22 involves multiple actin filaments, as 
suggested by the SM22 jellifying action of actin filaments, observed in specifie ionic 
strength conditions (Shapland, Lowings et al. 1988). This would obviously be missed 
when performing measurements at the molecular level but should be investigated at the 
cellular level. 
In summary, we have shown that the mRNA levels ofSM-B, SM22, and MLCK are 
increased in mild asthmatic bronchial biopsies. Furthermore, we showed that 
upregulation of SM-B and MLCK increase vrnax • This specifie contractile prote in gene 
upregulation most likely leads to increased SM velocity of shortening, thus contributing 
to the airway hyperresponsiveness observed in asthma. 
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VII- Tables and figures: 
Table 1: Clinical characteristics of subjects: 
Age of the subjects ranged from 24 to 47 year. FVC: forced vital capacity, FEV!: pre-
bronchodilator forced expiratory volume in 1 s (expressed in liter and % of predicted), 
PC20 : provocative concentration of methacholine inducing a 20% faH in FEV!. 
Concentrations of methacholine up to 128 mg/ml were used. AHergens: Skin response 
read at 10 min if mean wheal diameter >3 mm). C: Cat, D: Dog, DPt: D. Pteronyssinus, 
Du: Dust, Rw: Ragweed. 
Sex FVC 1 (%) FEV!l (%) PC20 (mg/ml) AHergens 
Asthmatics 
F* 4.63 (119) 4.07 (126) 0.07 C, D, Du, DPt 
F 4.18 (119) 3.18 (104) 2.41 C, Du, DPt 
M 6.76 (115) 5.55 (116) 2.1 C, D, Du, DPt 
F* 3.64 (113) 2.82 (107) 1.46 C, Du, Rw, 
M 5.22 (111) 3.33 (85) 3.02 C,D,Du 
Non asthmatics 
M* 6.24(119) 5.15 (112) >128 None 
F 4.52 (116) 3.77 (116) 19.06 None 
F 3.66 (111) 2.98 (104) >128 None 
F 4.05 (116) 3.17(104) 139.04 None 
F 3.23 (87) 2.64 (83) 84.16 None 
*Biopsies also used for immunohistochemistry 
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Table 2: Primers sequences: 
5' -GTGTGTGACAATGGCTCTGG-3' 
5' -TTTGCTCTGTGCTTCGTCAC-3' 
5' -CAGCTCTCGCACTCTGTTCTT -3' 
5' -GCAAAACCAGCTTTGCACAT -3' 
5' -GGCTTGTCTTCTTGGAGCTTT -3' 
5' -GGCAGAGGAGGAAGAGAAGG-3' 
5' -ATGGAGAGATGCCTGTGGAC-3' 
5' -TGCCAGAGTGTTTGTTCAGG-3' 
5' -TCATCCAGTTCCCTGAGGAC-3' 
5' -TTCTCGCTGTTCTCCACCTT -3' 
Acin a2 Sens 
Acina2 AS 
Acin yi Sens 
Acin yi AS 
Caldesmon Sens 
Caldesmon AS 
Linked Integrin kinase Sens 
Linked Integrin kinase AS 
MLCK Sens 
MLCKAS 
5'-GAGCCAGGCCAGTAATGAAG-3' Ribosomal S9 Sens 
5' -TGAGT AACATTCCATATACATCATGC-3' Ribosomal S9 AS 
5'-AAGAATGATGGGCACTACCG-3' SM22 Sens 
5'-ATGACATGCTTTCCCTCCTG-3' SM22 AS 
5' -AGCAAGCTCAGGCGAGGA-3' 
5' -ACAGTCTGCTGGGTTTTGCT-3' 
5' -CACAGGAAACTTCGCAGTGA-3' 
5' -CCGTGGTGCAAAACTGTAGA-3' 
5' -CAAGAAAGACACAAGTATCACGG-3' 
5' -GTTGGCTCCCACGATGTAAC-3' 
5' -CAAGGCCCATCTTTTGCCTAC-3' 
5' -GACCAGGATCTCATCCTCCA-3' 
5' -AGCAGCTACAGGCTGAAAGG-3' 
5' -GATCAAGGTCCTTTCCGACA-3' 
5' -AGCAGGCAGAGTGGATGAAC-3' 
5' -ACTGGACAACGCACTCAA TG-3' 
5' -GGGTGGAAGGGGATAGGT AA-3' 
SMMHC SM-I Sens 
SMMHC SM-I AS 
SMMHC SM-2 Sens 
SMMHC SM-2 AS 
SMMHC SM-A Sens 
SMMHC SM-A and SM-B AS 
SMMHC SM-B Sens 
Total SMMHC Sens 
Total SMMHC AS 
Tropomyosin a Sens 
Tropomyosin a AS 
Tropomyosin f3 Sens 
Tropomyosin f3 AS 
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Figure 1: Relative quantification of contractile genes by real-time PCR analysis: Results 
are presented as fold increase in endobronchial biopsies from asthmatic compared to 
normal subjects. Quantification is normalized for S9 levels and corrected for primers 
efficiency. SMMHC: Smooth Muscle myosin heavy chain, SM-l, SM-2, SM-A, SM-B: 
Smooth muscle myosin heavy chain isoforms -1, -2, -A and -B, respectively, SM22: 
transgelin, MLCK: Myosin light chain kinase, S9: Ribosomal prote in S9. t: Significant 
difference between asthmatics and normals. Total SMMHC: p< 0.01; SM-2: p< 0.01; 
SM-A: p< 0.01; SM-B p< 0.01; SM22: p< 0.01; MLCK: p= 0.05; Tropomyosin a: p= 
0.03; Y actin: p= 0.01. 
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Figure 2: Immunohistochemistry of the SM-B SMMHC isoform expressed in 
endobronchial biopsies from asthmatic and normal subjects: Representative 
immunohistochemistry of the SM-B isoform expression in an endobronchial biopsy from 
an asthmatic subject (A) and from a normal subject (B). Representative 
immunohistochemistry from a normal subject after adsorption of the antibody with the 
QGPSF A y peptide (C). Brown staining is positive for the SM-B isoform. 
Figure 2: 
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Figure 3: Immunohistochemistry of SM22 expressed in endobronchial biopsies from 
asthmatic and normal subjects: Representative immunohistochemistry of SM22 in an 
endobronchial biopsy from an asthmatic subject and enlarged view of the granular pattern 
(A). Representative immunohistochemistry of SM22 in an endobronchial biopsy from a 
normal subject (B). Representative immunohistochemistry of the SM-22 in an 
endobronchial biopy from a normal subject after adsorption of the antibody with 
recombinant SM-22 (C). Brown staining is positive for SM22. 
Figure 3: 
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Figure 4: Immunohistochemistry of MLCK expressed in endobronchial biopsies Jrom 
asthmatic and normal subjects: Representative immunohistochemistry of MLCK in an 
endobronchial biopsy from an asthmatic subject (A) and from a normal subject (B). 
Representative immunohistochemistry of MLCK in an endobronchial biopsy from a 
normal subject after adsorption of the antibody with purified MLCK. Brown staining is 
positive for MLCK. 
Figure 4: 
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Figure 5: Mo/ecu/ar mechanics and myosin isoform expression of the Fisher and Lewis 
rat trachealis muscle: A: Seatter plot of aetin filament propulsion velocity (vrnax) 
measured in the in vitro motility assay for myosin purified from Fisher and Lewis rat 
traeheae. Horizontal bars: mean v rnax• B: Representative Western blot analysis of myosin 
purified from eight Fisher and eight Lewis traeheae. Upper panel: SM-B isoform specifie 
antibody, lower panel: Total smooth muscle myosin specifie antibody. 
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Figure 6: Mo/ecu/ar mechanics of MLCK-bound skeleta/ myosin: Scatter plot of actin 
filament propulsion velocity (vmax) measured in the in vitro motility assay after incubation 
of skeletal myosin with MLCK. Horizontal bar: mean vmax. 
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Figure 7: Molecular mechanics of SM22-bound actin filaments: Scatter plot of actin 
filament propulsion velocity (vrnax) measured in the in vitro motility assay after incubation 
of actin with SM22. Horizontal bar: mean vmax. 
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Figure 8: Immunoprecipitalion of eosedimented aelin-SM22: A: Western blot (performed 
with an anti-SM22 antibody) of actin immunoprecipitated (with an anti-actin antibody) 
without pre-incubation with SM22 (left panel) and with pre-incubation with SM22 (right 
panel; shown in duplicate). B: Western blot (performed with an anti-actin antibody) of 
actin immunoprecipitated with non-actin antibodies (P44 and CCR5; left panel) and actin 
specifie antibodies (right panel). P: Pellet, S: Supernatant, IPP Ab: Antibodies used for 
immunoprecipitation. 
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Chapter 4: 
Tonie and phasie smooth muscle myosin affinity for adenosine 
diphosphate and unbinding force from aetin. 
116 
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1- Prologue: 
A remarkable property of smooth muscle is its ability to maintain force for long periods 
oftime at low levels of activation. This property, called the latch-state, is more prominent 
in tonic than phasic smooth muscle. Several models have been proposed to explain the 
latch phenomenon but they all remain speculative. To gain more information about the 
molecular mechanisms behind the latch-state, l measured the molecular mechanics of the 
different myosin isoforms at different activation levels and in presence of different 
concentrations of MgADP. l therefore tested the following two hypotheses: 1) 
unphosphorylated myosin can atlach to actin and maintain force; 2) the SM-B myosin 
isoform has a greater affinity for MgADP than SM-A thereby, explaining the greater 
propensity of tonic muscle to enter into latch . 
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11- Abstract: 
Smooth muscle is unique in its ability to maintain force at low MgA TP consumption. 
This property, called latch-state, is more prominent in tonic than phasic smooth muscle. 
Muscle strip studies have suggested that tonic muscle myosin has a greater affinity for 
MgADP and therefore remains attached to actin longer allowing for cross-bridge 
dephosphorylation and latch-bridge formation. A corollary hypothesis states that 
dephosphorylated myosin reattaches to actin and maintains force. These properties of 
myosin have been inferred from measurements made at the tissue level but have never 
been verified at the molecular level. Therefore, we investigated these mechanical 
properties ofmyosin directly at the molecular level. We used an in vitro motility assay to 
measure fluorescently labeled actin filament velocity (vmax) when propelled by myosin 
from phasic or tonic muscle, at increasing [MgADP]. A myosin mixture of 25% 
thiophosphorylated-75%unphosphorylated was used, to approximate in vivo steady-state 
conditions. The slope of Vmax vs [MgADP] was significantly greater for myosin from 
tonic (-O.51±O.04) than phasic muscle (-O.15±O.04) demonstrating its greater affinity for 
MgADP. We then used a laser trap assay to measure the unbinding force from actin of 
unphosphorylated myosin from tonic and phasic muscle. Both myosin types attached to 
actin and their unbinding force (O.092pN ±O.022 for phasic and O.084pN ±O.017 for 
tonic) was not significantly different. These results suggest that the greater affinity for 
MgADP of tonic muscle myosin and the reattachment of dephosphorylated myosin to 
actin could both contribute to the latch-state. 
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111- Introduction 
Smooth muscle is involved in a broad range of physiological processes such as blood 
vessel tone maintenance and intestinal peristalsis. Two types of smooth muscle have 
originally been described based on their electrophysiological properties (Somlyo and 
Somlyo 1968). Tonie smooth muscle is defined as slowly contracting, multi-unit, tone 
maintaining, as found in most blood vessels, while phasic smooth muscle is defined as 
rapidly contracting, single unit, as in the intestine. Tonic and phasic smooth muscles also 
differ in their expression of amino-terminus myosin heavy chain and essentiallight chain 
(LC17) isoforms. Tonic muscle expresses predominantly the (-)insert smooth muscle 
myosin heavy chain (SMMHC) and LCl7b isoforms whereas phasic muscle expresses 
mostly the (+)insert SMMHC and LC17a isoforms (Malmqvist and Amer 1991; White, 
Zhou et al. 1998). It is generally agreed that the regulation of smooth muscle is mostly 
achieved by phosphorylation of the regulatory light chains (LC20) (Sobieszek 1977). 
Interestingly, Murphy and coworkers have shown in carotid artery muscle strips that 
although the rate of shortening is correlated with LC20 phosphorylation, force can be 
maintained for long periods oftime even after dephosphorylation ofmost cross-bridges 
(Dillon, Aksoy et al. 1981). This property, called latch-state, remains po orly understood. 
Many theories have been suggested to explain this unique ability of smooth muscle to 
maintain force at low energy cost. Murphy and coworkers have suggested that if cross-
bridges were dephosphorylated (dePHOS) while attached to actin, they would remain 
attached and sustain force while no longer cycling or cycling slowly (Dillon, Aksoy et al. 
1981). From work performed at the muscle strip level, Somlyo and coworkers more 
recently proposed that the affinity for adenosine diphosphate (MgADP) oftonic smooth 
muscle myosin, where latch is most evident, is higher than that of phasic smooth muscle 
(Fuglsang, Khromov et al. 1993). Because MgADP release from myosin is necessary for 
its detachment from actin (Spudich 1994), an attractive mechanism to explain the latch-
state is that due to its greater affinity for MgADP, tonic muscle myosin remains attached 
longer to actin and gets dePHOS while attached (Hai and Murphy 1988), thus creating 
latch-bridges. Hai and Murphy even suggested that dephosphorylation may induce the 
latch-state simply by reducing the rate of MgADP release from cross-bridges (Hai and 
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Murphy 1988). However, these possibilities have never been investigated at the 
molecular level. 
Alternative views of the latch-state also exist in which, instead of remaining attached 
after dephosphorylation, myosin would have the ability of reattaehing to aetin by a Ca2+_ 
dependent regulatory mechanism other than myosin LC20 phosphorylation (Siegman, 
Butler et al. 1985), or sorne cooperativity mechanism between phosphorylated (PHOS-) 
and dePHOS myosin (Himpens, Matthijs et al. 1988; Vyas, Mooers et al. 1992). 
However, the attachment of dePHOS myosin to actin has never been demonstrated at the 
moleeular level. Indeed, bioehemical studies report that unphosphorylated (unPHOS) 
myosin is in a bent conformation so it may not have the capacity to attach to actin 
(Trybus and Lowey 1984; Trybus 1989). 
In the present study, we investigated fundamental mechanieal properties of smooth 
muscle myosin in order to gain more information about the mechanisms responsible for 
the latch-state. We used the in vitro motility assay to quantify the rate of aetin filament 
movement (vmax) when propelled by myosin from tonic and phasic smooth muscle, at 
increasing MgADP concentrations, and at different light chain phosphorylation levels. 
Furthermore, we used a laser trap to quantify the unbinding force (Funb) from actin of 
unPHOS myosin tonic and phasie smooth muscle. Our results demonstrate that Vmax 
decreases with inereasing [MgADP] but that at low levels of phsophorylation, the 
deerease is more pronouneed for myosin from tonic than phasic smooth muscle. These 
results suggest a greater affinity of tonie smooth muscle myosin for MgADP at low 
phosphorylation levels. Furthermore, we found that unPHOS myosin from both tonie and 
phasie smooth muscles ean attaeh to aetin and that their Funb is not signifieantly different. 
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IV - Material and methods 
Proteins: 
Myosin was purified from bovine aorta (Megerman and Lowey 1981) and chicken 
gizzard (Ebashi 1976; Trybus 2000) as previously described. Thiophosphorylation was 
performed using Ca2+, calmodulin (P2277 Sigma-Aldrich Canada Ltd, Ont.), myosin light 
chain kinase (generous gift from Dr 1. Haeberle), and ATPyS (A1388 Sigma-Aldrich 
Canada Ltd, Ont.) (Trybus and Lowey 1984). Actin was purified from chicken pectoralis 
acetone powder (Pardee and Spudich 1982) and fluorescently labeled by incubation with 
tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin (P 1951 Sigma-Aldrich 
Canada Ltd, Ont.) (Warshaw, Desrosiers et al. 1990). 
Western blot analysis of total and (+)insert SMMHC tissue content: 
The total SMMHC and (+)insert isoform content of the gizzard and aorta after protein 
purification was verified by Western blot analysis. An equivalent amount of protein was 
loaded on the gel as assessed by a Bradford assay. Electrophoresis was done on 6% SDS 
polyacrylamide gel using a Laemmli buffer system. Proteins were electroblotted onto 
nitrocellulose membrane (Bio-Rad Laboratories Ltd, Mississauga, Ont.). Membranes 
were probed either with a polyclonal antibody that specifically recognizes the 7 amino 
acid insert QGPSF A y (Rovner, Freyzon et al. 1997)), or with a polyclonal SMMHC 
antibody that recognizes all SMMHC isoforms (Biomedical Technologies Inc., 
Stoughton, MA). Antibody detection was done by Enhanced Chemiluminescence 
(Amersham Biosciences, Piscataway, NJ) and quantification was performed with a 
Fluorchem 8500 imaging system using AlphaEase software (Alpha Innotech. 
Buffers: 
Myosin buffer (300mM KCI, 25mM imidazole, ImM EGT A, 4mM MgCI2, 30mM 
dithiothreitol, pH adjusted to 7.4) and actin buffer (25mM KCI, 25mM imidazole, ImM 
EGT A, 4mM MgCI2, 30mM dithiothreitol, with an oxygen scavenger system consisting 
of 0.1 mg/ml glucose oxidase, 0.0 18mg/ml catalase, 2.3mglml glucose, pH adjusted to 
7.4) were used for both the in vitro motility assay and unbinding force experiments. The 
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motility assay buffer consisted of actin buffer to which MgA TP (2mM) and increasing 
concentrations of MgADP (0, 0.1, 0.2, 0.4, 0.6, 0.8 and ImM) were added. The ionic 
strength was kept constant by adjusting KCl (Chang 1981). Methylcellulose (0.5%) was 
added to favor binding between actin and myosin. The range of MgADP concentrations 
(up to ImM) was kept within physiological range. The laser trap unbinding assay buffer 
consisted of actin buffer to which MgATP (200f-tM) and methylcelullose (0.3%) were 
added. 
In vitro motility assay: 
The velocity of actin filament propulsion (vrnax) by myosin molecules was measured in 
the in vitro motility assay, following a previously described protocol (Lauzon, Tyska et 
al. 1998) with slight modifications. Briefly, ultracentrifugation (Optima TLX 
ultracentrifuge and TLA-120.2 rotor, Beckman Coulter Inc., Fullerton, CA) ofmyosin 
(500llgmrI) with equimolar filamentous actin and ImM MgATP in myosin buffer was 
performed to eliminate non-functional heads. unPHOS and PHOS myosins were mixed to 
obtain 100% unPHOS, 25% unPHOS, or 100% PHOS. The desired myosin mixture was 
perfused in a flow-through chamber (30111) constructed from a nitrocellulose coated 
coverslip and a glass microscope slide. Incubation for 2 min allowed random attacbment 
of myosin to the nitrocellulose and was followed by addition of bovine serum albumin 
(O.5mg/ml in actin buffer), unlabelled G-actin (lOf-tM in actin buffer), MgATP (lmM in 
actin buffer), actin buffer (two washes), TRITC-Iabeled actin (lOf-tM in actin buffer) 
incubated for 1 min, and motility assay buffer. For myosin MgADP affinity experiments, 
different MgADP concentrations were applied in random order. The flow-through 
chamber was then transferred to the stage of an inverted microscope (IX70, Olympus, 
Melville, NY) equipped with a high numerical aperture objective (100x magnification 
Ach 1.25n.a., Olympus, Melville, NY) and rhodamine epifluorescence. An image 
intensified video camera (VElOOOSIT, Dage-MTI of MC Inc., Michigan City, IN) was 
used to visualize and record the actin filament movement (SVO-5800, Sony Corporation 
of America, New-York City, NY). The actin images were digitized (VG5 PCI RS 170, 
Scion Corporation, Frederick, MD) and Vrnax was determined from the total path 
described by the filaments divided by the elapsed time using NIH tracking software (NIH 
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macro in Scion Image 4.02, Scion Corporation, Frederick, MD). AIl experiments were 
performed at 30°C. 
Unbinding force measurements (F!!!1!2L 
A single beam laser trap assay (Fig.1) was built using the Laser Tweezers® Workstation 
(Cell Robotics International Inc., Albuquerque, NM) combined to the motility assay to 
perform the unbinding force (Funb) measurements. Before coating with nitrocellulose, 
coverslips were sprayed with 4.5/lm polystyrene microspheres (Polybead®, Polysciences 
Inc., Warrington, PA) that served as pedestals. The trapping microspheres were made of 
3/lm polystyrene microspheres (Polybead®, Polysciences Inc., Warrington, PA) coated 
with N-ethylmaleimide (NEM)-modified skeletal myosin (generous gift from Dr. P. 
VanBuren) as previously described (Warshaw, Desrosiers et al. 1990; Lauzon, Tyska et 
al. 1998). The proteins and solutions were prepared as for the motility assay except that 
TRITC-Iabeled actin was mixed with microspheres (13"103 microspheres//ll) in the 
unbinding assay buffer. One microsphere, visualized in bright field by a CCD camera 
(XC-75, Sony Corporation of America, New York City, NY), was captured in the trap 
and its position was recorded as above. An actin filament, visualized by fluorescence 
imaging as above, was attached to the microsphere and brought down in contact with 
myosin molecules randomly adherent to a pedestal (Fig. lA). Approximately lOs were 
allowed for interaction between myosin and actin to occur. This established the baseline 
position of the microsphere in the trap and then, the trap was moved away from the 
pedestal at a constant velocity of 4/lffi"S-I. Despite pulling the trap away, the microsphere 
did not move until the force exerted by the trap on the microsphere was greater than that 
exerted by the myosin molecules on the actin filament (Fig. lB). At this point, the 
microsphere sprang back to its unloaded baseline position in the center of the trap (Fig. 
1 C). The total unbinding force (Funb) of the myosin molecules was ca1culated as 
(1) 
where k= trap stiffness and ~d = maximal displacement of the center of mass of the 
trapped microsphere from its baseline position (Fig. 1). kwas calibrated by applying a 
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viscous drag (or Stokes force) to a trapped microsphere, by moving it at a constant 
velocity (v) in 0.3% methylcellulose, and measuring the displacement (~d) ofthe 
microsphere from the trap center (Fig. 2). The Stokes force (Fr) on the microsphere was 
calculated as 
Ff= 6Jt1lrv (2) 
where 11= viscosity and r= microsphere radius. The viscosity of O.3%methylcellulose was 
measured with a viscometer (DV-I at 60 rpm, Brookfield®, Middleboro, MA). Thus 
k= Fr/ ~d (3) 
The value ofk used was the average of multiple measurements performed at many v. The 
reproducibility of our calibration and linearity of the trap stiffness are demonstrated in 
figure 2 where ~d is plotted as a function ofv. 
Funb is reported as the average force per myosin molecule, calculated by di vi ding the 
measured Funb by the number of myosin molecules estimated per actin filament length 
(VanBuren, Work et al. 1994), measured by imaging with the SIT camera. The 
concentration of myosin used was 0.1 mg/ml and the number of myosin molecules in 
contact with actin was estimated to be 24/~m ofactin filament (VanBuren, Work et al. 
1994). 
Because Funb measurements were performed on unPHOS myosin, the functioning of the 
myosin was assessed by measuring Vrnax of a 100% PHOS sample from the same 
purification. Furthermore, Funb control experiments were performed by bringing actin 
filaments in contact with pedestals coated with bovine serum albumin (BSA) instead of 
myosin molecules. No attachment was observed with BSA. 
Statistical analysis: 
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Differences in Funb and Vrnax between myosin from tonic and phasic smooth muscles were 
tested using a Student's (-test and a Wilcoxon signed rank test, respectively. Differences 
in affinities were tested using a Student's (-test applied to the slopes of the linear 
regressions of the Vrnax vs MgADP for the myosins compared. 
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V- Results 
Western blot analysis of total SMMHC and (+)insert isoform tissue content: 
The content of total SMMHC and (+ )insert isoform of the purified chicken gizzard 
(phasic) and bovine aorta (tonic) was quantified by Western blot analysis (Fig.7). Despite 
a greater total prote in loading for the aortic smooth muscle, the (+ )insert isoform was not 
detected. In contrast, a strong signal was observed for the (+ )insert isoform in the chicken 
gizzard smooth muscle. These data suggest that, as previously reported for other tissues 
(White, Zhou et al. 1998), chicken gizzard and bovine aorta are essentially constituted of 
the (+) and (-)insert isoforms, respectively. 
Affinity oftonic and phasic smooth muscle myosins for MgADP: 
The rate of actin filament movement (vrnax) when propelled by myosin from tonic and 
phasic smooth muscle was assessed using the in vitro motility assay. First, Vrnax for fully 
PHOS tonic and phasic smooth muscle myosin was measured. In accordance with the 
literature (Kelley, Takahashi et al. 1993; Rovner, Freyzon et al. 1997; Lauzon, Tyska et 
al. 1998), Vrnax for 100% PHOS myosin from phasic muscle (1.08 ±O.12flmls; mean ±SD) 
is significantly faster (p<0.00l) than for 100% PHOS myosin from tonic muscle (0.44 
±0.02flmlS) (Fig. 3). Next, Vrnax was measured for 25%PHOS-75%unPHOS myosin to 
mimic in vivo steady-state conditions (Dillon, Aksoy et al. 1981). We observed 
significantly slower (p<0.001) Vrnax for both myosin types compared to their respective 
100% PHOS values (Fig. 3). Those results showed that as for the 100%PHOS myosin, 
25% PHOS myosin from phasic muscle is also ~2-fold faster (p<0.00l) than 25%PHOS 
myosin from tonic muscle (0.50±0.07flmls for phasic vs 0.26±0.04flmls for tonic) (Fig. 
3). 
To quantify the difference in affinity for MgADP between tonic and phasic muscle 
myosin, we measured Vrnax at increasing MgADP concentrations, at a phosphorylation 
level of 100%. Vrnax for both phasic and tonic smooth muscle myosin decreased with 
increasing MgADP (Fig. 4a). Linear regression of of Vrnax vs [MgADP] at 100% 
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phosphorylation level revealed that the slopes were almost similar with no statistical 
differences between phasic (-0.30±0.11, R2=0.96) and tonic (-0.34±0.08, R2=0.98) 
muscle myosin (Fig. 4a). 
To test if the affinity of smooth muscle myosin for MgADP is affected by the level of 
phosphorylation, we measured Vrnax at increasing [MgADP] for 25% PHOS-75% 
unPHOS phasic muscle and tonic muscle myosin (Fig. 4b). Contrary to the slopes at 
100%PHOS (Fig. 4a), the slopes at 25%PHOS-75% unPHOS were different between 
phasic and tonic muscle myosin. The sI ope for tonic muscle myosin was significantly 
greater (-0.52±0.10, R2=0.96) than that ofphasic muscle (-0.29±0.07, R2=0.98). The 
greater sI ope oftonic muscle myosin suggests a greater affinity for MgADP at low 
phosphorylation level. lndeed, the concentrations of MgADP necessary to reach half of 
the initial Vrnax (i.e. Kr values) were 0.96mM for tonic (measured) and 1.74mM for phasie 
muscle (extrapolated). Furthermore, the slopes for phasic muscle myosin at 100% PHOS 
(-0.30±0.11, R2=0.96) and at 25%PHOS-75% unPHOS (-0.29±0.07, R2=0.98) were 
almost identical (Fig. 5a) whereas the si opes for tonic muscle myosin at 100% PHOS (-
0.34±0.08, R2=0.98) and at 25%PHOS-75%unPHOS (-0.52±0.1 0, R2=0.96) were 
significantly different (Fig. 5 b; P<O.OOI). This later result suggests that the 
phosphorylation level affects tonic and phasic muscle myosin affinity for MgADP 
differently. 
Funb of unPHOS myosin from tonie and phasic smooth muscle: 
To verifY ifunPHOS myosin can bind to actin and to quantifY its attaehment force, we 
used a single beam laser trap and measured the Funb ofunPHOS tonie and phasic muscle 
myosin. Table 1 shows Funb per myosin moleeule in contact with the aetin filament. Funb 
is not significantly different between tonic (0.084pN ±0.017) and phasic (0.092pN 
±0.022) muscle myosin. These values are approximately 10-times smaller than the 
previously reported unitary force generated by PHOS myosin, i.e. 1 pN (Lauzon, Tyska et 
al. 1998) and 0.6pN (VanBuren, Work et al. 1994; VanBuren, Guilford et al. 1995). 
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VI- Discussion 
The major findings of this study are: 1) the affinity for MgADP of myosin from tonic 
muscle, at low phosphorylation conditions (25%PHOS-75% unPHOS), is significantly 
greater than that of myosin from phasic muscle; 2) the affinity for MgADP of myosin 
from tonic muscle is greater at low (25%PHOS-75%unPHOS) than at high (100%) 
phosphorylation levels; 3) unPHOS myosin from tonic and phasic smooth muscle can 
atlach to actin; 4) the attachment forces to actin ofunPHOS myosin from tonic and 
phasic smooth muscle are not statistically different. 
Affinity oftonic and phasic smooth muscle myosin for MgADP: 
Several studies have suggested that tonic and phasic smooth muscles have a different 
affinity for MgADP. Somlyo and coworkers showed that relaxation from rigor, induced 
by flash-photolysis of caged MgATP, is significantly impeded in tonic smooth muscle 
strips in presence of MgADP (Fuglsang, Khromovet al. 1993; Khromov, Somlyo et al. 
1995). On the contrary, relaxation from rigor ofphasic smooth muscle is much faster and 
barely affected by the addition of MgADP. Similarly, Lofgren and coworkers 
demonstrated that the rate of shortening, as measured by the quick-release technique, 
decreases more rapidly as a function of [MgADP] in tonic than phasic smooth muscle 
strips (Lofgren, Malmqvist et al. 2001). Force and stiffness measurements performed in 
the (+ )insert isoform knockout mice bladder muscle strips also suggest a slower MgADP 
off-rate in the homozygous negative eompared to homozygous positive or heterozygous 
mice (Karagiannis, Babu et al. 2003). AH these studies, however, were performed at the 
muscle strip level and extrapolated to molecular level mechanisms. 
To verify at the moleeular level if tonie muscle myosin has a greater affinity for MgADP 
than phasie muscle myosin, we used the in vitro motility assay to assess the effeet of 
[MgADP] on actin propulsion. Note that we chose a range of [MgADP] from 0 to ImM 
beeause previous studies have demonstrated that intraeeHular free [MgADP] is in the 
range of 44 to 123J.1M (Krisanda and Paul 1983); (Askenasy and Koretsky 2002) but 
protein-bound MgADP including actin-bound MgADP may make it available in the 
proximity of the myosin heads (Butler and Davies 1980). Inereasing [MgADP] in the 
129 
~-
motility milieu should hinder the release of MgADP from the myosin nucleotide binding 
pocket. Because MgADP release is the rate-limiting step in the cross-bridge cycle 
(Spudich 1994), the greater the affinity for MgADP, the more pronounced will be the 
reduction in cycling rate, thus in vrnax• We found that when myosin was fully 
thiophosphorylated, there was no difference in Vrnax between tonic and phasic smooth 
muscle myosin (Fig. 4a). These results are in agreement with those previously reported 
by Rovner and co-workers who performed Vrnax measurements of the (+) and (-)insert 
isoforms in the in vitro motility assay at increasing MgADP concentration, although they 
had the confounding effect of ionic strength correction by MgATP adjustments (Rovner, 
Freyzon et al. 1997). However, our results at 100%PHOS level, as weIl as those of 
Rovner (Rovner, Freyzon et al. 1997), disagree with muscle strip experiments (Fuglsang, 
Khromov et al. 1993; Khromov, Somlyo et al. 1995) but steady state phosphorylation 
levels are never that high. 
To test if the affinity, oftonic muscle myosin is different from that ofphasic muscle 
myosin at physiological phosphorylation conditions, we repeated the Vrnax measurements 
with 25%PHOS-75%unPHOS myosin. In those conditions, MgADP slowed Vrnax to a 
greater extent when propelled by myosin from tonic muscle than by phasic muscle 
myosin (Fig. 4b). These results confirm that in physiological phosphorylation levels, 
myosin from tonic muscle has a greater affinity for MgADP than phasic muscle myosin. 
It is important to note, however, that laser trap studies (Lauzon, Tyska et al. 1998) and 
fluorescence transients of the ADP analog 3'-deac-eda-ADP studies (Khromov, Webb et 
al. 2004) reported differences in MgADP release rates between phasic and tonic muscle 
myosin even at high thiophosphorylation levels, whereas we observed differences only at 
low phosphorylation levels (Figs. 4). It is possible that MgADP release rate is different in 
unloaded conditions vs when loaded. This was recently suggested in a molecular model 
(Baker, Brosseau et al. 2003). 
Another interesting point regarding aIl of our Vrnax vs [MgADP] data is that better fits 
were obtained by linear regression than with logarithmic decays for both myosin types. 
This suggests that the behavior of smooth muscle myosin with increasing MgADP 
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concentration was not following a Michaelis-Menten kinetics model. Linear regression 
also yielded the best fits in other studies using the in vitro motility assay (Rovner, 
Freyzon et al. 1997) as weIl as the quick-release as say (Lofgren, Malmqvist et al. 2001). 
Because our purification procedures yielded essentially pure myosin devoid of 
contaminating actin and actin regulatory proteins (data not shown), the mechanical results 
reported here reflect properties of the myosin molecules themselves. Phasic muscle 
myosin expresses mostly the myosin heavy chain that includes the 7 amino acid insert in 
the surface 100p above the nucleotide binding pocket «+)insert isoform) whereas tonic 
muscle mostly expresses the heavy chain without the insert « -)insert) (White, Zhou et al. 
1998). Western blot analysis of our purified myosin also showed that chicken gizzard had 
a much greater content of the (+ )insert isoform than bovine aorta, in which the (+ )insert 
isoform expression was below the level of detection (Fig. 7). It must be mentioned, 
however, that a potentially relevant variable is the LC17 isoform composition. In our 
study, we had no control over the light chain isoforms, so the purified myosin proteins 
were extracted with the same LC17 isoforms that they associated with in vivo. However, 
is has previously been demonstrated with recombinant myosin in the in vitro motility 
as say that the LC 17 isoforms do not alter the myosin mechanical properties, thus 
attributing the 2-fold difference in Vrnax between the (+) and ( -)insert isoforms to the 
insert itself (Rovner, Freyzon et al. 1997). Although the role ofLC17 has not been 
addressed at low LC20 phosphorylation levels, a similar difference in Vrnax between phasic 
and tonic myosin were observed at 25%PHOS-75%unPHOS than at 100%PHOS level 
(Fig. 3), suggesting that the LC17 isoforms do not alter Vrnax at low LC20 phosphorylation 
levels either. Furthermore, the fact that the difference in Vrnax between phasic and tonic 
muscle myosin is maintained from 100%PHOS to 25%PHOS-75%dePHOS mixtures 
suggests that whatever is the mechanism responsible for slowing down Vrnax as a function 
of phosphorylation level, it is not different between tonic and phasic muscle. Our 
unbinding studies, as discussed below, suggest that because the force of attachment of 
unPHOS myosin is the same for tonic and phasic smooth muscle myosins, the reduction 
in Vrnax at low phsophorylation levels should be the same for phasic and tonic muscle 
myosin. 
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Funb ofunPHOS myosin from tonic and phasic smooth muscle: 
Using a single beam laser trap assay, we directly measured the binding force ofa 
population ofunPHOS myosin from both tonic and phasic smooth muscle. We found that 
both tonic and phasic unPHOS smooth muscle myosin can bind to actin and that their 
attachment force is not different. The advantage of our assay over a single myosin 
molecule technique is that it measures the binding force from many myosin molecules at 
a time, thus increasing the signal to noise ratio, neglecting compliance in the system such 
as microsphere-actin linkage (Guilford, Dupuis et al. 1997; Mehta, Finer et al. 1997). Our 
system therefore allows detection of forces lower than those generated by cycling PHOS 
myosin molecules. The limitation of our assay was the precision of the actin length 
measurement by fluorescence imaging. Nevertheless, this effect was reduced by using 
long filaments attaching to many myosin molecules on a large pedestal, thereby 
increasing contact length and improving resolution and decreasing variation. 
Using in vitro motility mixture assay data and mathematical modeling (Warshaw, 
Desrosiers et al. 1990) relating Vmax to the unitary force generated by myosin, Harris and 
co-workers (Harris, Work et al. 1994) predicted an unPHOS to PHOS force ratio of 0.11 
for gizzard smooth muscle myosin. Given that the unitary force generated by phasic 
muscle PHOS myosin has been reported to be between 0.6pN (VanBuren, Work et al. 
1994; VanBuren, Guilford et al. 1995) and 1 pN (Lauzon, Trybus et al. 1998), a value 
from 0.11 pN to 0.06pN was expected for the unPHOS myosin binding force. Our results 
of 0.084pN to 0.092pN for tonic and phasic muscle myosin are thus in very good 
agreement with the literature. 
Conclusion: 
We demonstrated at the molecular level that myosin from tonic muscle has a greater 
affinity for MgADP than myosin from phasic muscle. Because myosin must release 
MgADP before it can detach from actin, this greater affinity for MgADP of tonic muscle 
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myosin may increase its chances of being dePHOS while attached to actin and therefore 
may explain its greater propensity to enter the latch state. Furthermore, we showed that 
unPHOS tonic and phasic muscle myosin can bind to actin and generate a load. Further 
studies will be required to elucidate if both the dephosphorylation of attached cross-
bridges and the reattachment of dePHOS myosin contribute to the latch-state in presence 
of PHOS myosin and in a fully regulated system. 
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VII- Tables and Figures 
Table 1: Comparison of Funb generated by unPHOS myosin and Ftuù generated by 
PHOS myosin: 
Left: Average Funb ofunPHOS tonie and phasie myosin moleeules as measured by the 
single beam laser trap assay. Right: For eomparison purposes, FUni and average Funi for 
PHOS heavy meromyosin (HMM) as measured with the dual beam laser trap assay and 
mieroneedle, respeetively. 
Average force 
perSMMHC 
molecule 
(n=number of events) 
unPHOS 
Tonie 
SMMHC 
(pN ±SD) 
0.084 ±0.017 
(n=8) 
unPHOS 
Phasie 
SMMHC 
(pN ±SD) 
0.092 ±0.022 
(n=6) 
Funi 
PHOS Tonie PHOS Phasie 
HMM eonstruet HMM eonstruet 
(pN ±SE) (pN ±SE) 
1.2 ±0.1 * 
(n=8) 
0.9 ±0.1 * 
(n=7) 
0.6 (0.4-0.8)" 
(Averaged Funi) 
* Lauzon, AM., et al. 1998. J Muscle Res Cell Moti/19:825-837. 
If VanBuren, P., etai. 1994. Proc Natl Acad Sci USA 91:202-205. 
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Figure 1: A) A single beam laser trap is used to capture a 31lm diameter microsphere 
coated with NEM myosin. A TRITC-Iabelled actin filament is attached to the 
microsphere and brought in contact with unPHOS myosin randomly adhered to a 4.51lm 
pedestal on a coverslip. B) After allowing time for binding ofunPHOS myosin to actin, 
the laser trap is moved away from the pedestal at constant veiocity. Initially, the 
microsphere remains at the same position, now offset from the center of the trap. 
C) When the pulling force exerted by the trap exceeds the binding force of the unPHOS 
myosin molecules, the microsphere springs back into the trap center, its unloaded 
position. Funb is equal to the product of 8d (maximal distance between the bead and the 
trap center) by the trap stiffness (calibrated using the Stokes force method (Dupuis, 
Guilford et al. 1997)). 
B) 
A) 
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Figure 2 Trap calibration in 0.3% methylcellulose: The trapped microsphere was moved 
at increasing velocity (1.5- 50l-lmls) in 0.3% methylcellulose and its displacement (~d) 
with respect to the center of the trap was measured. Linear regression shows a very good 
fit (R2= 0.92). These data demonstrated that the calibration is reproducible and that ~d is 
proportional to velocity (v). 
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Figure 3: Baseline Vrnax for 100%PHOS and 25%PHOS tonic and phasic SM myosin as 
assessed by the in vitro motility assay, in presence of2mM MgATP and absence of 
MgADP. (CG: chicken gizzard). 
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-Figure 4: Relative Vrnax (normalized to Vrnax at OmM MgADP) at increasing 
concentrations of MgADP for: A- IOO%PHOS tonic (open circles) or phasic (filled 
squares) SM myosin and B- 25%PHOS-75%unPHOS tonic (open eircles) or phasie 
(filled squares) SM myosin. The difference between the slopes ofregression lines was not 
signifieant between 100%PHOS tonie and phasic myosin, but was signifieant between 
25%PHOS-75%unPHOS tonie and phasie myosin (p>O.OOOI). 
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Figure 5: Relative V rnax (nonnalized to V rnax at OmM MgADP) at increasing 
concentrations of MgADP for lOO%PHOS or 25%PHOS-75%unPHOS for A) phasic SM 
myosin (Open squares= 100%PHOS, Filled squares= 25%PHOS-75%unPHOS) and B) 
tonic SM myosin (Open eircles= 100%PHOS, Filled eircles= 25%PHOS-
75%unPHOS).The slopes ofthe regression lines were not significantly different between 
lOO%PHOS and 25%PHOS-75%unPHOS phasic and tonie myosin. 
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/'-- Figure 6: Representative microsphere center of mass (in x and y) with respect to the trap 
center during unbinding assay. The maximal displacement (~d) from unloaded baseline 
position is measured and multiplied by the trap stiffness to obtain Funb. Inset: 
Superimposed microsphere positions while pulling the trap towards the upper right 
direction: The microsphere remains at the same position while the trap is pulled away, 
showing a displacement with respect to the trap. When actin is released from myosin, the 
bead springs back to its unloaded baseline position. 
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Figure 7: Total SMMHC and (+)insert isoform content ofpurified tonic (bovine aorta) 
and phasic (chicken gizzard) as assessed by Western blot analysis. Arrows indicate 
200kDa. 
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Chapter 5: Discussion / Conclusions: 
ln this thesis, 1 studied the expression and function of the amino-terminus smooth 
muscle myosin heavy chain isoforms, as well as other contractile proteins, in normal 
tissues and in asthma. Up until my studies, the function of the amino terminus smooth 
muscle myosin heavy chain isoforms (SM-A and SM-B) had been addressed after 
purification from organs of different species, e.g. chicken gizzard and bovine aorta, or 
using artificial myosin constructs. My analysis of these myosin isoforms was the first to 
be performed in multiple organs from the same species. To do this in small animaIs like 
rats required the development of a very efficient myosin purification protocol. This was 
accompli shed by extracting myosin in folding conditions which decreases its affinity for 
actin, allowing for a betler yield. To our knowledge, this is the first report of functional 
myosin purification from such small tissue samples. Unfortunately, the efficiency ofthis 
purification protocol is still not sufficient to purify functional myosin from human 
bronchial biopsies and this will have to await for future development. However, it does 
open the door to the study of the function of myosin in several models of diseases. 
The rank correlation among organs observed in the SM-B myosin isoform 
expression and the rate of actin filament propulsion in the in vitro motility assay (vrnax) 
strongly suggests that the SM-B isoform is an important determinant of tissue shortening 
velocity. Indeed, we measured a greater SM-B expression in the rapidly contracting 
phasic muscles than in the slowly contracting tonic muscles. However, larger differences 
in rate of shortening between phasic and tonic smooth muscle are seen at the tissue level, 
than what we observed at the molecular level. This is, no doubt, due to our minimalist 
approach that is bound to either miss other important factors or overlook the ensemble 
effect. In particular, myosin filaments assembly in vivo, which is not addressed in the in 
vitro motility assay, may be dynamic and play an essential role in smooth muscle 
plasticity, as suggested in a recent model (Seow, Pratusevich et al. 2000; Herrera, Kuo et 
al. 2002). However, more than 50 years after smooth muscle cells were identified, data 
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showing the precise structure of thick filaments in the smooth muscle cells during 
contractions are stilliacking and are the subject of intense research (Herrera, Kuo et al. 
2002; Stephens 2002). 
The greater expression of the SM-B isoform in the asthmatic bronchial biopsies 
offers a molecular mechanism to explain, at least in part, their airway smooth muscle 
hypercontractility. Because of the size of bronchial biopsies, proper quantification of the 
contractile protein genes could only be performed at the mRNA level. However, we 
observed a good correlation between the mRNA and prote in measurements, at least in 
normal tissues, suggesting minor post-transcriptional regulation. Furthermore, because 
we quantified contractile proteins by referencing to a housekeeping gene ubiquitously 
expressed in cells, our results do not allow to distinguish hyperplasia from hypertrophy of 
airway smooth muscle cells in the endobronchial biopsies of the asthmatic subjects. To 
do such, precise stereomorphometric and cell counting techniques are necessary 
(Benayoun, Druilhe et al. 2003; Woodruff, Dolganov et al. 2004). 
The increased expression of MLCK also contributes to the asthmatic airway 
smooth muscle hypercontractility by increasing myosin activation. To our knowledge, 
our study is the first report of an increased V rnax induced by a mechanical action of MLCK 
on smooth muscle myosin. 
To fully appreciate the role ofthose contractile proteins in airway 
hyperresponsiveness, mice genetically modified to lack or overexpress given contractile 
proteins will be required. Indeed, the time course to maximal airway resistance was 
significantly prolonged in the knockout mi ce lacking the SM-B isoform (see 
introduction) (Tuck, Maghni et al. 2004). Measuring the pulmonary mechanics in a SM-B 
knockout mouse constructed in a hyperresponsive mouse strain should more definitely 
elucidate the role of SM-B in asthma. 
Many more questions remain regarding the sequence of the 7 amino acid insert. 
The effect of the flexibility and length of the surface loop on the mechanics of myosin 
have been investigated, but no study has addressed the role of the serine which is well 
conserved among species. Because serine is a phosphorylatable site, there is potential for 
additional regulation. 
143 
Finally, while the latch state was discovered in 1981, this thesis is the first effort 
that addresses its mechanism directly at the molecular level. It is no doubt because of the 
lack of technology that several molecularly based hypotheses were formulated but never 
tested. The limit of our approach is that our mechanical measurements were performed in 
a chemically static environment. To truly test the latch-state, mechanics measurements 
should be performed during active dephosphorylation to verify if indeed, force 
maintenance occurs in dynamic conditions. Nonetheless, our data support two previously 
postulated mechanisms for force maintenance: 1) reattachment of dephosphorylated 
myosin to actin and 2) high affinity oftonic muscle myosin (SM-A) for MgADP. The 
reattachrnent of dephosphorylated myosin suggests the addition of a new time constant in 
the Hai and Murphy model of the latch state since only detachment of myosin from actin 
is permitted so far in their model (fig. 1 in this section). We propose that K7 is 
bidirectional and results from K7' (detachment of dephosphorylated myosin from actin), 
and K7" (reattachment of dephosphorylated myosin to actin) (fig. 1 in this section). 
Further investigation is needed to test our hypothesis and calculate the values of K7" and 
K7'. This theory represents an innovative addition to the Hai and Murphy model that 
would allow a non-exclusive approach of both the latch bridges formation during 
dephosphorylation and the cooperativity theories. 
On the other hand, the high affinity of tonie muscle myosin offers in itself a 
mechanism to explain the greater propensity of tonic compared to phasie muscle to enter 
into latch. 
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Figure 1: The four-state model: A, actin; myosin crossbridge states are M, detached, 
dephosphorylated; Mp, detached, phosphorylated; AMp, attached, phosphorylated; AM, 
attached, dephosphorylated (latchbridge). KI-K7 are first order rate constants resolved 
from experimental data obtained from the swine carotid media. KI and K6 represent 
Ca2+, calmodulin (CaM)-dependent myosin light chain kinase (MLCK) activity; K2 and 
K5 represent myosin light chain phjosphatase (ML CP) activity. K3 and K4 represent 
attachment and detachment ofphosphorylated crossbriodgfes, and K7 represents 
latchbridges detachment. K7' (detachment of dephosphorylated myosin from actin) and 
K7" (reattachment of dephosphorylated myosin to actin) are additional rate constants we 
are proposing. Modified from (Hai and Murphy 1992). 
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Does the latch-state occur in asthma? This thesis does not answer that question. 
The original interest in the latch state in airway hyperresponsiveness and asthma came 
from the fact that asthmatic airways exhibit a deficient relaxation after deep inspirations. 
Our data, however, suggest that the latch-state should be more prominent in muscle 
containing a greater amount of the SM-A myosin isoform. To the contrary, we showed 
that asthmatic airway biopsies have an increased expression of the fast SM-B isoform, 
suggesting that the latch-state may not be an important mechanism in airway 
hyperresponsiveness and asthma. Conversely, our data are supportive of an increased 
rate of shortening in asthma. As previously suggested (see Introduction), a greater rate of 
shortening would allow asthmatic airway smooth muscle to rapidly contract between 
each breath thereby maintaining a permanently constricted state. The beneficial 
relaxation effect of tidal breath and deep inspiration would therefore be lost because the 
asthmatic airway smooth muscle would have time to catch back the constricted state 
between each breath. 
In conclusion, understanding the fundamental properties of smooth muscle such 
as the mechanical role of the isoformic compositon and the latch-state phenomenon, is 
the first step towards a better understanding of the altered smooth muscle contractility 
observed in diseases such as asthma. Because asthma is an inflammatory disease, it will 
be very interesting in the future to study the role of inflammatory mediators in potentially 
altering the contractile protein expression and function. Lastly, airway remodeling should 
not be neglected, and future studies are necessary to determine if it may prevent the 
return of airway function to normal even after the alterations of the contractile proteins 
are reversed back to normal. 
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Statement of originality: 
This thesis contributes to several novel findings on both the function of airway 
smooth muscle in asthma and the molecular mechanics of the latch-state. 
First, the sequence of two of the four smooth muscle myosin heavy chain 
isoforms was not available in human databanks. I was the first to reveal the sequence of 
those isoforms (SM-B-SMI and SM-B-SM2) in human tissues (Chapter 2). Furthermore, 
although the function of the myosin SM-B isoform had been extensively studied, no data 
were available comparing the molecular mechanics of smooth muscle myosin between 
different tissues of the same species. I developed a new myosin purification protocol that 
allows extraction of sufficient functional myosin from small samples such as rat organs to 
perform in vitro motility measurements. Thus, I showed that among organs of the same 
animaIs, Vmax is commensurate with the expression levels of the SM-B myosin isoform. 
In addition, I made a major contribution in the field of airway smooth muscle 
hypercontractility in asthma by showing that genes encoding for contractile proteins, 
namely the SM-B myosin isoform, SM22, and MLCK are upregulated in endobronchial 
biopsies from mild asthmatics. This result offers a molecular mechanism to support the 
hypothesis that the velocity of shortening of airway smooth muscle is a major contributor 
to airway hyperresponsiveness and asthma. Furthermore, I tested the functional 
significance in the in vitro motility assay of the overexpression of the se contractile 
protein genes. I found that overexpression of SM-B and MLCK increases vmax• 
Significantly, I showed that MLCK directly potentiates the mechanics ofmyosin beyond 
its enzymatic effect. 
Lastly, the manuscript in Chapter 4 represents the tirst and only effort in the 
literature addressing the molecular mechanisms responsible for the latch-state. Until now, 
all studies of the latch state have proposed molecular mechanisms based on whole muscle 
mechanics measurements. In this manuscript, I tested two corollaries of that latch-state at 
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the molecular level. Using state-of-the-art techniques, 1 showed that non-phopshorylated 
myosin can attach to actin filaments and maintain force. Secondly, 1 showed that tonie 
muscle myosin has a greater affinity for MgADP than phasic myosin, and that this 
difference is enhanced by dephosphorylation. 
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SUPPLEMENTARY S1 
Human (+)insert SMI SMMHC. Amino acid and nucleotide sequences are shown. The insert is bold-
underlined. Sequences are eut at the 3'end stop codon. 
1 M A Q K G Q L S ODE K F L F V 0 K N FIN S P V A Q A 0 W A A 
K R L V W V P S 
1 
ATGGCGCAGAAGGGCCAACTCAGTGACGATGAGAAGTTCCTCTTTGTGGACAAAAACTTCATCAACAGCCCAGTGGCCCAGGCTGACTGGGCCGCCAAGAGAC 
TCGTCTGGGTCCCCTCG 
41 E K Q G F E A A S l K E E K G 0 E V V V E L VEN G K K V T V G 
K 0 0 l Q K M N 
121 
GAGAAGCAGGGCTTCGAGGCAGCCAGCATTAAGGAGGAGAAGGGGGATGAGGTGGTTGTGGAGCTGGTGGAGAATGGCAAGAAGGTCACGGTTGGGAAAGA 
TGACATCCAGAAGATGAAC 
81 P P K F S K V E 0 M A E L T C L N E A S V L H N L RER Y F S G 
L l Y T Y S G L 
241 
CCACCCAAGTTCTCCAAGGTGGAGGACATGGCGGAGCTGACGTGCCTCAACGAAGCCTCCGTGCTACACAACCTGAGGGAGCGGTACTTCTCAGGGCTAAT 
ATATACGTACTCTGGCCTC 
121 F C V V V N P Y K H L PlY S E K l V 0 M Y K G K K R HEM P P 
H l Y A lAD T 
361 
TTCTGCGTGGTGGTCAACCCCTATAAACACCTGCCCATCTACTCGGAGAAGATCGTCGACATGTACAAGGGCAAGAAGAGGCACGAGATGCCGCCTCACAT 
CTACGCCATCGCAGACACG 
161 A Y R S M L Q 0 RED Q SIL C T G E S GAG K T E N T K K V l 
Q y L A V V A S 
481 
GCCTACCGGAGCATGCTTCAAGATCGGGAGGACCAGTCCATTCTATGCACAGGCGAGTCTGGAGCCGGGAAAACCGAAAACACCAAGAAGGTCATTCAGTA 
CCTGGCCGTGGTGGCCTCC 
201 S H K G K K 0 T S l T Q G P S F A Y GEL E K Q L L Q A N P l L 
E A F G N A K T 
601 
TCCCACAAGGGCAAGAAAGACACAAGTATCACGCAAGGCCCATCTTTTGCCTACGGAGAGCTGGAAAAGCAGCTTCTACAAGCAAACCCGATTCTGGAGGC 
TTTCGGCAACGCCAAAACA 
" 
l 
168 
241 V K N D N S S R F G K F l R l N F D V T G Y l V GAN lET Y L 
L E K S RAI R 
721 
GTGAAGAACGACAACTCCTCACGATTCGGCAAATTCATCCGCATCAACTTCGACGTCACGGGTTACATCGTGGGAGCCAACATTGAGACCTATCTGCTAGA 
AAAATCACGGGCAATTCGC 
281 Q A R DER T F H l F Y Y M l A G A K E K M R S D L L L E G F N 
N Y T F L S N G 
841 
CAAGCCAGAGACGAGAGGACATTCCACATCTTTTACTACATGATTGCTGGAGCCAAGGAGAAGATGAGAAGTGACTTGCTTTTGGAGGGCTTCAACAACTA 
CACCTTCCTCTCCAATGGC 
321 F V P l P A A Q D D E M F Q E T V E A MAI M G F S E E E Q L S 
l L K V V S S V 
961 
TTTGTGCCCATCCCAGCAGCCCAGGATGATGAGATGTTCCAGGAAACCGTGGAGGCCATGGCAATCATGGGTTTCAGCGAGGAGGAGCAGCTATCCATATT 
GAAGGTGGTATCATCGGTC 
361 L Q L G N l V F K KER N T D Q A S M P D N T A A Q K V C HLM 
GIN V T D F T 
1081 
CTGCAGCTTGGAAATATCGTCTTCAAGAAGGAAAGAAACACAGACCAGGCGTCCATGCCAGATAACACAGCTGCTCAGAAAGTTTGCCACCTCATGGGAAT 
TAATGTGACAGATTTCACC 
401 R SIL T P R l K V G R D V V Q K A Q T K E Q A D F A V E A L A 
KAT Y E R L F 
1201 
AGATCCATCCTCACTCCTCGTATCAAGGTTGGGCGAGATGTGGTACAGAAAGCTCAGACAAAAGAACAGGCTGACTTTGCTGTAGAGGCTTTGGCCAAGGC 
AACATATGAGCGCCTTTTC 
441 R W l L T R V N K A L D K T H R Q GAS F L G l L DIA G FEI 
F E V N S F E Q 
1321 
CGCTGGATACTCACCCGCGTGAACAAAGCCCTGGACAAGACCCATCGGCAAGGGGCTTCCTTCCTGGGGATCCTGGATATAGCTGGATTTGAGATCTTTGA 
GGTGAACTCCTTCGAGCAG 
481 L C l N Y T N E K L Q Q L F N H T M FIL E Q E E Y Q REG l E 
W N F l D F G L 
1441 
CTGTGCATCAACTACACCAACGAGAAGCTGCAGCAGCTCTTCAACCACACCATGTTCATCCTGGAGCAGGAGGAGTACCAGCGCGAGGGCATCGAGTGGAA 
CTTCATCGACTTTGGGCTG 
169 
521 0 L Q P CIE LIE R P N N P P G V L A LLO E E C W F P KAT 
o K S F V E K L 
1561 
GACCTACAGCCCTGCATCGAGCTCATCGAGCGACCGAACAACCCTCCAGGTGTGCTGGCCCTGCTGGACGAGGAATGCTGGTTCCCCAAAGCCACGGACAA 
GTCTTTCGTGGAGAAGCTG 
561 C T E Q G S H P K F Q K P K Q L K 0 K T E F SIl H Y A G K V D 
Y N A S A W L T 
1681 
TGCACGGAGCAGGGCAGCCACCCCAAGTTCCAGAAGCCCAAGCAGCTCAAGGACAAGACTGAGTTCTCCATCATCCATTATGCTGGGAAGGTGGACTATAA 
TGCGAGTGCCTGGCTGACC 
601 K N M D P L N D N V T S L L N A S S 0 K F V A D L W K D V D R l 
V G L 0 Q M A K 
1801 
AAGAATATGGACCCGCTGAATGACAACGTGACTTCCCTGCTCAATGCCTCCTCCGACAAGTTTGTGGCCGACCTGTGGAAGGACGTGGACCGCATCGTGGG 
CCTGGACCAGATGGCCAAG 
641 M TES S L P SAS K T K K G M F R T V G Q L Y K E Q L G K L M 
T T L R N T T P 
1921 
ATGACGGAGAGCTCGCTGCCCAGCGCCTCCAAGACCAAGAAGGGCATGTTCCGCACAGTGGGGCAGCTGTACAAGGAGCAGCTGGGCAAGCTGATGACCAC 
GCTACGCAACACCACGCCC 
681 N F V R CIl P N H E K R S G K L D A F L V L E Q L R C N G V L 
E G l R l C R Q 
2041 
AACTTCGTGCGCTGCATCATCCCCAACCACGAGAAGAGGTCCGGCAAGCTGGATGCGTTCCTGGTGCTGGAGCAGCTGCGGTGCAATGGGGTGCTGGAAGG 
CATTCGCATCTGCCGGCAG 
721 G F P N R l V F Q E F R Q RYE l L A A N A l P KGF M D G K Q 
A CIL M l K A 
2161 
GGCTTCCCCAACCGGATCGTCTTCCAGGAGTTCCGCCAACGCTACGAGATCCTGGCGGCGAATGCCATCCCCAAAGGCTTCATGGACGGGAAGCAGGCCTG 
CATTCTCATGATCAAAGCC 
761 L E L 0 P N L Y R l G Q SKI F F R TGV L A H LEE E R D L K 
l T D V l M A F 
! 
170 
) 
2281 
CTGGAACTTGACCCCAACTTATACAGGATAGGGCAGAGCAAAATCTTCTTCCGAACTGGCGTCCTGGCCCACCTAGAGGAGGAGCGAGATTTGAAGATCAC 
CGATGTCATCATGGCCTTC 
801 Q A M C R G Y L A R K A F A K R Q Q Q L T A M K V l Q R N C A A 
Y L K L R N W Q 
2401 
CAGGCGATGTGTCGTGGCTACTTGGCCAGAAAGGCTTTTGCCAAGAGGCAGCAGCAGCTGACCGCCATGAAGGTGATTCAGAGGAACTGCGCCGCCTACCT 
CAAGCTGCGGAACTGGCAG 
841 W W R L F T K V K P L L Q v T R Q E E E M Q A K EDE L Q K T K 
E R Q Q K A E N 
2521 
TGGTGGAGGCTTTTCACCAAAGTGAAGCCACTGCTGCAGGTGACACGGCAGGAGGAGGAGATGCAGGCCAAGGAGGATGAACTGCAGAAGACCAAGGAGCG 
GCAGCAGAAGGCAGAGAAT 
881 E L K E L E Q K H S Q L TEE K N L L Q E Q L Q A ETE L Y A E 
A E E M R V R L 
2641 
GAGCTTAAGGAGCTGGAACAGAAGCACTCGCAGCTGACCGAGGAGAAGAACCTGCTACAGGAACAGCTGCAGGCAGAGACAGAGCTGTATGCAGAGGCTGA 
GGAGATGCGGGTGCGGCTG 
921 
K K 
2761 
A A K 
M A Q 
K Q 
Q M 
E 
L 
L E E l L H E M E A R L E E E E o R G Q Q L Q A E R 
GCGGCCAAGAAGCAGGAGCTGGAGGAGATACTGCATGAGATGGAGGCCCGCCTGGAGGAGGAGGAAGACAGGGGCCAGCAGCTACAGGCTGAAAGGAAGAA 
GATGGCCCAGCAGATGCTG 
961 0 LEE Q LEE E E A A R Q K L Q L E K V T A E A K l K K LED 
E l L V M 0 0 Q 
2881 
GACCTTGAAGAACAGCTGGAGGAGGAGGAAGCTGCCAGGCAGAAGCTGCAACTTGAGAAGGTCACGGCTGAGGCCAAGATCAAGAAACTGGAGGATGAGAT 
CCTGGTCATGGATGATCAG 
1001 N N K L S KER K L LEE RIS 0 L T T N L A E E E E K A K N L 
T K L K N K H E 
3001 
AACAATAAACTATCAAAAGAACGAAAACTCCTTGAGGAGAGGATTAGTGACTTAACGACAAATCTTGCAGAAGAGGAAGAAAAGGCCAAGAATCTTACCAA 
GCTGAAAAACAAGCATGAA 
171 
1041 S MIS E LEV R L K K E E K S R Q E L E K L KRK L EGO A S 
o F H E Q lAD 
3121 
TCTATGATTTCAGAACTGGAAGTGCGGCTAAAGAAGGAAGAGAAGAGCCGACAGGAGCTGGAGAAGCTGAAACGGAAGCTGGAGGGTGATGCCAGCGACTT 
CCACGAGCAGATCGCTGAC 
1081 L Q A Q l A E L K M Q L A K K E E E L Q A A L A R LOD ElA Q 
K N N A L K K l 
3241 
CTCCAGGCGCAGATCGCAGAGCTCAAGATGCAGCTGGCCAAGAAGGAGGAGGAGCTGCAGGCGGCCCTGGCCAGGCTTGACGATGAAATCGCTCAGAAGAA 
CAATGCCCTGAAGAAGATC 
1121 REL E G HIS 0 L Q E 0 LOS E R A A R N K A E K Q K R 0 L G 
E E L E A L K T 
3361 
CGGGAGCTGGAGGGCCACATCTCAGACCTCCAGGAGGACCTGGACTCAGAGCGGGCCGCCAGGAACAAGGCTGAAAAGCAGAAGCGAGACCTCGGCGAGGA 
GCTGGAGGCCCTAAAGACA 
1161 E LED T LOS T A T Q Q E L R A K R E Q E V T V L K K A L 0 E 
E T R S H E A Q 
3481 
GAGCTGGAAGACACACTGGACAGCACAGCCACTCAGCAGGAGCTCAGGGCCAAGAGGGAGCAGGAGGTGACGGTGCTGAAGAAGGCCCTGGATGAAGAGAC 
GCGGTCCCATGAGGCTCAG 
1201 V Q E M R Q K H A Q A V E E L T E Q L E Q F KRA KAN L 0 K N 
K Q T L E KEN 
3601 
GTCCAGGAGATGAGGCAGAAACACGCACAGGCGGTGGAGGAGCTCACAGAGCAGCTTGAGCAGTTCAAGAGGGCCAAGGCGAACCTAGACAAGAATAAGCA 
GACGCTGGAGAAAGAGAAC 
1241 A 0 L AGE L R V L G Q A K Q EVE H K K K K L E A Q v Q E L Q 
S K C S D GER 
3721 
GCAGACCTGGCCGGGGAGCTGCGGGTCCTGGGCCAGGCCAAGCAGGAGGTGGAACATAAGAAGAAGAAGCTGGAGGCGCAGGTGCAGGAGCTGCAGTCCAA 
GTGCAGCGATGGGGAGCGG 
1281 A R A E L NOK V H K L Q N EVE S V T G M L N E A E G K A l K 
L A K 0 V A S L 
3841 
GCCCGGGCGGAGCTCAATGACAAAGTCCACAAGCTGCAGAATGAAGTTGAGAGCGTCACAGGGATGCTTAACGAGGCCGAGGGGAAGGCCATTAAGCTGGC 
CAAGGACGTGGCGTCCCTC 
Î 
172 
1321 
N S 
s S 
L Q 
Q L Q 0 
o Q L 0 
T Q E L L Q E E T R Q K L N v s T K L R Q L E E E R 
3961 
AGTTCCCAGCTCCAGGACACCCAGGAGCTGCTTCAAGAAGAAACCCGGCAGAAGCTCAACGTGTCTACGAAGCTGCGCCAGCTGGAGGAGGAGCGGAACAG 
CCTGCAAGACCAGCTGGAC 
1361 E E M E A K Q N L E R HIS T L N l Q L SOS K K K L Q 0 FAS 
T V E ALE E G 
4081 
GAGGAGATGGAGGCCAAGCAGAACCTGGAGCGCCACATCTCCACTCTCAACATCCAGCTCTCCGACTCGAAGAAGAAGCTGCAGGACTTTGCCAGCACCGT 
GGAAGCTCTGGAAGAGGGG 
1401 K K R F Q K E l E N L T Q Q y E E K A A A Y 0 K L E K T K N R L 
Q Q E LOD L V 
4201 
AAGAAGAGGTTCCAGAAGGAGATCGAGAACCTCACCCAGCAGTACGAGGAGAAGGCGGCCGCTTATGATAAACTGGAAAAGACCAAGAACAGGCTTCAGCA 
GGAGCTGGACGACCTGGTT 
1441 VOL 0 N Q R Q L V S N L E K K Q R K F 0 Q L L A E E K N l S S 
K y ADE R 0 R 
4321 
GTTGATTTGGACAACCAGCGGCAACTCGTGTCCAACCTGGAAAAGAAGCAGAGGAAATTTGATCAGTTGTTAGCCGAGGAGAAAAACATCTCTTCCAAATA 
CGCGGATGAGAGGGACAGA 
1481 A E A E ARE K E T K A L S L A R ALE E ALE A K E E L E R T 
N K M L K A E M 
4441 
GCTGAGGCAGAAGCCAGGGAGAAGGAAACCAAGGCCCTGTCCCTGGCTCGGGCCCTTGAAGAGGCCTTGGAAGCCAAAGAGGAACTCGAGCGGACCAACAA 
AATGCTCAAAGCCGAAATG 
1521 E 0 L V S S K 0 0 V G K N V HEL E K S KRA LET Q MEE M K 
T Q LEE LED 
4561 
GAAGACCTGGTCAGCTCCAAGGATGACGTGGGCAAGAACGTCCATGAGCTGGAGAAGTCCAAGCGGGCCCTGGAGACCCAGATGGAGGAGATGAAGACGCA 
GCTGGAAGAGCTGGAGGAC 
1561 
Q N 
E L QAT E 
E E K R R Q 
OAK L R L E V N M Q A L K G Q F E R o L Q A R o E 
173 
) 
4681 
GAGCTGCAAGCCACGGAGGACGCCAAACTGCGGCTGGAAGTCAACATGCAGGCGCTCAAGGGCCAGTTCGAAAGGGATCTCCAAGCCCGGGACGAGCAGAA 
TGAGGAGAAGAGGAGGCAA 
1601 L Q R Q L H E Y ETE LED E R K Q R A L A A A A K K K L E G D 
L K D L E L Q A 
4801 
CTGCAGAGACAGCTTCACGAGTATGAGACGGAACTGGAAGACGAGCGAAAGCAACGTGCCCTGGCAGCTGCAGCAAAGAAGAAGCTGGAAGGGGACCTGAA 
AGACCTGGAGCTTCAGGCC 
1641 D SAI K GRE E A l K Q L R K L Q A Q M K D F Q REL E DAR 
A S R DEI F A 
4921 
GACTCTGCCATCAAGGGGAGGGAGGAAGCCATCAAGCAGCTACGCAAACTGCAGGCTCAGATGAAGGACTTTCAAAGAGAGCTGGAAGATGCCCGTGCCTC 
CAGAGATGAGATCTTTGCC 
1681 T A KEN E K K A K S L E A D L M Q L Q E D L A A A E R A R K Q 
A D L E K E E L 
5041 
ACAGCCAAAGAGAATGAGAAGAAAGCCAAGAGCTTGGAAGCAGACCTCATGCAGCTACAAGAGGACCTCGCCGCCGCTGAGAGGGCTCGCAAACAAGCGGA 
CCTCGAGAAGGAGGAACTG 
1721 A E ELA S S L S G RNA L Q D E K R R L E A RIA Q LEE E L 
E E E Q G N M E 
5161 
GCAGAGGAGCTGGCCAGTAGCCTGTCGGGAAGGAACGCACTCCAGGACGAGAAGCGCCGCCTGGAGGCCCGGATCGCCCAGCTGGAGGAGGAGCTGGAGGA 
GGAGCAGGGCAACATGGAG 
1761 
A R 
A M S 
Q Q L 
D R V 
E R Q 
R K A T Q Q A E Q L S N E L A T E R S T A Q K N E s 
5281 
GCCATGAGCGACCGGGTCCGCAAAGCCACACAGCAGGCCGAGCAGCTCAGCAACGAGCTGGCCACAGAGCGCAGCACGGCCCAGAAGAATGAGAGTGCCCG 
GCAGCAGCTCGAGCGGCAG 
1801 
L E 
N K E 
E Q V 
L R S 
E Q E 
K L H E M E G A V K S K F K S T l A A L E A K l A Q 
5401 
AACAAGGAGCTCCGGAGCAAGCTCCACGAGATGGAGGGGGCCGTCAAGTCCAAGTTCAAGTCCACCATCGCGGCGCTGGAGGCCAAGATTGCACAGCTGGA 
GGAGCAGGTCGAGCAGGAG 
174 
1841 
E Q 
AREKQAAT 
Y K E Q A E 
K S L K Q K 0 K K L K E l L L Q v E o E R K M A 
5521 
GCCAGAGAGAAACAGGCGGCCACCAAGTCGCTGAAGCAGAAAGACAAGAAGCTGAAGGAAATCTTGCTGCAGGTGGAGGACGAGCGCAAGATGGCCGAGCA 
GTACAAGGAGCAGGCAGAG 
1881 K G N A R V K Q L K R Q LEE A E E E S Q R INA N R R K L Q R 
E L 0 E A TES 
5641 
AAAGGCAATGCCAGGGTCAAGCAGCTCAAGAGGCAGCTGGAGGAGGCAGAGGAGGAGTCCCAGCGCATCAACGCCAACCGCAGGAAGCTGCAGCGGGAGCT 
GGATGAGGCCACGGAGAGC 
1921 N E A MGR E V N A L K S K L R R G NET S F V P S R R S G G R 
R VIE NAD G 
5761 
AACGAGGCCATGGGCCGCGAGGTGAACGCACTCAAGAGCAAGCTCAGGCGAGGAAACGAGACCTCTTTCGTTCCTTCTAGAAGGTCTGGAGGACGTAGAGT 
TATTGAAAATGCAGATGGT 
1961 S E E E TOT RDA 0 F N G T KAS E 
5881 TCTGAGGAGGAAACGGACACTCGAGACGCAGACTTCAATGGAACCAAGGCCAGTGAATAA 
\ 
175 
Supplementary S2 
Human (+)insert SM2 SMMHC. Amino acid and nucleotide sequences are shown. The insert is bold-
underlined. Sequences are cut at the 3'end stop codon. 
1 M A Q K G Q L S D D E K F L F V D K N FIN S P V A Q A D W A A 
K R L V W V P S 
1 
ATGGCGCAGAAGGGCCAACTCAGTGACGATGAGAAGTTCCTCTTTGTGGACAAAAACTTCATCAACAGCCCAGTGGCCCAGGCTGACTGGGCCGCCAAGAGAC 
TCGTCTGGGTCCCCTCG 
41 E K Q G F E A A S l K E E K G D E V V V E L VEN G K K V T V G 
K D D l Q K M N 
121 
GAGAAGCAGGGCTTCGAGGCAGCCAGCATTAAGGAGGAGAAGGGGGATGAGGTGGTTGTGGAGCTGGTGGAGAATGGCAAGAAGGTCACGGTTGGGAAAGA 
TGACATCCAGAAGATGAAC 
81 P P K F S K V E D M A E L T C L N E A S V L H N L RER Y F S G 
L l Y T Y S G L 
241 
CCACCCAAGTTCTCCAAGGTGGAGGACATGGCGGAGCTGACGTGCCTCAACGAAGCCTCCGTGCTACACAACCTGAGGGAGCGGTACTTCTCAGGGCTAAT 
ATATACGTACTCTGGCCTC 
121 F C V V V N P Y K H L PlY S E K l V D M Y K G K K R HEM P P 
H l Y A lAD T 
361 
TTCTGCGTGGTGGTCAACCCCTATAAACACCTGCCCATCTACTCGGAGAAGATCGTCGACATGTACAAGGGCAAGAAGAGGCACGAGATGCCGCCTCACAT 
CTACGCCATCGCAGACACG 
161 A Y R S M L Q D RED Q SIL C T G E S GAG K T E N T K K V l 
Q y L A V V A S 
481 
GCCTACCGGAGCATGCTTCAAGATCGGGAGGACCAGTCCATTCTATGCACAGGCGAGTCTGGAGCCGGGAAAACCGAAAACACCAAGAAGGTCATTCAGTA 
CCTGGCCGTGGTGGCCTCC 
201 S H K G K K D T S l T Q G P S F A Y GEL E K Q L L Q A N P l L 
E A F G N A K T 
601 
TCCCACAAGGGCAAGAAAGACACAAGTATCACGCAAGGCCCATCTTTTGCCTACGGAGAGCTGGAAAAGCAGCTTCTACAAGCAAACCCGATTCTGGAGGC 
TTTCGGCAACGCCAAAACA 
176 
241 V K NON S S R F G K F l R l N F 0 V T G Y l V GAN lET Y L 
L E K S RAI R 
721 
GTGAAGAACGACAACTCCTCACGATTCGGCAAATTCATCCGCATCAACTTCGACGTCACGGGTTACATCGTGGGAGCCAACATTGAGACCTATCTGCTAGA 
AAAATCACGGGCAATTCGC 
281 Q A ROE RTF H l F Y Y M l A G A K E K M R SOL L L E G F N 
N Y T F L S N G 
841 
CAAGCCAGAGACGAGAGGACATTCCACATCTTTTACTACATGATTGCTGGAGCCAAGGAGAAGATGAGAAGTGACTTGCTTTTGGAGGGCTTCAACAACTA 
CACCTTCCTCTCCAATGGC 
321 F V P l P A A Q ODE M F Q E T V E A MAI M G F S E E E Q L S 
l L K V V S S V 
961 
TTTGTGCCCATCCCAGCAGCCCAGGATGATGAGATGTTCCAGGAAACCGTGGAGGCCATGGCAATCATGGGTTTCAGCGAGGAGGAGCAGCTATCCATATT 
GAAGGTGGTATCATCGGTC 
361 L Q L G N l V F K KER N T 0 Q A S M P 0 N T A A Q K V C HLM 
GIN V T 0 F T 
1081 
CTGCAGCTTGGAAATATCGTCTTCAAGAAGGAAAGAAACACAGACCAGGCGTCCATGCCAGATAACACAGCTGCTCAGAAAGTTTGCCACCTCATGGGAAT 
TAATGTGACAGATTTCACC 
401 R SIL T P R l K V G R 0 V V Q K A Q T K E Q A 0 F A V E A L A 
KAT Y E R L F 
1201 
AGATCCATCCTCACTCCTCGTATCAAGGTTGGGCGAGATGTGGTACAGAAAGCTCAGACAAAAGAACAGGCTGACTTTGCTGTAGAGGCTTTGGCCAAGGC 
AACATATGAGCGCCTTTTC 
441 R W l L T R V N K A L 0 K T H R Q GAS F L G l LOI A G FEI 
F E V N S F E Q 
1321 
CGCTGGATACTCACCCGCGTGAACAAAGCCCTGGACAAGACCCATCGGCAAGGGGCTTCCTTCCTGGGGATCCTGGATATAGCTGGATTTGAGATCTTTGA 
GGTGAACTCCTTCGAGCAG 
481 L C l N Y T N E K L Q Q L F N H T M FIL E Q E E Y Q REG l E 
W N F lOF G L 
1441 
CTGTGCATCAACTACACCAACGAGAAGCTGCAGCAGCTCTTCAACCACACCATGTTCATCCTGGAGCAGGAGGAGTACCAGCGCGAGGGCATCGAGTGGAA 
CTTCATCGACTTTGGGCTG 
177 
) 
521 D L Q P CIE LIE R P N N P P G V L A L L D E E C W F P KAT 
D K S F V E K L 
1561 
GACCTACAGCCCTGCATCGAGCTCATCGAGCGACCGAACAACCCTCCAGGTGTGCTGGCCCTGCTGGACGAGGAATGCTGGTTCCCCAAAGCCACGGACAA 
GTCTTTCGTGGAGAAGCTG 
561 C T E Q G S H P K F Q K P K Q L K D K T E F SIl H Y A G K V D 
Y N A S A W L T 
1681 
TGCACGGAGCAGGGCAGCCACCCCAAGTTCCAGAAGCCCAAGCAGCTCAAGGACAAGACTGAGTTCTCCATCATCCATTATGCTGGGAAGGTGGACTATAA 
TGCGAGTGCCTGGCTGACC 
601 K N M D P L N D N V T S L L N A S S D K F V A D L W K D V D R l 
V G L D Q M A K 
1801 
AAGAATATGGACCCGCTGAATGACAACGTGACTTCCCTGCTCAATGCCTCCTCCGACAAGTTTGTGGCCGACCTGTGGAAGGACGTGGACCGCATCGTGGG 
CCTGGACCAGATGGCCAAG 
641 M TES S L P SAS K T K K G M F R T V G Q L Y K E Q L G K L M 
T T L R N T T P 
1921 
ATGACGGAGAGCTCGCTGCCCAGCGCCTCCAAGACCAAGAAGGGCATGTTCCGCACAGTGGGGCAGCTGTACAAGGAGCAGCTGGGCAAGCTGATGACCAC 
GCTACGCAACACCACGCCC 
681 N F V R CIl P N H E K R S G K L D A F L V L E Q L R C N G V L 
E G l R l C R Q 
2041 
AACTTCGTGCGCTGCATCATCCCCAACCACGAGAAGAGGTCCGGCAAGCTGGATGCGTTCCTGGTGCTGGAGCAGCTGCGGTGCAATGGGGTGCTGGAAGG 
CATTCGCATCTGCCGGCAG 
721 G F P N R l V F Q E F R Q RYE l L A A N A l P KGF M D G K Q 
A CIL M l K A 
2161 
GGCTTCCCCAACCGGATCGTCTTCCAGGAGTTCCGCCAACGCTACGAGATCCTGGCGGCGAATGCCATCCCCAAAGGCTTCATGGACGGGAAGCAGGCCTG 
CATTCTCATGATCAAAGCC 
761 L E L D P N L Y R l G Q SKI F F R TGV L A H LEE E R D L K 
l T D V l M A F 
\. 
1 
178 
) 
2281 
CTGGAACTTGACCCCAACTTATACAGGATAGGGCAGAGCAAAATCTTCTTCCGAACTGGCGTCCTGGCCCACCTAGAGGAGGAGCGAGATTTGAAGATCAC 
CGATGTCATCATGGCCTTC 
801 Q A M C R G Y L A R K A F A K R Q Q Q L T A M K V l Q R N C A A 
Y L K L R N W Q 
2401 
CAGGCGATGTGTCGTGGCTACTTGGCCAGAAAGGCTTTTGCCAAGAGGCAGCAGCAGCTGACCGCCATGAAGGTGATTCAGAGGAACTGCGCCGCCTACCT 
CAAGCTGCGGAACTGGCAG 
841 W W R L F T K V K P L L Q V T R Q E E E M Q A K EDE L Q K T K 
E R Q Q K A E N 
2521 
TGGTGGAGGCTTTTCACCAAAGTGAAGCCACTGCTGCAGGTGACACGGCAGGAGGAGGAGATGCAGGCCAAGGAGGATGAACTGCAGAAGACCAAGGAGCG 
GCAGCAGAAGGCAGAGAAT 
881 E L K E L E Q K H S Q L TEE K N L L Q E Q L Q A ETE L Y A E 
A E E M R V R L 
2641 
GAGCTTAAGGAGCTGGAACAGAAGCACTCGCAGCTGACCGAGGAGAAGAACCTGCTACAGGAACAGCTGCAGGCAGAGACAGAGCTGTATGCAGAGGCTGA 
GGAGATGCGGGTGCGGCTG 
921 
K K 
2761 
A A K 
M A Q 
K Q 
Q M 
E 
L 
L E E l L H E M E A R L E E E E D R G Q Q L Q A E R 
GCGGCCAAGAAGCAGGAGCTGGAGGAGATACTGCATGAGATGGAGGCCCGCCTGGAGGAGGAGGAAGACAGGGGCCAGCAGCTACAGGCTGAAAGGAAGAA 
GATGGCCCAGCAGATGCTG 
961 D LEE Q LEE E E A A R Q K L Q L E K V T A E A K l K K LED 
E l L V M D 0 Q 
2881 
GACCTTGAAGAACAGCTGGAGGAGGAGGAAGCTGCCAGGCAGAAGCTGCAACTTGAGAAGGTCACGGCTGAGGCCAAGATCAAGAAACTGGAGGATGAGAT 
CCTGGTCATGGATGATCAG 
1001 N N K L S KER K L LEE RIS 0 L T T N L A E E E E K A K N L 
T K L K N K H E 
3001 
AACAATAAACTATCAAAAGAACGAAAACTCCTTGAGGAGAGGATTAGTGACTTAACGACAAATCTTGCAGAAGAGGAAGAAAAGGCCAAGAATCTTACCAA 
GCTGAAAAACAAGCATGAA 
179 
) 
1041 S MIS E LEV R L K K E E K S R Q E L E K L KRK L E G D A S 
D F H E Q lAD 
3121 
TCTATGATTTCAGAACTGGAAGTGCGGCTAAAGAAGGAAGAGAAGAGCCGACAGGAGCTGGAGAAGCTGAAACGGAAGCTGGAGGGTGATGCCAGCGACTT 
CCACGAGCAGATCGCTGAC 
1081 L Q A Q l A E L K M Q L A K K E E E L Q A A L A R L D DEI A Q 
K N N A L K K l 
3241 
CTCCAGGCGCAGATCGCAGAGCTCAAGATGCAGCTGGCCAAGAAGGAGGAGGAGCTGCAGGCGGCCCTGGCCAGGCTTGACGATGAAATCGCTCAGAAGAA 
CAATGCCCTGAAGAAGATC 
1121 REL E G HIS D L Q E D L D S E R A A R N K A E K Q K R D L G 
E E L E A L K T 
3361 
CGGGAGCTGGAGGGCCACATCTCAGACCTCCAGGAGGACCTGGACTCAGAGCGGGCCGCCAGGAACAAGGCTGAAAAGCAGAAGCGAGACCTCGGCGAGGA 
GCTGGAGGCCCTAAAGACA 
1161 E LED T L DST A T Q Q E L R A K R E Q E V T V L K K A L D E 
E T R S H E A Q 
3481 
GAGCTGGAAGACACACTGGACAGCACAGCCACTCAGCAGGAGCTCAGGGCCAAGAGGGAGCAGGAGGTGACGGTGCTGAAGAAGGCCCTGGATGAAGAGAC 
GCGGTCCCATGAGGCTCAG 
1201 V Q E M R Q K H A Q A V E E L T E Q L E Q F KRA KAN L D K N 
K Q T L E KEN 
3601 
GTCCAGGAGATGAGGCAGAAACACGCACAGGCGGTGGAGGAGCTCACAGAGCAGCTTGAGCAGTTCAAGAGGGCCAAGGCGAACCTAGACAAGAATAAGCA 
GACGCTGGAGAAAGAGAAC 
1241 A D L AGE L R V L G Q A K Q EVE H K K K K L E A Q v Q E L Q 
S K C S D GER 
3721 
GCAGACCTGGCCGGGGAGCTGCGGGTCCTGGGCCAGGCCAAGCAGGAGGTGGAACATAAGAAGAAGAAGCTGGAGGCGCAGGTGCAGGAGCTGCAGTCCAA 
GTGCAGCGATGGGGAGCGG 
1281 A R A E L N D K V H K L Q N EVE S V T G M L N E A E G K A l K 
L A K D V A S L 
3841 
GCCCGGGCGGAGCTCAATGACAAAGTCCACAAGCTGCAGAATGAAGTTGAGAGCGTCACAGGGATGCTTAACGAGGCCGAGGGGAAGGCCATTAAGCTGGC 
CAAGGACGTGGCGTCCCTC 
180 
) 
1321 
N S 
3961 
S S 
L Q 
Q L Q D 
D Q L D 
T Q E L L Q E E T R Q K L N v S T K L R Q L E E E R 
AGTTCCCAGCTCCAGGACACCCAGGAGCTGCTTCAAGAAGAAACCCGGCAGAAGCTCAACGTGTCTACGAAGCTGCGCCAGCTGGAGGAGGAGCGGAACAG 
CCTGCAAGACCAGCTGGAC 
1361 E E M E A K Q N L E R HIS T L N l Q L S D S K K K L Q D FAS 
T V E ALE E G 
4081 
GAGGAGATGGAGGCCAAGCAGAACCTGGAGCGCCACATCTCCACTCTCAACATCCAGCTCTCCGACTCGAAGAAGAAGCTGCAGGACTTTGCCAGCACCGT 
GGAAGCTCTGGAAGAGGGG 
1401 K K R F Q K E l E N L T Q Q y E E K A A A Y D K L E K T K N R L 
Q Q E L D D L V 
4201 
AAGAAGAGGTTCCAGAAGGAGATCGAGAACCTCACCCAGCAGTACGAGGAGAAGGCGGCCGCTTATGATAAACTGGAAAAGACCAAGAACAGGCTTCAGCA 
GGAGCTGGACGACCTGGTT 
1441 V D L D N Q R Q L V S N L E K K Q R K F D Q L L A E E K N l S S 
K y ADE R D R 
4321 
GTTGATTTGGACAACCAGCGGCAACTCGTGTCCAACCTGGAAAAGAAGCAGAGGAAATTTGATCAGTTGTTAGCCGAGGAGAAAAACATCTCTTCCAAATA 
CGCGGATGAGAGGGACAGA 
1481 A E A E ARE K E T K A L S L A R ALE E ALE A K E E L E R T 
N K M L K A E M 
4441 
GCTGAGGCAGAAGCCAGGGAGAAGGAAACCAAGGCCCTGTCCCTGGCTCGGGCCCTTGAAGAGGCCTTGGAAGCCAAAGAGGAACTCGAGCGGACCAACAA 
AATGCTCAAAGCCGAAATG 
1521 E D L V S S K D D V G K N V HEL E K S KRA LET Q MEE M K 
T Q LEE LED 
4561 
GAAGACCTGGTCAGCTCCAAGGATGACGTGGGCAAGAACGTCCATGAGCTGGAGAAGTCCAAGCGGGCCCTGGAGACCCAGATGGAGGAGATGAAGACGCA 
GCTGGAAGAGCTGGAGGAC 
1561 
Q N 
E L QAT E 
E E K R R Q 
D A K L R L E V N M Q A L K G Q F E R D L Q A R D E 
') 
181 
) 
4681 
GAGCTGCAAGCCACGGAGGACGCCAAACTGCGGCTGGAAGTCAACATGCAGGCGCTCAAGGGCCAGTTCGAAAGGGATCTCCAAGCCCGGGACGAGCAGAA 
TGAGGAGAAGAGGAGGCAA 
1601 L Q R Q L H E Y ETE LED E R K Q R A L A A A A K K K L EGO 
L K 0 L E L Q A 
4801 
CTGCAGAGACAGCTTCACGAGTATGAGACGGAACTGGAAGACGAGCGAAAGCAACGTGCCCTGGCAGCTGCAGCAAAGAAGAAGCTGGAAGGGGACCTGAA 
AGACCTGGAGCTTCAGGCC 
1641 0 SAI K GRE E A l K Q L R K L Q A Q M K 0 F Q REL E 0 A R 
A S ROE l F A 
4921 
GACTCTGCCATCAAGGGGAGGGAGGAAGCCATCAAGCAGCTACGCAAACTGCAGGCTCAGATGAAGGACTTTCAAAGAGAGCTGGAAGATGCCCGTGCCTC 
CAGAGATGAGATCTTTGCC 
1681 T A KEN E K K A K S L E A 0 L M Q L Q E 0 L A A A E R A R K Q 
A 0 L E K E E L 
5041 
ACAGCCAAAGAGAATGAGAAGAAAGCCAAGAGCTTGGAAGCAGACCTCATGCAGCTACAAGAGGACCTCGCCGCCGCTGAGAGGGCTCGCAAACAAGCGGA 
CCTCGAGAAGGAGGAACTG 
1721 A E ELA S S L S G RNA L Q 0 E K R R L E A RIA Q LEE E L 
E E E Q G N M E 
5161 
GCAGAGGAGCTGGCCAGTAGCCTGTCGGGAAGGAACGCACTCCAGGACGAGAAGCGCCGCCTGGAGGCCCGGATCGCCCAGCTGGAGGAGGAGCTGGAGGA 
GGAGCAGGGCAACATGGAG 
1761 A M SOR V R KAT Q Q A E Q L SNE LAT ERS T A Q K NES 
A R Q Q L E R Q 
5281 
GCCATGAGCGACCGGGTCCGCAAAGCCACACAGCAGGCCGAGCAGCTCAGCAACGAGCTGGCCACAGAGCGCAGCACGGCCCAGAAGAATGAGAGTGCCCG 
GCAGCAGCTCGAGCGGCAG 
1801 
L E 
5401 
N K E 
E Q V 
L R S 
E Q E 
K L H E M E G A V K S K F K S T l A A L E A K l A Q 
AACAAGGAGCTCCGGAGCAAGCTCCACGAGATGGAGGGGGCCGTCAAGTCCAAGTTCAAGTCCACCATCGCGGCGCTGGAGGCCAAGATTGCACAGCTGGA 
GGAGCAGGTCGAGCAGGAG 
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) 
1841 ARE 
E Q Y K E 
K Q 
Q A 
A 
E 
A T K s L K Q K o K K L K E l L L Q v E o E R K M A 
5521 
GCCAGAGAGAAACAGGCGGCCACCAAGTCGCTGAAGCAGAAAGACAAGAAGCTGAAGGAAATCTTGCTGCAGGTGGAGGACGAGCGCAAGATGGCCGAGCA 
GTACAAGGAGCAGGCAGAG 
1881 K G N A R V K Q L K R Q LEE A E E E S Q R INA N R R K L Q R 
E L 0 E A TES 
5641 
AAAGGCAATGCCAGGGTCAAGCAGCTCAAGAGGCAGCTGGAGGAGGCAGAGGAGGAGTCCCAGCGCATCAACGCCAACCGCAGGAAGCTGCAGCGGGAGCT 
GGATGAGGCCACGGAGAGC 
1921 N E A MGR E V N A L K S K L R G PPP Q E T S Q 
5761 AACGAGGCCATGGGCCGCGAGGTGAACGCACTCAAGAGCAAGCTCAGAGGGCCCCCCCCACAGGAAACTTCGCAGTGA 
') 
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